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Abstract: Epidemiological studies have strongly suggested that reduced plasma levels of HDL cholesterol
are associated with an increased risk of coronary artery disease. Raising HDL Cholesterol is therefore
being examined as a potentially important therapeutic strategy. However, recent genetic data and clin-
ical trials have been inconclusive on the beneficial effects of raising HDL cholesterol levels. Clinical
trials using the HDL cholesterol raising agents torcetrapib, dalcetrapib and niacin have shown that no
significant reduction of cardiovascular events was observed in patients with coronary disease. These re-
cent failures in treatments that raise HDL cholesterol levels have cast doubt on whether HDL plays a
truly protective role in cardiovascular disease. In recent years, various biological functions of HDL have
been identified, that may account for the ability of HDL to protect against atherosclerosis. Endothelial
dysfunction is suggested to play a critical role in development and progression of atherosclerosis and
recent studies have suggested that HDL exerts direct endothelial-protective effects, such as stimulation
of endothelial production of the anti-atherogenic molecule nitric oxide, anti-inflammatory, anti-apoptotic,
and anti-thrombotic effects. However, accumulating evidence suggests that the vascular effects of HDL
may be highly heterogenous and vasoprotective properties of HDL may be impaired in patients with
inflammatory or cardiovascular disease. It is therefore essential to elucidate the mechanisms leading to
impaired vascular effects of HDL in coronary artery disease and to understand the importance of raising
HDL with atheroprotective quality. The first aim of this thesis was to investigate the effects of HDL
isolated from patients with coronary artery disease (CAD) on endothelial function and to characterize
the mechanisms leading to impaired vascular effects of HDL in patients with CAD, in particular the
effects of HDL on endothelial apoptotic signaling pathways. The second aim of my thesis was to optimize
cell-based assays that allow for high-throughput assessment of the endothelial effects of HDL. Finally,
in order to elucidate the mechanisms of action of HDL and its altered vascular effects in cardiovascular
diseases, there is a need to characterize HDL cargo. The third aim of my thesis was to use targeted
proteomics to investigate changes in the protein compositions of HDL that may modulate its function
in coronary artery disease. In order to investigate the effects of HDL on endothelial apoptosis signaling
and its alterations in coronary disease, I have isolated HDL from patients with CAD and characterized
its mechanisms of action. In contrast to HDL from healthy subjects, HDL isolated from patients with
CAD failed to inhibit endothelial cell apoptosis in vitro and in apoE-deficient-mice in vivo. Instead, HDL
isolated from these patients stimulated endothelial pro-apoptotic pathways, in particular p38-MAPK-
mediated activation of the pro-apoptotic Bcl- 2-protein tBid. This study further suggests that differences
in the proteome of HDL from patients with CAD, in particular reduced HDL-associated clusterin and
increased HDL-associated apoC-III, play an important role for altered activation of endothelial anti- and
pro-apoptotic signaling pathways. I have optimized cell-based assays for the assessment of HDL func-
tion, in particular the capacity of HDL to inhibit TNF-￿-induced VCAM-1 expression, to reduce active
caspase-3 activation and to stimulate nitric oxide production. These assays were used to evaluate the
impact of cholesteryl ester transfer protein (CETP) inhibitor treatment on the endothelial effects of HDL.
Treatment with dalcetrapib failed to restore HDL functions to the level of healthy subjects, which may
explain, at least in part, the lack of benefit on endothelial function seen in the dal-VESSEL trial. Inter-
estingly, despite the failure of torcetrapib in clinical trial resulting in increased cardiovascular mortality,
no impairment in HDL functions was observed following torcetrapib treatment in this study. This finding
may explain the lack of improvement in the quality of HDL following torcetrapib treatment, however the
adverse effects observed in the clinical trial of torcetrapib were likely caused by off-target side effects,
which may have been due to direct deleterious actions of torcetrapib on endothelial function, indepen-
dent of the HDL cholesterol raising effect. Last but not least, using quantitative proteomics analysis with
selected reaction monitoring (SRM), it was observed that HDL from patients with CAD has significantly
altered protein compositions as compared to HDL from healthy subjects, further supporting our earlier
observations. Notably, significant differences were observed in the HDL proteome between patients with
CAD who died from cardiovascular events versus patients who did not develop any events during the
entire follow-up study period. This finding may identify potential markers in determining patients at
risk of developing future cardiovascular events. More importantly, some of the proteins identified will
allow better understanding of the mechanisms of action of HDL and its alterations in cardiovascular dis-
ease. Of note, some of the proteins identified to be differentially regulated are not related to lipoprotein
metabolism, indicating that HDL physiology and its pathophysiology in CAD is beyond simply regula-
tion of lipid metabolism but also other metabolic processes such as innate immunity and regulation of
oxidative stress. In epidemiologischen Studien waren verringerte Plasmaspiegel des HDL-Cholesterols mit
einem erhöhten Risiko für koronare Herzerkrankung (KHK) assoziiert. Daher wird derzeit untersucht, ob
die Steigerung der HDL-Cholesterolspiegels im Blut eine erfolgreiche therapeutische Strategie bei KHK
darstellt. Jedoch lieferten aktuelle genetische Untersuchungen und klinische Studien widersprüchliche
Daten zum Effekt einer Steigerung der HDL-Spiegel. Klinische Studien, bei denen die HDL-steigernden
Substanzen Torcetrapib, Dalcetrapib und Niacin eingesetzt wurden, konnte bei Patienten mit KHK
keine signifikante Verringerung kardiovaskulärer Ereignisse beobachtet werden. Diese Studienergebnisse
führten zu Zweifeln an der postulierten protektiven Wirkung einer HDL-Steigerung bei KHK. In den ver-
gangenen Jahren wurden verschiedene biologische Funktionen des HDL-Cholesterols identifiziert, welche
dessen atheroprotektive Wirksamkeit beeinflussen könnten. Besonders der endothelialen Dysfunktion
wird eine wichtige Rolle in der Entstehung und Entwicklung der Atherosklerose zugeschrieben und von
aktuellen Studienergebnissen wurde eine endothel-protektive Wirkung des HDL-Cholesterols abgeleitet,
beispielsweise die Produktion des anti-atherogenen Stickstoffmonoxids durch Endothelzellen, sowie weit-
ere inflammationshemmende, überlebensfördernde und thrombosehemmende Eigenschaften. Allerdings
deuten die Ergebnisse mehrerer Studien darauf hin dass die Eigenschaften des isolierten HDLs sehr het-
erogen und abhängig vom Gesundheitszustand des Spenders sind. Die gefässprotektiven Eigenschaften
des HDL könnten bei Patienten mit inflammatorischen oder kardiovaskulären Erkrankungen verringert
sein. Es ist daher wichtig, die Mechanismen zu verstehen, die zu einer Einschränkung der gefässschützen-
den Eigenschaften des HDL bei Patienten mit KHK führen und die Bedeutung einer Erhöhung speziell
von HDL mit gefässschützenden Eigenschaften zu verstehen. Das Ziel dieser Dissertation war daher
zunächst, die Effekte von HDL von Patienten mit KHK auf die Endothelfunktion zu untersuchen und die
Mechanismen zu charakterisieren, welche die vaskulären Eigenschaften des HDLs bei Patienten mit KHK
einschränken, speziell die Effekte des HDLs auf apoptose- relevante Signalwege in Endothelzellen. Das
zweite Ziel war, zellbasierte Tests für die Hochdurchsatz- Analyse der endothelialen Effekte des HDLs zu
optimieren. Weiterhin war es wichtig, die Proteinbeladung des HDLs zu charakterisieren, um die Wirk-
mechanismen des HDLs und seine veränderten vaskulären Effekte bei kardiovaskulären Erkrankungen
besser zu verstehen. Das dritte Ziel der Dissertation war daher, die gezielte Proteomanalyse einzusetzen,
um Veränderungen in der Proteinzusammensetzung des HDLs zu identifizieren, die dessen Funktion bei
Patienten mit KHK verändern könnten. Für die Charakterisierung der molekularen Effekte des HDL auf
zelluläre Signalwege zur Steuerung der endothelialen Apoptose und deren Änderung bei KHK habe ich
zunächst HDL von Patienten mit KHK sowie von gesunden Probanden isoliert und dessen molekulare Ef-
fekte untersucht. Im Vergleich zu gesundem HDL war HDL von Patienten mit KHK nicht in der Lage, die
Apoptose von Endothelzellen in vitro und in vivo in ApolipoproteinE-defizienten Mäusen zu verhindern.
Stattdessen stimulierte das HDL von KHK-Patienten pro-apoptotische Signalwege in Endothelzellen, wie
die Aktivierung des pro-apoptotischen Proteins tBid, eines Mitglieds der Bcl-2-Proteinfamilie, durch die
Kinase p38-MAPK. Die Studienergebnisse deuten weiterhin darauf hin, dass Unterschiede im Proteom
des HDL von KHK-Patienten, einschliesslich einer Verringerung von HDL-assoziiertem Clusterin und
einer Erhöhung von HDL-assoziiertem ApoC-III, eine wichtige Rolle bei der Modulierung von endothe-
lialen pro- und anti-apoptotischen Signalwegen spielen. Ich habe zellbasierte Untersuchungsmethoden der
HDL-Funktion für Hochdurchsatzanalysen optimiert, speziell die Bestimmung der Fähigkeit des HDLs,
die TNF-￿-induzierte Hochregulation der VCAM-1- Expression und die Aktivierung der Caspase-3 zu ver-
ringern, sowie die Produktion von Stickstoffmonoxid zu induzieren. Diese Methoden wurden verwendet,
um den Einfluss von Inhibitoren des Cholesterylester- Transferproteins (CETP) auf die endothelialen Ef-
fekte des HDLs zu testen. Die Behandlung mit Dalcetrapib bei KHK-Patienten konnte die HDL-Funktion
nicht auf die Werte des HDLs von gesunden Probanden anheben. Dies könnte, zummindest teilweise, erk-
lären warum in der “Dal-VESSEL”-Studie keine Verbesserung der Endothelfunktion beobachtet werden
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konnte. Interessant ist, dass wir trotz des Versagens von Torcetrapib in klinischen Studien, bei de-
nen eine erhöhte Mortalität beschrieben wurde, keine Verschlechterung der HDL-Funktion beobachteten.
Dies mag erklären, warum keine Verbesserung der HDL- Qualität durch Torcetrapib erreicht werden
konnte. Die beobachteten unerwünschten Ereignisse, die in der Torcetrapib-Studie beobachtet wurden,
wurden möglicherweise durch Nebenwirkungen des Medikaments hervorgerufen, beispielsweise durch di-
rekte, HDL-unabhängige Effekte des Torcetrapibs auf die Endothelfunktion. Im letzten Teil der Disserta-
tion konnte mithilfe der quantitativen Proteomanalyse, bei der die Technik „selected reaction monitoring
(SRM)“ eingesetzt wurde, gefunden werden, dass sich die Proteinzusammensetzung des HDLs von Pa-
tienten mit KHK signifikant vom HDL gesunder Probanden unterscheidet. Dies unterstützt zusätzlich
unsere früheren Beobachtungen. Von besonderer Bedeutung ist die Identifizierung von Unterschieden
in der HDL-Zusammensetzung von Patienten mit KHK, die später an einem kardiovaskulären Ereignis
verstarben, im Vergleich zu Patienten, welche während des follow-up- Zeitraums kein Ereignis erlitten hat-
ten. Diese Beobachtung könnte in der Zukunft zur Identifizierung von Markern dienen, um Patienten zu
erkennen, die ein erhöhtes Risiko haben, ein kardiovaskuläres Ereignis zu erleiden. Weiterhin ermöglichen
einige der identifizierten Proteine ein besseres Verständnis der Wirkmechanismen des HDLs und seiner
Veränderungen bei kardiovaskulären Erkrankungen. In diesem Zusammenhang ist von besonderem Inter-
esse, dass für einige der verändert vorhandenen Proteine bislang keine Rolle im Lipoproteinmetabolismus
bekannt war. Dies legt den Schluss nahe, dass die physiologische Rolle des HDL, sowie seine pathophys-
iologischen Veränderungen bei KHK , sich über die einfache Regulation des Lipidmetabolismus erstreckt
und weitere Prozesse, beispielsweise die unspezifische Immunabwehr und die Regulation des oxidativen
Stresses beeinflusst.
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Abstract 
Epidemiological studies have strongly suggested that reduced plasma levels of HDL cholesterol are 
associated with an increased risk of coronary artery disease. Raising HDL Cholesterol is therefore being 
examined as a potentially important therapeutic strategy. However, recent genetic data and clinical trials 
have been inconclusive on the beneficial effects of raising HDL cholesterol levels. Clinical trials using the 
HDL cholesterol raising agents torcetrapib, dalcetrapib and niacin have shown that no significant 
reduction of cardiovascular events was observed in patients with coronary disease. These recent failures in 
treatments that raise HDL cholesterol levels have cast doubt on whether HDL plays a truly protective role 
in cardiovascular disease. 
In recent years, various biological functions of HDL have been identified, that may account for the ability 
of HDL to protect against atherosclerosis. Endothelial dysfunction is suggested to play a critical role in 
development and progression of atherosclerosis and recent studies have suggested that HDL exerts direct 
endothelial-protective effects, such as stimulation of endothelial production of the anti-atherogenic 
molecule nitric oxide, anti-inflammatory, anti-apoptotic, and anti-thrombotic effects. However, 
accumulating evidence suggests that the vascular effects of HDL may be highly heterogenous and 
vasoprotective properties of HDL may be impaired in patients with inflammatory or cardiovascular disease. 
It is therefore essential to elucidate the mechanisms leading to impaired vascular effects of HDL in 
coronary artery disease and to understand the importance of raising HDL with atheroprotective quality. 
The first aim of this thesis was to investigate the effects of HDL isolated from patients with coronary 
artery disease (CAD) on endothelial function and to characterize the mechanisms leading to impaired 
vascular effects of HDL in patients with CAD, in particular the effects of HDL on endothelial apoptotic 
signaling pathways. The second aim of my thesis was to optimize cell-based assays that allow for high-
throughput assessment of the endothelial effects of HDL. Finally, in order to elucidate the mechanisms of 
action of HDL and its altered vascular effects in cardiovascular diseases, there is a need to characterize 
HDL cargo. The third aim of my thesis was to use targeted proteomics to investigate changes in the protein 
compositions of HDL that may modulate its function in coronary artery disease.  
In order to investigate the effects of HDL on endothelial apoptosis signaling and its alterations in coronary 
disease, I have isolated HDL from patients with CAD and characterized its mechanisms of action. In 
contrast to HDL from healthy subjects, HDL isolated from patients with CAD failed to inhibit endothelial 
cell apoptosis in vitro and in apoE-deficient-mice in vivo. Instead, HDL isolated from these patients 
stimulated endothelial pro-apoptotic pathways, in particular p38-MAPK-mediated activation of the pro-
apoptotic Bcl-2-protein tBid. This study further suggests that differences in the proteome of HDL from 
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patients with CAD, in particular reduced HDL-associated clusterin and increased HDL-associated apoC-
III, play an important role for altered activation of endothelial anti- and pro-apoptotic signaling pathways. 
I have optimized cell-based assays for the assessment of HDL function, in particular the capacity of HDL 
to inhibit TNF-α-induced VCAM-1 expression, to reduce active caspase-3 activation and to stimulate 
nitric oxide production. These assays were used to evaluate the impact of cholesteryl ester transfer protein 
(CETP) inhibitor treatment on the endothelial effects of HDL. Treatment with dalcetrapib failed to restore 
HDL functions to the level of healthy subjects, which may explain, at least in part, the lack of benefit on 
endothelial function seen in the dal-VESSEL trial.  
Interestingly, despite the failure of torcetrapib in clinical trial resulting in increased cardiovascular 
mortality, no impairment in HDL functions was observed following torcetrapib treatment in this study. 
This finding may explain the lack of improvement in the quality of HDL following torcetrapib treatment, 
however the adverse effects observed in the clinical trial of torcetrapib were likely caused by off-target 
side effects, which may have been due to direct deleterious actions of torcetrapib on endothelial function, 
independent of the HDL cholesterol raising effect. 
Last but not least, using quantitative proteomics analysis with selected reaction monitoring (SRM), it was 
observed that HDL from patients with CAD has significantly altered protein compositions as compared to 
HDL from healthy subjects, further supporting our earlier observations. Notably, significant differences 
were observed in the HDL proteome between patients with CAD who died from cardiovascular events 
versus patients   who did not develop any events during the entire follow-up study period. This finding 
may identify potential markers in determining patients at risk of developing future cardiovascular events. 
More importantly, some of the proteins identified will allow better understanding of the mechanisms of 
action of HDL and its alterations in cardiovascular disease. Of note, some of the proteins identified to be 
differentially regulated are not related to lipoprotein metabolism, indicating that HDL physiology and its 
pathophysiology in CAD is beyond simply regulation of lipid metabolism but also other metabolic 
processes such as innate immunity and regulation of oxidative stress. 
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Zusammenfassung 
In epidemiologischen Studien waren verringerte Plasmaspiegel des HDL-Cholesterols mit einem erhöhten 
Risiko für koronare Herzerkrankung (KHK) assoziiert. Daher wird derzeit untersucht, ob die Steigerung 
der HDL-Cholesterolspiegels im Blut eine erfolgreiche therapeutische Strategie bei KHK darstellt. Jedoch 
lieferten aktuelle genetische Untersuchungen und klinische Studien widersprüchliche Daten zum Effekt 
einer Steigerung der HDL-Spiegel. Klinische Studien, bei denen die HDL-steigernden Substanzen 
Torcetrapib, Dalcetrapib und Niacin eingesetzt wurden, konnte bei Patienten mit KHK keine signifikante 
Verringerung kardiovaskulärer Ereignisse  beobachtet werden.  Diese Studienergebnisse führten zu 
Zweifeln an der postulierten protektiven Wirkung einer HDL-Steigerung bei KHK. 
In den vergangenen Jahren wurden verschiedene biologische Funktionen des HDL-Cholesterols 
identifiziert, welche dessen atheroprotektive Wirksamkeit beeinflussen könnten. Besonders der 
endothelialen Dysfunktion wird eine wichtige Rolle in der Entstehung und Entwicklung der 
Atherosklerose zugeschrieben und von aktuellen Studienergebnissen wurde eine endothel-protektive 
Wirkung des HDL-Cholesterols abgeleitet, beispielsweise die Produktion des anti-atherogenen 
Stickstoffmonoxids durch Endothelzellen, sowie weitere inflammationshemmende, überlebensfördernde 
und thrombosehemmende Eigenschaften. Allerdings deuten die Ergebnisse mehrerer Studien darauf hin 
dass die Eigenschaften des isolierten HDLs sehr heterogen und abhängig vom Gesundheitszustand des 
Spenders sind. Die gefässprotektiven Eigenschaften des HDL könnten bei Patienten mit 
inflammatorischen oder kardiovaskulären Erkrankungen verringert sein. Es ist daher wichtig, die 
Mechanismen zu verstehen, die zu einer Einschränkung der gefässschützenden Eigenschaften des HDL bei 
Patienten mit KHK führen und die Bedeutung einer Erhöhung speziell von HDL mit gefässschützenden 
Eigenschaften zu verstehen.  
Das Ziel dieser Dissertation war daher zunächst, die Effekte von HDL von Patienten mit KHK auf die 
Endothelfunktion zu untersuchen und die Mechanismen zu charakterisieren, welche die vaskulären 
Eigenschaften des HDLs bei Patienten mit KHK einschränken, speziell die Effekte des HDLs auf 
apoptose-relevante Signalwege in Endothelzellen. Das zweite Ziel war, zellbasierte Tests für die 
Hochdurchsatz-Analyse der endothelialen Effekte des HDLs zu optimieren. Weiterhin war es wichtig, die 
Proteinbeladung des HDLs zu charakterisieren, um die Wirkmechanismen des HDLs und seine 
veränderten vaskulären Effekte bei kardiovaskulären Erkrankungen besser zu verstehen. Das dritte Ziel der 
Dissertation war daher, die gezielte Proteomanalyse einzusetzen, um Veränderungen in der 
Proteinzusammensetzung des HDLs zu identifizieren, die dessen Funktion bei Patienten mit KHK 
verändern könnten. 
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Für die Charakterisierung der molekularen Effekte des HDL auf zelluläre Signalwege zur Steuerung der 
endothelialen Apoptose und deren Änderung bei KHK habe ich zunächst HDL von Patienten mit KHK 
sowie von gesunden Probanden isoliert und dessen molekulare Effekte untersucht. Im Vergleich zu 
gesundem HDL war HDL von Patienten mit KHK nicht in der Lage, die Apoptose von Endothelzellen in 
vitro und in vivo in ApolipoproteinE-defizienten Mäusen zu verhindern. Stattdessen stimulierte das HDL 
von KHK-Patienten pro-apoptotische Signalwege in Endothelzellen, wie die Aktivierung des pro-
apoptotischen Proteins tBid, eines Mitglieds der Bcl-2-Proteinfamilie, durch die Kinase p38-MAPK. Die 
Studienergebnisse deuten weiterhin darauf hin, dass Unterschiede im Proteom des HDL von KHK-
Patienten, einschliesslich einer Verringerung von HDL-assoziiertem Clusterin und einer Erhöhung von 
HDL-assoziiertem ApoC-III, eine wichtige Rolle bei der Modulierung von endothelialen pro- und anti-
apoptotischen Signalwegen spielen. 
Ich habe zellbasierte Untersuchungsmethoden der HDL-Funktion für Hochdurchsatzanalysen optimiert, 
speziell die Bestimmung der Fähigkeit des HDLs, die TNF-α-induzierte Hochregulation der VCAM-1-
Expression und die Aktivierung der Caspase-3 zu verringern, sowie die Produktion von Stickstoffmonoxid 
zu induzieren. Diese Methoden wurden verwendet, um den Einfluss von Inhibitoren des  Cholesterylester-
Transferproteins (CETP) auf die endothelialen Effekte des HDLs zu testen. Die Behandlung mit 
Dalcetrapib bei KHK-Patienten konnte die HDL-Funktion nicht auf die Werte des HDLs von gesunden 
Probanden anheben. Dies könnte, zummindest teilweise, erklären warum in der “Dal-VESSEL”-Studie 
keine Verbesserung der Endothelfunktion beobachtet werden konnte.  Interessant ist, dass wir trotz des 
Versagens von Torcetrapib in klinischen Studien, bei denen eine erhöhte Mortalität beschrieben wurde, 
keine Verschlechterung der HDL-Funktion beobachteten. Dies mag erklären, warum keine Verbesserung 
der HDL-Qualität durch Torcetrapib erreicht werden konnte. Die beobachteten unerwünschten Ereignisse, 
die in der Torcetrapib-Studie beobachtet wurden, wurden möglicherweise durch Nebenwirkungen des 
Medikaments hervorgerufen, beispielsweise durch direkte, HDL-unabhängige Effekte des Torcetrapibs auf 
die Endothelfunktion. 
Im letzten Teil der Dissertation konnte mithilfe der quantitativen Proteomanalyse, bei der die Technik 
„selected reaction monitoring (SRM)“ eingesetzt wurde, gefunden werden, dass sich die 
Proteinzusammensetzung des HDLs von Patienten mit KHK signifikant vom HDL gesunder Probanden 
unterscheidet. Dies unterstützt zusätzlich unsere früheren Beobachtungen. Von besonderer Bedeutung ist 
die Identifizierung von Unterschieden in der HDL-Zusammensetzung von Patienten mit KHK, die später 
an einem kardiovaskulären Ereignis verstarben, im Vergleich zu Patienten, welche während des follow-up-
Zeitraums kein Ereignis erlitten hatten. Diese Beobachtung könnte in der Zukunft zur Identifizierung von 
Markern dienen, um Patienten zu erkennen, die ein erhöhtes Risiko haben, ein kardiovaskuläres Ereignis 
zu erleiden. Weiterhin ermöglichen einige der identifizierten Proteine ein besseres Verständnis der 
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Wirkmechanismen des HDLs und seiner Veränderungen bei kardiovaskulären Erkrankungen. In diesem 
Zusammenhang ist von besonderem Interesse, dass für einige der verändert vorhandenen Proteine bislang 
keine Rolle im Lipoproteinmetabolismus bekannt war. Dies legt den Schluss nahe, dass die physiologische 
Rolle des HDL, sowie seine pathophysiologischen Veränderungen bei KHK , sich  über die einfache 
Regulation des Lipidmetabolismus erstreckt und weitere Prozesse, beispielsweise die unspezifische 
Immunabwehr und die Regulation des oxidativen Stresses beeinflusst. 
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Abbreviations 
A1AT alpha-1-antitrypsin 
A2MG alpha-2-macroglobulin 
ABCA1 ATP binding casette transporter A1 
ABCG1 ATP binding casette transporter G1 
ACS acute coronary syndrome 
apoA-I apolipoprotein A1 
apoA-II apolipoprotein A2 
apoC-III apolipoprotein C-III 
APOL1 apolipoprotein L1 
AQUA peptide absolute quantification peptide 
Bad Bcl-2-associated death promoter 
Bcl-xL B-cell lymphoma-extra large 
Bid BH3 interacting domain death agonist 
CAD coronary artery disease 
caspase cysteine-aspartic proteases 
CETP cholesteryl ester transfer protein 
CHD coronary heart disease 
eNOS endothelial nitric oxide synthase 
EPC endothelial progenitor cells 
ESRD end stage renal disease 
FACS fluorescence-activated cell sorting  
FC fold change 
GAPDH glyceraldehyde-3-phosphate-dehydrogenase 
HDL high density lipoprotein 
HDL-ACS HDL isolated from patients with an acute coronary syndrome 
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1.1 Abstract 
Epidemiological studies suggest that reduced plasma levels of HDL cholesterol are associated with an 
increased risk of coronary artery disease and myocardial infarction.  Experimental and translational studies 
have revealed several potential anti-atherogenic effects of HDL, including beneficial effects of HDL on 
endothelial cell functions.   HDL from healthy subjects can exert direct endothelial-atheroprotective 
effects, such as stimulation of endothelial production of the anti-atherogenic molecule nitric oxide, anti-
inflammatory, anti-apoptotic, and anti-thrombotic effects. Furthermore, it has been observed that HDL 
may stimulate endothelial repair processes, involving mobilisation and promotion of endothelial repair 
capacity by circulating endothelial repair-promoting mononuclear cells.  
However, in recent clinical trials using the HDL cholesterol raising agents torcetrapib, dalcetrapib and 
niacin, no significant reduction of cardiovascular events was observed in patients with coronary disease.  
Of note, growing evidence suggests that the vascular effects of HDL can be highly heterogenous and 
vasoprotective properties of HDL are altered in patients with inflammatory or coronary disease. 
Characterization of underlying mechanisms and understanding of the clinical relevance of this “HDL 
dysfunction” are currently an active field of cardiovascular research. A greater understanding of 
mechanisms of action of HDL and its altered vascular effects is therefore crucial within the context of 
HDL-targeting therapies.  In this chapter, I will address different effects of HDL on endothelial cell 
functions and how these are altered in patients with cardiovascular disease.  Furthermore, mechanisms 
leading to the heterogeneity of HDL particles and their function will be highlighted.   
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1.2 Introduction 
Epidemiological studies have suggested that reduced plasma levels of HDL cholesterol are associated with 
an increased risk of coronary artery disease (CAD).
1-6
 Moreover, in patients with CAD that are treated 
intensely with statin and have low levels of low-density lipoprotein (LDL) cholesterol (<70 mg/dL), 
reduced HDL cholesterol levels were still predictive of major cardiovascular events.
5
 In recent years, 
various biological functions of HDL have been identified, whereby HDL may exert anti-atherogenic 
effects.
7-9
 Besides promoting macrophage cholesterol efflux and reverse cholesterol transport, HDL from 
healthy subjects has been shown more recently to exert direct vasoprotective effects, such as endothelial-
protective, anti-inflammatory and anti-thrombotic effects.
8, 10-13
 Accordingly, interventions to increase 
HDL-cholesterol levels and/or HDL-function are beeing intensely evaluated as a potential therapeutic 
strategy to reduce cardiovascular risk.  However, recent evidence suggests that the vascular effects of HDL 
are highly heterogenous and vasoprotective properties of HDL may be limited in certain patient 
populations, such as patients with coronary disease.
14-17
  
Several studies have examined the association of genetic variations leading to altered HDL cholesterol 
plasma levels with coronary disease risk. Polymorphisms in the cholesteryl ester transfer protein (CETP) 
gene, with a modestly higher HDL cholesterol levels, have been associated with a reduced coronary risk 
and a lower risk of future myocardial infarction. 
18, 19
 However, in another study lower plasma levels of 
HDL cholesterol due to mutations in the ATP binding cassette transporter A1 (ABCA1) gene were not 
associated with an increased risk of ischemic heart disease.
20
 More recently, a mendelian randomization 
analyses of a relatively common single nucleotide polymorphism in the endothelial lipase gene and other 
single nucleotide polymorphisms associated with HDL cholesterol suggest that some genetic mechanisms 
that increase plasma HDL cholesterol levels do not decrease the risk of myocardial infarction.
21
  
Recent clinical trials have not been able to demonstrate that some therapies that also increase HDL 
cholesterol levels reduce cardiovascular risk in patients with coronary disease. The Investigation of Lipid 
Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial testing the 
impact of the CETP inhibitor torcetrapib on clinical outcome showed an increase in cardiovascular events 
and total mortality, despite elevations in HDL cholesterol.
22
 Dalcetrapib, another CETP inhibitor, raised 
the HDL-cholesterol level in patients hospitalized with an acute coronary syndrome, but the trial was 
terminated before completion due to lack of clinical benefit.
23
 And very recently, HSP2-THRIVE trial 
results showed that adding extended-release niacin/laropiprant, another HDL-raising agent, to statins does 
reduce the risk of cardiovascular disease.
24
 
Taken together, these observations likely suggest that plasma HDL cholesterol level alone may not be an 
optimal therapeutic target.  Given the heterogeneity of HDL particles, greater emphasis should therefore 
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be placed on HDL functionality, especially within the context of HDL-raising therapies, since it is likely, 
that only raising of HDL with vasoprotective properties can exert cardiovascular protection.  
 Figure 1.1 Left panel – HDL from healthy subjects exerts direct vasoprotective effects, such as 
endothelial anti-inflammatory, anti-oxidative, anti-apoptotic and anti-thrombotic effects. HDL from 
healthy subjects stimulates endothelial cell nitric oxide production and promote endothelial repair after 
vascular injury. Right panel - Accumulating evidence suggests that the vascular effects of HDL can be 
highly heterogeneous. HDL loses important anti-atherosclerotic properties in patients with chronic 
inflammatory diseases, such as coronary artery disease. These proinflammatory HDL particles have been 
termed HDL dysfunction.  
Importantly, accumulating evidence suggests that the vascular effects of HDL can be highly 
heterogeneous.
25
  We and others have observed that HDL loses important anti-atherosclerotic properties in 
patients with chronic inflammatory disorders, such as the antiphospholipid syndrome,
26
 systemic lupus 
erythematosus and rheumatoid arthritis,
27
 scleroderma,
28
 the metabolic syndrome,
29
 diabetes,
14, 30
 and 
coronary disease.
16, 17, 31
 Notably, in a study of 189 patients with chronic kidney disease on hemodialysis 
an impaired anti-inflammatory capacity of HDL was correlated with a poor clinical outcome.
32
 
Furthermore, HDL isolated from subjects with type 1 or type 2 diabetes mellitus or abdominal obesity had 
reduced capacity to reverse the inhibition of aortic ring endothelium-dependent relaxation by oxLDL as 
compared to HDL from healthy control subjects.
30, 33, 34
 These proinflammatory HDL particles have been 
termed ’dysfunctional’ HDL. The heterogeneity of the vascular effects of HDL may be attributed to 
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changes in the HDL-associated proteome and lipids, i.e. post-translational protein modifications and 
changes in the amount and type of proteins and lipids bound to the HDL particle.  In particular, high-
density lipoprotein is susceptible to oxidation/modification in vitro by a variety of oxidants, such as metal 
ions, peroxyl and hydroxyl radicals, aldehydes, various myeloperoxidase (MPO)-generated oxidants, 
lipoxygenase, phospholipase A2, elastase, non-enzymatic glycation and homocysteinylation.
35
  
In this chapter, I will address different mechanisms whereby HDL exert effects on endothelial cell 
functions. In particular, the effects of HDL on the regulation of endothelial nitric oxide synthase (eNOS) 
and endothelial cell NO production, endothelial inflammatory activation, endothelial apoptotic regulation, 
endothelial repair from vascular injury, lipid oxidation and endothelial thrombotic activation will be 
discussed.  Importantly, recent advances highlighting the pathophysiology of HDL dysfunction affecting 
these endothelial effects of HDL will be explored. 
1.3 Effects of HDL on lipid oxidation  
1.3.1 Effects of HDL from healthy subjects on lipid oxidation 
Oxidation of LDL has long been suggested as a relevant mechanism for atherogenesis.
36, 37
 LDL is 
entrapped in the subendothelial space where it is subject to oxidative modification through the reactive 
nitrogen species, myeloperoxidase pathways and others.
38
  Once formed, oxidized LDL (oxLDL) is a 
potent inducer of inflammatory molecules.
39
 OxLDL also promotes the differentiation of monocytes into 
macrophages that take-up oxLDL in a process that converts them into foam cells, hallmark cells of 
atherosclerotic plaques.
40
  
Hessler et al. early on reported that HDL protects against LDL-induced cytotoxicity.
41
 HDL was 
demonstrated to prevent LDL oxidation by cultured endothelial cells.
42-44
 HDL is a major carrier of lipid 
peroxidation products,
45, 46
 which are thought to play an important role in the initiation and progression of 
atherosclerotic vascular disease.
47
 HDL can directly inhibit oxidation of low-density lipoprotein via 
transfer of oxidation products from LDL to HDL.
45
 In addition, circulating HDL accumulates oxidized 
phospholipids, such as hydroperoxides, lysophosphatidylcholine (lyso-PC) and F2-isoprostanes. 
45, 46
 The 
transfer of lipid hydroperoxides from LDL prevents the initiation of a free radical chain reaction of 
oxidation.
48
 Furthermore, some of the advanced products of phospholipid oxidation may serve as ligands 
for scavenger receptor type B (SR-B) and promote uptake of modified lipoproteins by macrophages as 
well as prothrombotic effects mediated by platelet scavenger receptor CD36.
49, 50
  
A study by Navab et al. demonstrated that apoA-I binds to and removes lipid hydroperoxides of LDL in 
vitro and in vivo.
48
 ApoA-I and an apoA-I peptide mimetic removed seeding molecules, 
hydroperoxyoctadecadienoic acid (HPODE) and hydroperoxyeicosatetraenoic acid (HPETE), from human 
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LDL, rendering LDL resistant to oxidation by human artery wall cells.
48
 Furthermore, Injection of apoA-I, 
but not apoAII or murine serum albumin, into mice rendered their LDL resistant to cell-mediated 
oxidation. Infusion of apoA-I into humans also rendered their LDL resistant to cell-mediated oxidation.
48
 
Treatment of human artery wall cells with apoA-I, but not apoA-II, or treatment with an apoA-I peptide 
mimetic, or with normal HDL, or paraoxonase, also rendered the cells unable to oxidize LDL.
51
 
Human HDL can also directly reduce cholesteryl ester hydroperoxides and phosphatidylcholine 
hydroperoxides via Met residues 112 and 148 of apoA-I.
52
 Recombinant HDL containing only apoA-I and 
1-palmitoyl-2-oleoyl-phosphatidylcholine (POPC) was as effective as native HDL in preventing LDL 
oxidation, supporting a key anti-oxidant role for apoA-I.
53
 Multiple in vivo studies have demonstrated that 
apoA-I is a potent anti-oxidative, anti-inflammatory and anti-atherosclerotic agent.
7, 54-58
 Recent clinical 
studies have demonstrated that although very high HDL–cholesterol and large-size HDL particles are 
associated with a twofold increase in cardiovascular risk,
59
 a high concentration of apoA-I is an 
independent negative predictor of cardiovascular risk.
59, 60
  
Interestingly, several other HDL-associated apolipoproteins have also been shown to exert anti-oxidant 
effects.  ApoA-II-enriched HDL from mice transgenic for human apoA-II protected VLDL from oxidation 
more efficiently than control HDL.
61
 However, in other studies, overexpression of human apoA-II in 
dyslipidemic mice accelerates atherosclerosis and reduces antioxidative activity of HDL.
62, 63
 The authors 
postulated that the proatherogenic actions of apoA-II may be related to the displacement of apoA-I and 
PON1 by apoA-II from HDL particles.
62
 
Meanwhile, apolipoprotein E has been shown to have allele-specific anti-oxidant activity.
64
 
Apolipoprotein E2 stimulates endothelial nitric oxide (NO) release and has anti-inflammatory activities.
65
 
In contrast, apolipoprotein E4 has been described as pro-inflammatory.
66
 It has also been reported that 
HDL-associated apolipoprotein J can inhibit LDL oxidation by artery wall cells.
67
 In addition, apoA-IV 
has been demonstrated to exert anti-oxidant, anti-inflammatory and anti-atherosclerotic actions in vivo.
68-70
 
Notably, HDL carries other anti-oxidant enzymes that may be involved in prevention of lipid oxidation or 
degradation of lipid hydroperoxides, such as PON1, LCAT and platelet-activating factor acetylhydrolase 
(PAF-AH). In particular, PON-1 has been suggested to be an important regulator of the anti-atherogenic 
capacity of HDL.
71, 72
 Various studies have suggested that the direct anti-oxidant effect of HDL on LDL 
oxidation, measured as a reduction in lipid peroxides, is to a significant extent mediated by PON1.
73-75
 
PON1 enhances cholesterol efflux from macrophages by promoting HDL binding mediated by ABCA1.
76
 
This effect of PON1 can indirectly reduce pro-inflammatory signalling in cells in vivo and contribute to 
the anti-atherosclerotic effects of PON1.
71, 72
 Mice deficient in PON1 displayed significantly larger aortic 
atherosclerotic lesions as compared to their wild type controls and HDL isolated from PON1-deficient 
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mice was unable to prevent LDL oxidation in a cell co-culture model of the arterial wall.
71
 Moreover, 
signs of oxidative stress, vascular inflammation and thrombotic activation have been observed in PON1-
deficient mice.
77
 In human studies, higher PON1 activity is associated with a lower incidence of major 
cardiovascular events.
78
 Pathological conditions associated with oxidative stress, such as chronic renal 
failure, rheumatoid arthritis and Alzheimer’s disease, are frequently associated with reduced activity of 
PON1.
78
 Furthermore, a pro-atherosclerotic high-fat diet leads to reduced PON1 activity.
78
 
The anti-oxidant role of LCAT has been nicely illustrated by a study demonstrating its capacity to directly 
hydrolyse oxidized polar phospholipids.
79
 PAF-AH is another HDL-associated enzyme that can hydrolyse 
oxidized phospholipids.
80, 81
 Lipoproteins isolated from mice expressing human PAF-AH are more 
resistant to oxidative stress, inhibit foam cell formation and promote cholesterol efflux in macrophages.
81
 
In arteries of non-hyperlipidaemic rabbits, local expression of PAF-AH reduced the accumulation of 
oxidatively modified LDL without changing plasma levels of PAF-AH and reduced the expression of 
endothelial cell adhesion molecules.
82
 In human studies, PAF-AH deficiency through a missense mutation 
of the gene is an independent risk factor for coronary artery disease in Japanese men.
83
 Circulating levels 
of PAF-AH is also shown to be an independent marker of the risk of CAD.
84
  
HDL has also been shown to promote efflux of 7-ketocholesterol
85, 86
 at sites of inflammation and thereby 
reduces endothelial cell inflammatory activation.
87
 Accordingly, Nicholls et al. have reported that 
reconstituted HDL inhibits superoxide production and vascular inflammation induced by a non-occlusive 
carotid periarterial collar in normocholesterolemic rabbits.
88
 In addition, Van Linthout et al. have observed 
that human apoA-I gene transfer in rats with streptozotocin-induced diabetes mellitus resulted in a 1.9-fold 
increase in HDL cholesterol levels and inhibition of angiotensin II type 1 receptor-mediated NAD(P)H 
oxidase activation and generation of reactive oxygen species.
89
  
1.3.2 Alterations of the effects of HDL on lipid oxidation after surgery and in CAD or 
diabetes 
Early studies by van Lenten et al. have demonstrated that the anti-inflammatory capacity of HDL is 
affected by acute phase responses in both humans and rabbits.
90
 The authors isolated human HDL from the 
patients before and immediately after surgery and characterized the effects of HDL on LDL-induced 
monocyte transmigration and lipid hydroperoxide formation.
90
 Before cardiac surgery, HDL completely 
inhibited the LDL-induced increase in monocyte transmigration and lipid hydroperoxide formation. In 
marked contrast, “acute phase” HDL obtained from the same patients 2-3 days after surgery amplified the 
LDL-induced monocyte transmigration and was less effective in inhibiting lipid hydroperoxide formation, 
i.e. HDL in the same patient had been transformed from an anti-inflammatory towards a pro-inflammatory 
particle.
90
 Interestingly, the changes in HDL functionality in this study were paralled by an increase in 
Chapter 1 Regulation of endothelial functions by HDL: From physiology to pathophysiology 
 
 
8 
 
HDL-associated acute phase reactants (i.e. coeruloplasmin and serum amyloid A), while the activities of 
the HDL-associated anti-oxidant enzymes paraoxonase and platelet-factor activating acetylhydrolase were 
reduced in acute phase HDL.
90
 Similarly, an acute Influenza A infection in wild type mice progressively 
impaired the ability of HDL to inhibit LDL oxidation and LDL-induced monocyte chemotactic activity in 
human artery wall cell cocultures up to 9 days after inoculation.
91
  
In marked contrast to the anti-oxidative and anti-inflammatory effects of HDL from healthy subjects, HDL 
from normolipidemic patients with angiographically confirmed CAD increased LDL-induced monocyte 
chemotactic activity by human artery wall cells and promoted LDL oxidation.
92
 A subsequent study by 
Ansell et al suggested that the capacity of HDL to alter LDL-induced monocyte chemotactic activity in 
patients with CAD was somewhat improved after 6 weeks of simvastatin therapy.
31
 However, HDL from 
patients with CAD on statin therapy remained proinflammatory in contrast to HDL from age- and sex-
matched healthy subjects. 
Navab et al. developed a fluorescent cell-free assay to detect the capacity of HDL to inhibit the oxidation 
of LDL, or inhibit the oxidation of l-α-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine 
(PAPC) by hydroperoxyoctadecadienoic acid (HPODE), or inactivate oxidized PAPC (Ox-PAPC).
93
 Using 
this assay, HDL isolated from 27 patients with coronary atherosclerosis failed to inhibit the fluorescent 
signal generated by a control LDL, whereas HDL from 31 matched normal subjects with the same levels 
of HDL cholesterol significantly inhibited the signal.
93
 
The presence of oxidized lipids in HDL has been proposed to play a role in the altered anti-oxidant 
properties of HDL.
94
 Administration of apoA-1 mimetic peptides, L-4F, to apoE deficient mice has been 
shown to reduce plasma levels of oxidized fatty acids (15-HETE, 5-HETE, 13-HODE and 9-HODE ) and 
improve the HDL anti-oxidant capacity and the capacity of HDL to inhibit LDL-induced monocyte 
chemotactic activity in cultured human aortic endothelial cells.
95
 Moreover, in a recent study by 
Morgantini et al., HDL from patients with type 2 diabetes had impaired anti-oxidant properties and 
increased oxidized fatty acids content.
96
 The authors postulated that elevated content of oxidized fatty 
acids (5-HETE, 9-HETE, 12-HETE, 15-HETE, 9-HODE, and 13-HODE) in HDL isolated from the type 2 
diabetics patients may account for the impaired anti-oxidant properties of the lipoprotein.
96
   
1.4 Effects of HDL on endothelial NO-synthase dependent Nitric Oxide production 
and alterations in cardiovascular disease 
1.4.1 Effects of HDL from healthy subjects on endothelial NO synthase  
Endothelial nitric oxide (NO) plays a crucial role in the regulation of vascular tone and structure. 
Endothelial NO synthase derived NO has been shown to exert a variety of atheroprotective effects in the 
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vasculature, such as anti-inflammatory  and anti-thrombotic  effects.
97
 Reduced endothelial NO 
bioavailability has therefore been suggested to promote initiation and progression of atherosclerosis.
97
  
Accumulating evidence suggests that HDL can directly stimulate endothelial NO synthase mediated NO 
production as well as induce endothelium dependent, NO-mediated vasodilation via endothelial SR-BI.
10
 
Of note, experimental studies have consistently demonstrated the capacity of HDL to modulate eNOS 
expression and to stimulate endothelial NO production in vitro and in vivo.
11, 14, 16, 98-100
 Moreover, in 
human studies, administration of reconstituted HDL has been shown to improve endothelial function in 
subjects with hypercholesterolemia and in subjects with isolated low HDL due to heterozygous loss-of-
function mutations in the ABCA-1 gene locus.
101, 102
 
Several mechanisms have been proposed to account for the endothelial NO-stimulating capacity of HDL. 
Early studies have shown that HDL prevents oxidized LDL-mediated eNOS displacements from caveolae 
and restores enzyme stimulation.
103
 A study by Yuhanna et al. suggested that HDL can bind to endothelial 
SR-BI and thus directly stimulate eNOS-mediated NO production.
10
 HDL binding to SR-BI initiates 
tyrosine kinase Src-mediated activation of phosphoinositide (PI) 3-kinase, which in turn activates Akt and 
the MAP kinase/extracellular signal-regulated kinase pathway.
99
 Activation of endothelial Akt by HDL 
stimulates phosphorylation of eNOS at serine residue 1177,
11, 99
 which is known to be an important 
regulatory mechanism leading to eNOS activation.
104
 
Another mechanism has also been identified whereby HDL can maintain endothelial cell NO production 
and availability in mice fed a high-cholesterol diet.
85
 These authors suggested that HDL-induced ABCG1-
mediated efflux of oxysterols from endothelial cells plays a role since 7-ketosterol, a dietary oxysterol, 
accumulated in endothelial cells of ABCG1- deficient mice on a western diet.
85
 Interestingly, incubation of 
human aortic endothelial cells with HDL prevented 7-ketosterol-induced production of reactive oxygen 
species and disruption of the active eNOS dimer. Furthermore, HDL-mediated cholesterol efflux via 
ABCG-1 reduced the inhibitory interaction of eNOS with caveolin-1 and thereby restored eNOS activity 
in cholesterol-loaded endothelial cells.
105
 These data suggest that the ability of HDL to preserve 
endothelial function in the presence of hypercholesterolemia may, at least in part, relate to an increased 
endothelial efflux of oxysterols. 
Various components of HDL have been suggested to play a role in its endothelial NO-stimulating 
capacity. In cultured endothelial cells, the potential interaction of apoA-I with eNOS has been reported.
100
 
However, despite being the major SR-BI ligand of HDL, lipid-free apoA-I failed to activate eNOS, 
suggesting that other HDL components are likely important for the eNOS-stimulating capacity of HDL. In 
isolated endothelial cell plasma membranes, anti-apoA-I antibody inhibits eNOS activation by HDL, 
whereas anti-apoA-II antibody further enhances eNOS stimulation by HDL.
10
 Several studies have 
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suggested that HDL-associated lysophospholipids may play a role in eNOS activation. Of note, HDL-
associated sphingosylphosphorylcholine, sphingosine-1-phosphate, lysosulfatide may cause eNOS-
dependent relaxation of precontracted aortic rings from mice via binding to the lysophospholipid receptor 
S1P3 expressed on endothelial cells.
11
 The vasodilatory response to HDL, however, was not completely 
inhibited in S1P3 deficient mice.
11
  
Recently, we observed that the HDL-associated antioxidant enzyme paraoxonase (PON) 1 as an important 
determinant of the capacity of HDL to stimulate endothelial NO production and to exert NO-dependent 
endothelial- atheroprotective effects.
16
 Inhibition of PON1 in HDL from healthy subjects impaired the 
capacity of HDL to stimulate endothelial NO production and HDL isolated from PON1-deficient mice 
failed to stimulate NO production in mouse aortic endothelial cells.
16
 Furthermore, inhibition of eNOS-
mediated NO production prevented the inhibitory effects of HDL from healthy subjects on nuclear factor 
kB (NF-kB) activity, vascular cell adhesion molecule (VCAM)-1 expression and endothelial monocyte 
adhesion, suggesting that the capacity of HDL to stimulate endothelial NO production is important for 
these endothelial anti-inflammatory effects of HDL.
16
 
1.4.2 Alterations of the effects of HDL on eNOS in patients with cardiovascular disease 
We and others have recently shown that direct endothelial effects of HDL from patients with CAD, 
diabetes, or antiphospholipid syndrome are markedly altered when compared to HDL from healthy 
subjects. In contrast to HDL from healthy subjects, HDL from patients with diabetes and low levels of 
HDL cholesterol failed to stimulate endothelial cell NO production and to promote endothelial repair in a 
carotid artery injury model in mice.
14
 We also reported that HDL from patients with antiphospholipid 
syndrome had reduced nitric oxide bioavailability and had impaired anti-inflammatory and antioxidant 
properties. Moreover, HDL from patients with either stable CAD or an acute coronary syndrome, in 
contrast to HDL from age- and gender-matched healthy subjects, inhibited rather than stimulated 
endothelial cell NO production and lost the capacity to limit endothelial inflammatory activation as well as 
to promote endothelial repair in vivo.
16
 
Notably, we have observed that malondialdehyde (MDA) content is elevated in HDL from coronary 
disease patients compared with HDL from healthy subjects, which blunts endothelial NO production.
16
 
The antagonistic action of MDA was determined to be mediated by lectin-type oxidized LDL receptor 1 
activation of protein kinase C-βII, which inhibits Akt-activating phosphorylation (Akt- Ser473) and 
eNOS-activating phosphorylation at Ser1177. Because MDA formation is decreased by HDL-associated 
paraoxonase 1 (PON1),
106
 PON1 activity was evaluated and was found to be markedly decreased in HDL 
from patients with coronary disease.
16
 Furthermore, PON1 inactivation in HDL from healthy subjects 
results in greater protein kinase C-βII activation in cultured endothelial cells, decreased activating eNOS-
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Ser1177 phosphorylation, and increased inactivating eNOS-Thr495 phosphorylation, resulting in 
attenuated NO production. Furthermore, HDL from PON1-deficient mice failed to stimulate endothelial 
cell NO production.
16
 These observations suggest that alterations of HDL-associated PON1 may have a 
major impact on endothelial effects of HDL.  
An inverse relationship between PON1 serum activity and cardiovascular events has previously been 
reported.
107, 108
 A recent analysis of SNPs for paraoxonase-1 identified in genome wide association studies 
did not reveal a significant association between the lead SNPs for paraoxonase-1, that was associated with 
mildly reduced paraoxonase activity,  and  the  risk of cardiovascular events.
109
  A difficulty with respect 
to paraoxonase-1 is that it is not known to what extent the paraoxon and arylesterase activity of the 
enzyme represent biologically relevant functions.  We and others have observed important post-
translational modifications of the enzyme, that could lead to further alterations of biological properties of 
the enzyme.
16, 110
 
1.5 Effects of HDL on endothelial inflammatory activation 
1.5.1 Effects of HDL from healthy subjects on endothelial inflammatory activation 
Atheroscleorsis is a chronic inflammatory disease.  Endothelial adhesion and subsequent infiltration and 
accumulation of monocytes/macrophages and T lymphocytes into the arterial intima represent critical 
steps in initiation and progression of atherosclerotic lesions.
47
 HDL has been shown to inhibit the 
expression of monocyte chemoattractant protein (MCP)-1, an important pro-inflammatory chemokine in 
endothelial cells.
94, 111
 Studies have demonstrated that native HDL and reconstituted HDL containing 
apoA-I or the apoA-I Milano mutant inhibit the expression of leukocyte adhesion molecules in endothelial 
cells that are activated by pro-inflammatory stimuli.
112-115
 Furthermore, HDL has been suggested to inhibit 
endothelial monocyte adhesion induced by oxidized LDL
116
 or TNF-α
115
 and monocyte transmigration in 
co-cultures of human aortic endothelial cells and smooth muscle cells stimulated with LDL.
94
  
The anti-inflammatory effects of HDL have also been demonstrated by several in vivo studies. 
Administration of reconstituted human HDL in apoE-deficient mice reduced VCAM-1 expression and 
decreased monocyte/macrophage infiltration following carotid artery cuff injury.
117
 Recently, it was shown 
that apoA-I gene transfer caused not only an increased HDL cholesterol plasma levels, but also inhibited 
diabetes-induced myocardial mRNA expression of VCAM-1 and ICAM-1 in mice with streptozotocin- 
induced diabetic cardiomyopathy.
118
 In contrast, in apoE-deficient mice with transgenic overexpression of 
human apoA-I, endothelial VCAM-1 expression was not reduced in the aortic branch sites and was not 
associated with reduced monocyte adherence, despite reducing aortic atherosclerotic lesion formation.
119
 
Hence, the anti-inflammatory capacity of HDL may be heterogeneous. This is consistent with findings of 
recent studies demonstrating that the inhibitory effects of HDL isolated from different human subjects on 
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TNF-α stimulated endothelial VCAM-1 expression varied considerably.
90, 120
 In human studies, it has been 
suggested that administration of reconstituted HDL increased the anti-inflammatory capacity of HDL from 
patients with type-2 diabetes.
121
 
Several mechanisms have been suggested to explain the inhibitory effects of HDL on endothelial 
inflammatory activation.
9
 HDL can inhibit activation of the endothelial pro-inflammatory transcription 
factor NF-κB.
114, 115
 Interestingly, impaired endothelial NO bioavailability and increased endothelial 
superoxide production have been implicated in activation of NF-κB.
122
 Furthermore, it was demonstrated 
that endothelial anti-inflammatory effects of HDL are mediated via SR-BI, PDZK1, PI3 kinase, eNOS, 
and S1P receptors.
123
 Recently, we have observed that inhibition of eNOS-mediated NO production 
prevented the inhibitory effects of HDL from healthy subjects on nuclear  factor kB (NF-kB) activity, 
vascular cell adhesion molecule (VCAM)-1 expression and endothelial monocyte adhesion, suggesting 
that the capacity of HDL to stimulate endothelial NO production is important for these endothelial anti-
inflammatory effects of HDL.
16
  
It has been proposed that apoA-1, the major protein constituent of HDL, is able to recapitulate the anti-
inflammatory capacity of HDL. In an in vivo study, infusion of apoA-I to rabbits subjected to acute 
vascular inflammation reduced neutrophil infiltration and endothelial cell inflammatory activation.
124
 
Furthermore, administration of apoA-1 mimetic peptides, D-4F and L-4F has been shown to reduce 
vascular inflammation in type I diabetic rats and improved insulin sensitivity in obese mice.
125, 126
 
Furthermore, lipid-free apoA-I and rHDL treatment reduced the expression of chemokines and 
chemokines receptors in vivo and in vitro via modulation of NF-κB and peroxisome proliferator–activated 
receptor γ.
127
 One of the potential mechanisms for the anti-inflammatory effect of apoA-I is by mediating 
cellular cholesterol efflux through ABCA1, an ATP-binding transporter.
128, 129
 Interestingly, apoA-I has 
also been shown to attenuate palmitate-induced NF-kB activation by reducing toll-like receptor-4 
recruitment into lipid rafts.
130
  
Besides apoA-I, the lipid component of HDL has also been proposed to be important for the anti-
inflammatory effects of HDL. In vitro studies using discoidal reconstituted HDL containing apoA-I as the 
sole protein suggested that inhibitory effects of HDL on endothelial cell adhesion molecule expression are 
also, at least in part, dependent on HDL-associated phospholipid species.
131
 The inhibition of cytokine 
induced expression of VCAM-1 by reconstituted HDL varied substantially when different 
phosphatidylcholine species were compared, indicating that the lipid composition of HDL influences its 
anti-inflammatory capacity and might be an important determinant of HDL functionality.
9, 131
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1.5.2 Alterations of endothelial anti-inflammatory effects of HDL   
Early studies have demonstrated that the anti-inflammatory capacity of HDL is lost during acute phase 
responses in both humans and rabbits.
90, 91
 Furthermore, the capacity of HDL to inhibit LDL-induced 
monocyte chemotactic activity has also been shown to be impaired in CAD patients,
92
 which can be 
improved following simvastatin therapy.
31
 Recent studies have also described the loss of HDL anti-
inflammatory capacity in patients with CAD, diabetes, as well as end-stage renal disease.
16, 96, 132
 
Various mechanisms have been proposed to account for the impaired endothelial anti-inflammatory effects 
of HDL. The decrease in HDL apoA-I levels in inflammatory states has been related to decreased apoA-I 
synthesis in the liver, accelerated HDL catabolism, and apoA-I replacement in HDL particles by serum 
amyloid A (SAA).
133, 134
 Upon induction of the acute phase, SAA is able to replace apoA-I in small, dense 
HDL, resulting in reduced plasma levels of apoA-I.
135-137
 In rabbits and mice, SAA can completely replace 
apoA-I in a subset of small, dense HDL particles, therefore functioning as a structural apolipoprotein.
137, 
138
 Accordingly, SAA was recently found to be enriched in HDL from ESRD patients, which correlated 
with its reduced anti-inflammatory capacity.
132
 
In addition, certain amino acid residues in apoA-I, such as methionine, cysteine, tyrosine, and lysine 
residues are susceptible to oxidative modifications
139-141
 ApoA-I isolated from plasma and human 
atherosclerotic lesions contain oxidized amino acid residues, including chlorotyrosines, nitrotyrosines and 
oxidized lysine and methionine residues.
139, 140, 142
 In vitro studies have demonstrated that MPO-catalysed 
oxidative modification of HDL or apoA-I leads to the loss of ABCA1-dependent cholesterol efflux 
function of the lipoprotein and converts HDL into a pro-inflammatory particle which promotes NF-κB 
activation and endothelial VCAM-1 expression 
139, 140, 143
  
Glycation of HDL and apoA-I, a process that is known to occur in diabetes in vivo,
144
 has also been 
proposed to impact on the anti-inflammatory capacity of HDL.
145
 In contrast to normal lipid-free Apo-AI, 
glycated lipid-free Apo-AI infusion did not decrease adhesion molecule expression following vascular 
injury.
145
 Glycation of HDL has also been shown to impair the HDL capacity to inhibit oxLDL-induced 
monocyte adhesion to human aortic endothelial cells in vitro.
146
 
1.6 Effects of HDL on endothelial apoptotic regulation 
1.6.1 Effects of HDL from healthy subjects on endothelial apoptosis 
Endothelial dysfunction and injury contribute importantly to the pathogenesis of atherosclerosis and other 
vascular disorders.
97, 147, 148
  Experimental studies have shown that atherosclerotic lesion-prone vascular 
regions are characterized by a high endothelial cell turn-over,
149
 which has been attributed to an increased 
rate of endothelial cell apoptosis. Endothelial cell apoptosis has therefore been suggested to contribute 
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importantly to the pathophysiology of coronary disease.
150-153
 The capacity of HDL to attenuate 
endothelial cell apoptosis may therefore represent a potentially important anti-atherogenic property of 
HDL.
154-157
 
HDL inhibits apoptosis of endothelial cells induced by both death-receptor-mediated and mitochondrial 
mediated apoptotic pathways. HDL may inhibit apoptosis triggered by various proatherogenic factors, 
such as TNF-α, oxidized LDL and growth factor deprivation.
154-156
 Both HDL-associated proteins and 
lipids have been suggested to contribute to the anti-apoptotic capacity of HDL. ApoA-I has been shown to 
inhibit of endothelial cell apoptosis induced by oxidized LDL, VLDL, and TNF-α.
155, 156, 158
 HDL 
subpopulations enriched with apoA-I account for approximately 70% of the anti-apoptotic activity of HDL 
in human microvascular endothelial cells that were treated with mildly oxidized LDL and reconstitution of 
HDL with apoA-I, cholesterol and phospholipids potently decreased oxidized LDL-induced apoptosis in 
these cells,
157
 suggesting that apoA-I plays an important role for the anti-apoptotic capacity of HDL in 
oxidized LDL-stimulated endothelial cells.  We have recently identified HDL-associated clusterin and 
apolipoprotein C-III to be implicated in the regulation of endothelial apoptosis in CAD.
17
 Our results 
suggest that reduced clusterin and increased apolipoprotein C-III content in HDL isolated from patients 
with CAD alters the effects of HDL on endothelial anti- and pro-apoptotic signaling pathways, leading to a 
loss of the endothelial anti-apoptotic capacity of HDL in patients with CAD.
17
  
HDL-associated lysosphingolipids have also been shown to inhibit endothelial cell apoptosis triggered by 
growth factor deprivation
154, 159, 160
 The anti-apoptotic capacity of HDL-associated lipids was further 
supported by the findings that the ratio of sphingosine-1-phosphate and sphingomyelin was increased in 
small dense HDL3 particles and positively correlated with the capacity of these HDL subpopulations to 
attenuate endothelial cell apoptosis.
161
  
Several mechanisms have been proposed for the endothelial anti-apoptotic effects of HDL, depending on 
the trigger of apoptosis. OxLDL causes a delayed but sustained increase in intracellular calcium in 
endothelial cells, leading to cell death, and this effect is reversed by HDL and mediated by prevention of 
the calcium increase.
156
 Tumor necrosis factor-α–induced endothelial cell apoptosis is also inhibited by 
HDL, and this is associated with attenuated induction of CPP32-like protease (caspase 3), which is a 
component of all primary apoptotic pathways.
155
 Growth factor deprivation activates the mitochondrial 
pathway of apoptosis, which can be suppressed by HDL. HDL inhibits the dissipation of mitochondrial po-
tential, oxygen-derived free radical generation, cytochrome c release to the cytoplasm, and activation of 
caspase 3 and caspase 9. HDL also activates Akt and causes phosphorylation of the Akt target Bcl-2-
associated death promoter Bad, preventing it from binding to Bcl-xL. Bcl-xL, an anti-apoptotic Bcl-2 
family protein, is then free to inhibit mitochondria-mediated apoptosis.
154
 In addition, HDL causes 
phosphoinositide 3 (PI3) kinase mediated up-regulation of the Bcl-xL expression.
17
 Interestingly, HDL 
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retained its anti-apoptotic activity after knockdown of eNOS using specific RNA interference or 
pharmacological inhibition using L-NAME,
17
 suggesting that HDL may exert its anti-apoptotic activity 
independently of eNOS activation. The lysophospholipid sphingosine-1-phosphate (S1P) enhances 
endothelial cell survival, and these effects are inhibited by knockdown of the S1P receptor endothelial 
differentiation gene-1/S1P1 by pertussis toxin and by phosphoinositide 3 (PI3) kinase and Erk pathway 
antagonists, suggesting that signaling by lysophospholipid components of HDL may be important for the 
inhibition of apoptosis.
160
  
 
Figure 1.2 Signaling pathways mediating the effects of HDL on endothelial NO production and 
endothelial apoptosis. HDL from healthy subjects binds to SR-BI via apoA-I, leading to PDZK1-
dependent activation of Src family kinases, PI3K and Akt, which phosphorylates eNOS at serine residue 
1177, therefore increasing eNOS activity. PI3K-dependent MAPK activation and binding of HDL-
associated lysophospholipids to the S1P3 receptor also activate eNOS. In contrast, HDL from patients with 
CAD suppresses eNOS activation. Inactivation of PON1 and greater accumulation of MDA in HDL lead 
to LOX-1-mediated activation of PKCβII and inhibit phosphorylation of eNOS at threonine 495. HDL-
associated clusterin promotes endothelial anti-apoptotic signaling via activation of PI3K and Akt leading 
to increased expression of anti-apoptotic Bcl-xL. Akt activation also phosphorylates Bcl-2-associated 
death promoter Bad, preventing it from binding to Bcl-xL, which is then free to inhibit mitochondria-
mediated apoptosis. In CAD, the level of HDL-associated clusterin is reduced, whereas HDL-associated 
apoC-III content is increased. HDL-associated apoC-III activates MAPK signaling via phosphorylation of 
p38 leading to increased activation of pro-apoptotic tBid, which promotes cytochrome C release from the 
mitochondria and downstream caspase-3 mediated apoptosis.   
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1.6.2 Alterations of the effects of HDL on endothelial apoptosis in cardiovascular disease  
Recently, we have observed that reduced clusterin and increased apolipoprotein C-III content in HDL 
isolated from patients with CAD lead to activation of pro-apoptotic signaling pathways in endothelial 
cells.
17
 In contrast to HDL from healthy subjects, HDL isolated from patients with stable CAD or an acute 
coronary syndrome failed to inhibit endothelial cell apoptosis in vitro and in apoE-deficient-mice in vivo. 
Instead, HDL isolated from these patients stimulated endothelial pro-apoptotic pathways, in particular 
p38-MAPK-mediated activation of the pro-apoptotic Bcl-2-protein tBid. Our studies further suggest that 
differences in the proteome of HDL from patients with CAD, in particular reduced HDL-associated 
clusterin and increased HDL-associated apoC-III, play an important role for altered activation of 
endothelial anti- and pro-apoptotic signaling pathways.
17
 Furthermore, oxidative modifications of HDL 
may also play a role in the loss of anti-apoptotic activity of HDL, as demonstrated by Undurti et al. 
showing that MPO-catalyzed oxidation of HDL resulted in the impaired capacity to inhibit endothelial 
apoptosis in vitro.
143
   
1.7 Effects of HDL on endothelial repair after vascular injury 
1.7.1 Effects of HDL from healthy subjects on endothelial repair processes 
Recent studies have also suggested that HDL may stimulate endothelial repair processes. Endothelial 
repair process have long been thought of to be only dependent on the proliferation and migration of local 
adjacent endothelial cells,
149
 however several recent studies have clearly demonstrated that bone-marrow 
derived endothelial progenitor cells (EPC) may promote endothelial repair after vascular injury,
162-164
 
contribute to endothelial repair processes in lesion-prone areas of experimental atherosclerosis and 
improve endothelial function.
165, 166
  
HDL stimulates endothelial repair by promotion of endothelial cell proliferation or migration and 
stimulation of the recruitment and endothelial repair capacity of EPC.
14, 167, 168
 HDL induces a marked 
increase in endothelial cell migration in vitro with effects comparable to endothelial growth factors, such 
as basic fibroblast growth factor or vascular endothelial growth factor.
160, 167, 169
 Native HDL and the HDL-
associated lysosphingolipid sphingosine-1-phosphate stimulate endothelial cell migration via sphingosine-
1-phosphate receptors S1P1 and S1P3 and the effects could be blocked by pertussis toxin which inhibits 
the interactions between G proteins and G protein-coupled receptors.
160
 The importance of sphingosine-1-
phosphate for endothelial cell migration was supported by another study demonstrating that sphingosine-1-
phosphate induced tube formation of human coronary artery endothelial cells in vitro by Ras/Raf1-
dependent ERK activation.
170
 In contrast, in a work by Seetharam et al. pertussis toxin did not affect HDL-
mediated endothelial cell migration,
167
 suggesting the presence of another pathway and agonist, which 
induces the migration of endothelial cells by HDL. Indeed, the authors observed that reconstituted HDL 
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consisting of apoA-I, palmitoyloleylphosphatidylcholine and cholesterol was able to induce endothelial 
cell migration
167
 Moreover, native HDL induced rapid changes in the actin cytoskeleton of endothelial 
cells (i.e. a decrease in stress fibers, an increase in lamellipodia, and membrane ruffling) paralleled by an 
activation of the small GTPase Rac, that is known to mediate lamellipodia formation.
167
 Interestingly, the 
authors were able to demonstrate that endothelial Rac activation and migration in response to HDL is 
independent of endothelial NO production, but requires binding of HDL to SR-BI and activation of Src 
kinase, PI3-kinase and MAP kinase.
167
 PDZ domain-containing protein PDZK1 was identified as an 
adaptor protein of SR-BI in endothelial cells and it was suggested that PDZK1 is required for the initiation 
of HDL signalling via SR-BI in endothelial cells and plays an important role for endothelial cell migration 
induced by HDL.
168
 Interestingly, further studies have suggested that HDL and SR-BI promote re-
endothelialization of the carotid artery after perivascular electric injury in mice.
14, 167
 In this model, carotid 
artery re-endothelialization was impaired in apoA-I deficient mice with low HDL levels as well as in SR-
BI deficient mice. Of note, reconstitution of apoA-I expression by liver-directed apoA-I gene transfer with 
subsequent normalisation of HDL plasma levels restored the re-endothelialization response in apoA-I 
deficient mice, strongly suggesting that apoA-I and HDL promote endothelial monolayer integrity in 
vivo.
167
 In another study, elevation of HDL levels in apoE-deficient mice induced by adenoviral human 
apoA-I (AdA-I) transfer increased the number of Flk1 / Sca-1 double-positive cells in peripheral blood and 
the number of DiIacLDL / FITC-isolectin double positive cells after 4 days of ex vivo culture of spleen 
mononuclear cells.
171
  
Besides increasing the number of EPC, AdA-I transfer in apoE-deficient mice improved the migratory 
capacity of spleen-derived early EPC in response to HDL, the adhesion of spleen-derived early EPC to 
fibronectin and the invasion of spleen-derived early EPC in solidified Matrigel.
171
 Finally, AdA-I transfer 
also promoted the incorporation of EPCs in Balb/c common carotid artery allografts transplanted 
paratopically in C57BL/6 ApoE-/- mice that was associated with an increase in endothelial regeneration 
and inhibition of transplant arteriosclerosis.
171
 In a follow-up study, the same group observed that murine 
and human early EPC express SR-BI, as indicated by immunocytochemistry analysis of human early EPCs 
and murine spleen-derived early EPCs after 4 and 7 days of ex vivo culture.
172
 Of note, the authors did not 
observe an increase in circulating Flk1 / Sca-1 double-positive cells and DiI-acLDL / FITC-isolectin 
double positive cells after ex vivo culture of spleen mononuclear cells after AdA-I transfer in mice 
transplanted with SR-BI deficient bone marrow, suggesting that expression of SR-BI in bone marrow is 
critical for EPC mobilisation induced by HDL.
172
 Furthermore, the migratory capacity of bone-marrow 
derived early EPC deficient in SR-BI in response to HDL was reduced as compared to early EPC 
containing SR-BI and this was at least in part due to an impaired activation of extracellular signal-
regulated kinases (ERK) and decreased NO production in SR-BI deficient early EPC.
172
 In vivo, SR-BI 
deficiency in bone marrow abrogated the inhibitory effect of AdA-I transfer on allograft vasculopathy 
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after paratopical transplantation of a common carotid artery of a female BALB/c donor mouse into the 
recipient male C57BL/6 mice, that was paralleled by impaired endothelial regeneration and EPC 
incorporation in allografts.
172
 Besides increasing HDL levels by adenoviral human apoA-I transfer, 
intravenous infusion of reconstituted HDL has also been shown to increase the number of Sca-1 positive 
cells in the aortic endothelium of apoE deficient mice, supporting a role for HDL in promoting progenitor-
mediated endothelial repair.
173
 Furthermore, intravenous injection of reconstituted HDL increased blood 
flow recovery and capillary density in a murine ischemic hindlimb model.
174
  
Of note, a pivotal role for eNOS in the regulation of EPC mobilization was shown with eNOS-deficient 
mice, which show impaired capacity to mobilize EPCs and impaired function of isolated EPCs.
175
 Studies 
have demonstrated that colony-forming capacity and migratory function of circulating EPCs are impaired 
in conditions associated with reduced NO bioavailability, suggesting a link between eNOS activity and 
EPC function.
176, 177
 The effects of HDL on circulating EPCs may also involve increasing cell survival and 
prevention of apoptosis. HDL prevents apoptosis of circulating EPCs through inhibition of caspase-3 
activity.
178
 Furthermore, administration of D-4F has been shown to cause EPCs to produce a robust 
increase in eNOS and heme oxygenase-1 thereby enhancing its survival which may contribute to vascular 
repair in diabetic rats.
125
 
1.7.2 Alterations of the effects of HDL on endothelial repair processes in diabetes or CAD 
Reconstituted HDL has been described to improve EOC availability in patients with type 2 diabetes, which 
were previously been shown to have reduced availability and impaired function of EOCs.
179
 Meanwhile, 
HDL from patients with type 2 diabetes has recently been found to have a diminished capacity to stimulate 
endothelial cell proliferation, migration and adhesion to extracellular matrix and this impairment is 
associated with down regulation of SR-BI expression.
180
 Notably, we have observed that HDL from 
patients with CAD has impaired endothelial repair capacity following vascular injury in vivo using nude 
mice carotid artery injury model.
16
    
1.8 Effects of HDL on endothelial thrombotic function 
1.8.1 Effects of HDL from healthy subjects on endothelial thrombotic function 
Studies have shown that patients with arterial atherothrombosis have lower plasma levels of large HDL 
particles,
181-183
 and an inverse relationship between the abundance of large HDL particles and the 
recurrence of adverse arterial events has been documented.
184
 There has been some direct evidence 
demonstrating the anti-thrombotic actions of HDL. Infusion of reconstituted HDL limits the development 
of a procoagulant state in healthy volunteers given low doses of endotoxin.
185
 In a rat model of acute 
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arterial thrombosis, infusion of apoA-I Milano caused a prolongation in the time of thrombus formation 
and a reduction in the weight of the thrombus.
186
  
One potential mechanism contributing to the anti-thrombotic effects of HDL is the increased endothelial 
prostacyclin synthesis, which can modify thrombosis as well as other intravascular events. Prostacyclin 
acts synergistically with NO to induce vascular smooth muscle relaxation, inhibit platelet activation, and 
diminish the release of growth factors that stimulate the local proliferation of smooth muscle cells.
187
 
Incubation with native HDL increases prostacyclin production in cultured endothelial cells,
188, 189
 and the 
effects can be recapitulated partially by delipidated HDL,
190
 suggesting that both HDL-associated lipids 
and  apolipoproteins are involved in the process. Prostacyclin release has also been shown to increase 
when isolated rabbit and rat hearts are infused with HDL.
191, 192
 The impact of HDL on prostacyclin 
production in endothelium occurs by both the provision of arachidonate
188, 190, 193
 and upregulation of Cox-
2 expression.
194, 195
 It has also been shown that HDL3 induces Cox-2 expression and prostacyclin release 
via a p38 MAP kinase/CREB-dependent pathway in endothelium.
195-198
. Recently, it was demonstrated 
that apoA-I, but not apoA-II, induced the expression of Cox-2 and the production of prostacylcin through 
the p38 MAPK, ERK1/2 and JAK2 pathways via ABCA1 in endothelial cells.
199
 Involvement of SR-BI 
mediated PI3K-Akt-eNOS signaling in HDL-induced Cox-2 expression and prostacyclin release in 
endothelial cells has also been reported.
200
 
Increased tissue factor and selectin expression on platelets and endothelial cells have been identified as 
critical factors in the initiation of thrombus formation. The phospholipid components of HDL have been 
demonstrated to contribute to the downregulation of E-selectin expression on endothelial cell surfaces.
9, 194
  
Furthermore, reconstituted HDL has been shown to downregulate thrombin-induced endothelial cell tissue 
factor expression in vitro.
201
 HDL has also been shown to exert antithrombotic effects by inhibiting 
platelet activation. The administration of reconstituted HDL to humans or the infusion of apoA-I Milano 
into rats inhibits platelet aggregation.
185, 202
 HDL may regulate platelet function by downregulating the 
release of platelet activating factor or by upregulating NO synthesis and release from endothelial cells.
195, 
203
 HDL also downregulates the biosynthesis of thromboxaneA2 (TxA2) and upregulates prostacyclin 
production which can decrease platelet aggregation as well as blunt leukocyte-endothelial cell interactions 
and thereby prevent the initiation and progression of atherogenesis.
204
  
 1.8.2 Alterations of the effects of HDL on endothelial thrombotic function in patients with 
diabetes 
While there is no direct evidence showing that the anti-thrombotic actions of HDL may be impaired in 
inflammatory conditions, the involvement of PI3K-Akt-eNOS pathways
200
 and also p38 MAPK, ERK1/2 
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and JAK2 pathways
195, 199
 in HDL-induced Cox2 expression and prostacyclin release suggests that 
disruption in these pathways may likely lead to altered thrombotic actions of HDL on endothelial cells.  
However, interestingly, a study showed that oxidized HDL strongly inhibits platelet activation and 
aggregation.
205
 This anti-thrombotic action of oxidized HDL is mediated by SR-BI but independently of 
eNOS/Akt pathway.
205
 More recently, HDL from patients with early stages of type 2 diabetes has been 
reported to upregulate Cox-2 expression and prostacyclin release in endothelial cells, mediated via S1P 
receptors.
206
 The authors suggest that the increased in HDL-associated S1P levels in the early stage of type 
2 diabetes may contribute to the anti-thrombotic actions of HDL indicating a compensatory protective 
mechanism during the early course of the disease.
206
     More studies will be needed in this area to better 
understand the interaction between HDL and thrombotic pathways. 
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1.10 Motivation of the PhD thesis 
As highlighted in this chapter, plasma HDL cholesterol level is not an optimal therapeutic target. 
Given the heterogeneity of HDL particles, there needs to be a greater understanding of the quality and 
function of HDL, which may be mechanistically more important in relation to cardiovascular disease. 
It is increasingly evident that not all HDL particles are equally protective, and current clinical assays 
that simply measure the total quantity of HDL cholesterol fail to capture the qualitative functional 
differences. It remains unclear which function(s) of HDL are truly relevant for its cardiovascular 
effects. Furthermore, it also remains to be determined which alterations in the HDL particles that may 
account for its impaired vascular-protective properties. Therefore, there is a need for a better 
understanding of the mechanisms of action of HDL as well as a better characterization of the HDL 
particles. These goals form the foundation of my PhD thesis, the specific aims of which I elaborate 
further in detail below. 
The first aim of my PhD thesis was to investigate the effects of HDL isolated from patients with CAD 
as compared to HDL from healthy subjects on endothelial function and to characterize the 
mechanisms leading to impaired vascular effects of HDL in patients with CAD, in particular the 
effects of HDL on endothelial apoptotic signaling pathways. Endothelial dysfunction, manifested as 
reduced endothelial nitric oxide availability, pro-inflammmatory activation and endothelial cell 
apoptosis, has been recognized as key mechanisms in the development and progression of 
atherosclerosis and other vascular disorders. The capacity of HDL to protect against endothelial 
dysfunction may therefore represent an important anti-atherogenic property of HDL. We found that 
HDL isolated from patients with CAD has impaired endothelial-protective capacity; findings that 
have consistently been reproduced also by other groups. More importantly, we found that this 
dysfunction is mediated via activation of specific signaling pathways in endothelial cells, suggesting 
that HDL from these patients carry a different sets of cargo that lead to the alterations in the vascular 
effects of HDL. This brings me to the second and third aims of my thesis.  
As we learned that HDL isolated from patients with coronary disease is rather pro-inflammatory, it is 
of great interest to understand the effects of raising HDL from these patients. In order to test the HDL 
function hypothesis, we need to develop new metrics for assessing HDL function, instead of relying 
solely on HDL cholesterol level. The second aim of my thesis was to optimize cell-based assays that 
allow for relatively high-throughput assessment of the endothelial effects of HDL. Based on our 
earlier observations, we found that different endothelial effects of HDL may be accounted for by 
different components of HDL. Using these cell-based assays, we evaluated whether treatment that 
raise HDL cholesterol level may modulate the effects of HDL from patients with coronary disease on 
endothelial function.    
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Finally, in order to elucidate the mechanisms of action of HDL and its altered vascular effects in 
cardiovascular diseases, there is a need to characterize HDL cargo. The third aim of my thesis was to 
use targeted proteomics to investigate changes in the protein compositions of HDL that may modulate 
its function in coronary artery disease. The goal of this quantitative proteomics analysis of HDL was 
to identify novel candidate proteins that may provide new insights into the mechanisms of action of 
HDL and its alterations in cardiovascular disease.   
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2.1 Abstract 
Endothelial dysfunction and injury are thought to play an important role in progression of coronary-artery-
disease (CAD).  High-density-lipoprotein from healthy subjects (HDLHealthy) has been proposed to exert 
endothelial anti-apoptotic effects that may represent an important anti-atherogenic property of the 
lipoprotein.  The present study therefore aimed to compare effects of HDLCAD and HDLHealthy on activation 
of endothelial anti- and pro-apoptotic pathways and to determine which changes of the lipoprotein are 
relevant for these processes. 
HDL was isolated from patients with stable CAD (HDLsCAD), an acute coronary syndrome (HDLACS) and 
healthy subjects.  HDLHealthy induced expression of the endothelial anti-apoptotic Bcl-2 protein Bcl-xL and 
reduced endothelial cell apoptosis in vitro and in apoE-deficient-mice in vivo. In contrast, HDLsCAD and 
HDLACS did not inhibit endothelial apoptosis, failed to activate endothelial Bcl-xL and stimulated 
endothelial pro-apoptotic pathways, in particular p38-MAPK-mediated activation of the pro-apoptotic Bcl-
2-protein tBid. Endothelial anti-apoptotic effects of HDLHealthy were observed after inhibition of 
endothelial nitric-oxide-synthase and after delipidation, but not completely mimicked by apoA-I or 
reconstituted HDL, suggesting an important role of the HDL-proteome. HDL proteomics analyses and 
subsequent validations and functional characterizations suggested a reduced clusterin- and increased apoC-
III-content of HDLsCAD and HDLACS as mechanisms leading to altered effects on endothelial apoptosis. 
In this chapter, I will present a study that demonstrates for the first time that HDLCAD does not activate 
endothelial anti-apoptotic pathways, but rather stimulates potential endothelial pro-apoptotic pathways. 
HDL-proteome remodeling plays an important role for these altered functional properties of HDL. These 
findings provide novel insights into mechanisms leading to altered vascular effects of HDL in coronary 
disease.  
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2.2 Introduction 
Reduced plasma levels of HDL cholesterol are associated with an increased risk of coronary artery disease 
(CAD).
1
 Moreover, in patients with CAD that are treated with statin and have low levels of low-density 
lipoprotein (LDL) cholesterol, reduced HDL cholesterol levels were predictive of major cardiovascular 
events.
2
 Besides promoting reverse cholesterol transport,
3, 4
 HDL has been demonstrated to exert anti-
atherosclerotic effects, including anti-inflammatory properties and stimulation of endothelial nitric oxide 
(NO) production.
5-9
  However, these effects of HDL have been observed to be highly heterogenous in 
patients with CAD or diabetes.
10-12
 
Endothelial dysfunction and injury are thought to contribute importantly to the progression of CAD.
13-15
  
Experimental studies have indicated that atherosclerotic lesion-prone vascular regions are characterized by 
a high endothelial cell turn-over,
16
 which has been attributed to an increased rate of endothelial cell 
apoptosis. Moreover, superficial atherosclerotic plaque erosion with loss of an intact endothelial cell 
monolayer is observed quite frequently in patients with an acute coronary syndrome (ACS) based on 
pathological
17, 18
 as well as on observations from clinical high-resolution intracoronary imaging studies.
19
  
In pathological studies of coronary atherosclerotic plaque erosion thrombi were observed in direct contact 
with the intima in areas with absent endothelium likely promoting disease progression.
17
  Endothelial cell 
apoptosis has therefore been suggested to contribute importantly to the pathophysiology of coronary 
disease.
20-22
 The capacity of HDL to attenuate endothelial cell apoptosis may therefore represent a 
potentially important anti-atherogenic property of HDL.
23-26
 
However, as described above, the vascular effects of HDL can be highly variable in patients with 
cardiovascular disease, a phenomenon referred to as “HDL dysfunction”.
10, 12, 27
  The present study was 
therefore designed to compare the effects of HDL from patients with stable CAD or an ACS and healthy 
subjects on endothelial anti-apoptotic and pro-apoptotic signaling pathways.  Moreover, we aimed to 
characterize alterations in HDL from patients with CAD that may lead to altered functional properties of 
HDL with respect to activation of endothelial anti-apoptotic and pro-apoptotic signaling pathways.   
2.3  Methods 
An expanded description of the methods is available in Supplementary Methods. 
Patient Characteristics.  Patients with stable CAD or an ACS (STEMI or NSTEMI) and healthy subjects 
(without cardiovascular risk factors) were recruited at the University Hospital of Zurich.  Exclusion 
criteria were accompanying infectious, inflammatory or autoimmune disorders, advanced kidney or liver 
failure, diabetes, neoplastic disorders and a history of major surgery or trauma within the previous month.  
Chapter 2 Altered activation of endothelial apoptotic pathways by HDL in CAD: Role of proteome remodeling 
 
 
38 
 
Isolation of High-Density Lipoprotein and HDL-delipidation. HDL was isolated by either sequential 
ultracentrifugation (d=1.063-1.21g/ml) or gel filtration chromatography. For proteomics studies and 
functional studies HDL was delipidated using methanol/chloroform extraction.  Detailed description of the 
methods is provided in Supplementary Methods.  
Measurement of Endothelial Cell Apoptosis In Vitro. Endothelial apoptosis was measured by FACS 
analysis with annexin-V-staining or TUNEL assay, as well as using fluorescence microscopy with 
annexin-V-staining. Caspase-3 activity was measured using a colorimetric assay. Detailed description of 
the methods is provided in Supplementary Methods.  
Measurement of Endothelial Cell Apoptosis In Vivo using FACS Analysis and Active Caspase-3 
Staining.  Male apoE(-/-).C57BL/6 mice, aged 12-16 weeks, were used for tail-vein injection of HDL 
(14mg HDL-protein/kg body-weight), following anaesthesia with inhalation of isoflurane(3%). Twenty-
four hours after the injection of HDL or PBS-buffer, mice were euthanized and the aorta were harvested 
and immediately digested for FACS analysis of endothelial cell apoptosis or fixated for histological 
staining.  For detailed description of the methods, please refer to the Supplementary Methods.  
Biochemical Validation of HDL-associated Proteins.  ELISA was used for validation of changes in 
clusterin-(BioVendor R&D, USA) and apoC-III-(AssayPro, USA) content of HDL. 
Western Blot analysis. Phosphorylation of Akt at serine residue473, phosphorylation of MAPK-p38 and 
expression of Bcl-2, Bcl-xL, tBid, Bak were determined by western blot analysis. Anti-human phospho-
Akt(Ser473), anti-human total Akt, anti-human phospho-p38-MAPK, anti-human total p38-MAPK were 
purchased from Cell Signaling Technology. Antibodies against human Bcl2, Bcl-xL, tBid and Bak were 
from Cell Signaling Technology.   
Statistical Analysis. All data are expressed as mean±SEM. All analyses were performed with SPSS 21.0 
(IBM SPSS). Significance was tested using Student’s-t-test and
 
ANOVA with Dunnett post-hoc test for 
multiple comparison
 
analysis. A value of p<0.05 was considered statistically significant. 
 
2.4  Results 
HDL was isolated from patients with coronary disease (HDLCAD), with either stable CAD (HDLsCAD) or an 
acute coronary syndrome (HDLACS), and age- and gender-matched healthy subjects (HDLHealthy). The 
characteristics of the study population are shown in Table 2.1.  
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Table 2.1 Characteristics of the study population. 
 
Characteristics 
Healthy  
subjects 
Stable coronary 
artery disease 
Acute coronary 
syndrome 
P-value 
  n=20 n=20 n=20  
Demographics     
Age, mean (years) 58±5 59±7 61±6 n.s 
Sex (male/female) 12/8 14/6 11/9  
BP systolic, mean (mm Hg) 119.9±8.7 127.2±17.3 121.2±16.4 n.s 
BP diastolic, mean (mm Hg) 76.6±9.1 77.9±8.4 71.6±10.5 n.s 
BMI, mean (kg/m
2
) 23±2 27±3 26±4 <0.05 
MAP, mean (mm Hg) 91.0±8.0 94.3±9.4 88.1±11.7 n.s 
Laboratory parameters     
Fasting glucose (mmol/l) 5.6±1.3 5.9±1.4 6.3±1.3 n.s 
HbA1c (in %) 5.7±0.3 5.8±0.8 5.9±0.4 n.s 
Total cholesterol (mmol/l)   5.8±0.8 4.3±0.7 4.7±1.3 <0.05 
HDL cholesterol (mmol/l) 1.9±0.5 1.3±0.3 1.3±0.3 <0.05 
LDL cholesterol (mmol/l) 3.2±0.7 2.4±0.6 3.0±1.2 n.s 
Triglyceride (mmol/l) 0.9±0.4 1.3±0.5 1.2±0.6 n.s 
CRP (μmol/l) 0.8±0.4 2.8±4.9 4.5±4.9 <0.05 
Creatinine (μmol/l) 75.6±13.3 86.6±26.0 73.1±14.3 n.s 
Medications     
Statins (in %) 0 90 75  
Beta blocker (in %) 0 70 50  
Diuretics (in %) 0 35 20  
ACE-I/ARB (in %) 0 75 75  
Calcium blocker 0 10 5  
Aspirin (in %) 0 95 100  
Clopidogrel (in %) 0 60 60  
Abbreviations: BP, blood pressure; BMI, body mass index; MAP, mean arterial pressure; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein; CRP, C-reactive protein; ACE-I, angiotensin-converting enzyme 
inhibitor; ARB, angiotensin receptor blocker. 
Reported P values are from one-way ANOVA.       
     
 
2.4.1 Effects of HDLHealthy and HDLCAD on endothelial cell apoptosis in vitro and in vivo 
HDLHealthy markedly reduced endothelial cell apoptosis in vitro, whereas in marked contrast, HDLsCAD or 
HDLACS did not limit endothelial apoptosis induced by serum and growth factor deprivation (Figures 
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2.1A-C,E-F).  Endothelial caspase-3 activity was reduced by HDLHealthy, but not after treatment with 
HDLsCAD or HDLACS (Figure 2.1D). Similarly, detection of fragmented DNA using TUNEL staining 
showed significantly attenuated endothelial apoptosis by HDLHealthy (26.7%±12.0% vs control 
41.6%±10.3%, p<0.05), but not HDLsCAD or HDLACS (36.9%±9.1% and 32.2%±13.6%, respectively).  
Furthermore, HDLHealthy but not HDLsCAD or HDLACS reduced endothelial apoptosis induced by another 
stimulus, i.e. TNF-α, as measured by annexin-V staining (Figure 2.1G) or TUNEL assay (apoptotic 
endothelial cells after HDLHealthy vs. HDLCAD 23.02%±14.4% vs. 39.7%±13.7%; p<0.05).   The rate of 
TNF-α-induced endothelial apoptosis was similar as compared to previous studies, such as the study by 
Spyridopoulos et al.
28
  reporting 39.3% apoptotic endothelial cells after TNF-α exposure.  
Moreover, we examined the capacity of HDL to impact on endothelial apoptosis in vivo by injecting 
isolated HDL to apoE-/- mice.  Administration of HDLHealthy (14mg HDL-protein/kg body weight) to 
apoE-/- mice reduced endothelial apoptosis in the aorta (harvested after 24hours) while HDLCAD did not 
reduce endothelial apoptosis as determined by Annexin-V measurement as well as immunofluorescence 
staining with TUNEL and active caspase-3 assay (Figure 2.2A-D). In these studies, we did not observe a 
significant difference between the anti-apoptotic capacity of HDLsCAD as compared to HDLACS (7.2±3.1% 
vs 6.3±3.8%; p=0.51).  
2.4.2 HDLHealthy reduces endothelial apoptosis after inhibition of endothelial NO-synthase 
Endothelial NO synthase is a potentially important regulator of endothelial apoptosis and effects of HDL 
on eNOS are adversely affected in patients with CAD.
10, 29
 We therefore examined whether the effects of 
HDL on endothelial cell apoptosis are critically dependent on eNOS. Notably, inhibition of eNOS-
mediated NO production by both, pharmacological inhibition with N-nitro-L-arginine methyl ester (L-
NAME) and eNOS-specific RNA interference did not prevent endothelial anti-apoptotic effects of 
HDLHealthy (Figure 2.3A), suggesting that HDL  activates endothelial anti-apoptotic pathways independent 
of eNOS.  
2.4.3 Role of protein moiety for endothelial anti-apoptotic capacity of HDLHealthy  
To investigate which alterations of the HDL particle may impair the capacity to limit endothelial 
apoptosis, we examined effects of the HDL protein fraction (delipidated HDL), rHDL, purified apoA-I and 
recombinant apoA-I on endothelial apoptosis.  Interestingly, delipidated HDLHealthy exerted a potent 
endothelial anti-apoptotic activity as measured by annexin-V staining (Figure 2.3B). The endothelial anti-
apoptotic effects of delipidated HDLHealthy were more profound as compared to purified or recombinant 
apoA-I or rHDL (Figure 2.3B), suggesting an important role of the HDL proteome and its remodeling for 
altered effects of HDLCAD on endothelial apoptosis. Similarly, by using TUNEL staining we observed that 
HDLHealthy and delipidated HDLHealthy significantly reduced the number of apoptotic endothelial cells 
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(22.2%±8.0% and 19.0%±14.1% vs control 37.6±10,2%, p<0.05), that was not observed with apoA-1 or 
rHDL alone (29.0%±8.7% and 25.3%±10.4%, respectively, p=0.11 and p=0.08 vs. control).    
 
 
Figure 2.1 Effects of HDLHealthy, HDLsCAD or HDLACS on endothelial apoptosis in vitro. (A) The 
impact of HDLHealthy, HDLsCAD or HDLACS (50µg/ml based on protein measurement) on endothelial 
apoptosis was determined by annexin-V staining using FACS analysis after 16 hours of serum deprivation 
(n=20 per group) (B) Representative examples of flow cytometry analyses of annexin-V staining. Dark 
grey solid line: control cells for autofluoresence, Light grey dotted line: serum withdrawal, Red line: HDL-
treated cells with serum withdrawal. (C) Endothelial apoptosis in the absence or presence of HDL 
(50µg/ml) was determined for the indicated time intervals following serum/growth factor deprivation. The 
dotted line represents buffer-treated cells with serum withdrawal. (D) Caspase-3 activity was measured 
from the lysate of endothelial cells treated with or without HDL (50µg/ml; n=20 per group). (E,F) 
Fluorescence microscopy of apoptotic endothelial cells stained with annexin-V-FITC. Number of annexin-
V+ cells was counted per high power field (average values were taken from 5 hp-fields). (G) Effect of 
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HDLHealthy, HDLsCAD or HDLACS (50µg/ml) on endothelial cell apoptosis induced by TNF-α as measured 
by annexin-V staining using FACS analysis. 
 
 
Figure 2.2 Effects of HDLHealthy, HDLsCAD or HDLACS on endothelial apoptosis in vivo. (A) 
Administration of HDLHealthy, but not HDLCAD (14mg HDL protein/kg body weight) to ApoE-/- mice via 
tail-vein injection reduced endothelial apoptosis as detected in the aorta after 24 hours (n=8-9 per group) 
as measured by co-staining of annexin-V+ and CD31+ using FACS analysis. (B) Immunofluorescence 
staining showed reduced active caspase-3 staining of endothelial cells of mouse aortic sections after 
treatment with HDLHealthy, but not with HDLCAD.  (C, D)  TUNEL-FITC staining of mouse aortic sections 
co-stained with CD31-Texas-red. Number of TUNEL+ cells / Number of CD31+ cells was counted per 
high power field and the average was taken from 5 fields.     
2.4.4 Proteomics analysis comparing HDLHealthy and HDLCAD using LC-ESI-MS/MS   
We therefore used a mass spectrometric-based approach to identify changes in HDL-associated proteins in 
coronary disease. The spectral index was used for relative quantification of each protein of interest,
30, 31
 as 
described in detail in the Supplementary Material. Based on this approach, we identified 78 HDL-
associated proteins with substantial differences in their quantitative abundance between HDLHealthy and 
HDLCAD (Figure 2.3C, Supplementary Table 2.1). We further applied gene ontology analysis to identify 
proteins that are related to regulation of apoptosis. Based on these analyses two proteins, clusterin and 
apoC-III, were selected for further assessment of their potential relevance in mediating effects of HDL on 
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endothelial apoptosis, given their differential abundance in HDLCAD and their potential role in regulation 
of apoptotic processes.  
 
Figure 2.3 Evaluation of the role of endothelial NO synthase and the effects of different HDL 
components (HDLHealthy) on endothelial apoptosis (A) HDLHealthy reduced endothelial apoptosis after 
inhibition of eNOS-mediated endothelial NO production by siRNA knockdown of eNOS or treatment with 
L-NAME (1 mM) (n=6-8 per group). Scr: scrambled. (B) Effects of HDLHealthy (50µg/ml), delipidated 
HDL (50µg/ml), apo A-1 (50µg/ml) or reconstituted HDL (50µg/ml) on endothelial apoptosis as measured 
by FACS analysis with annexin-V staining (n=6 per group). Reconstituted HDL was prepared with the 
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sodium cholate dialysis method using an apoA-I/POPC/cholesterol molar ratio of 1:80:10. (C) LC-ESI-
MS/MS analysis of HDLHealthy and HDLCAD (n=6 per group).  Proteins identified were quantified using 
spectral index and data are presented as proteins reduced or enriched in HDLCAD. 
 
2.4.5 Validation of altered clusterin levels in HDLCAD as compared to HDLHealthy and its 
relevance for endothelial anti-apoptotic effects of HDL  
Proteomics analysis indicated reduced clusterin levels in HDLCAD relative to HDLHealthy (spectral index of -
0.323) (Supplementary Table 2.1). An MS/MS fragmentation pattern of a proteotypic peptide of clusterin 
is shown in Figure 2.4A. To further validate this finding, we quantified clusterin in HDLHealthy and 
HDLCAD isolated by two different methods, i.e. ultracentrifugation and gel filtration. Independent of the 
isolation method, substantially lower clusterin levels were detected in HDLsCAD and HDLACS as compared 
to HDLHealthy (Figure 2.4B, Table 2.2).  
To further investigate a potential functional role of clusterin in HDL for effects on endothelial apoptosis, 
we pre-incubated HDLHealthy with specific clusterin blocking antibodies (Santa Cruz Biotechnology, USA) 
and supplemented HDLCAD with clusterin. Pre-incubation of HDLHealthy with clusterin-blocking antibodies 
(1:50 or 1:100 dilution), but not with an IgG isotype control, reduced endothelial anti-apoptotic effects of 
HDLHealthy in a dose-dependent manner as measured by annexin-V staining (Figure 2.4C). The presence of 
the clusterin-blocking antibody decreased the capacity of HDLHealthy to reduce endothelial cell apoptosis as 
measured by caspase-3 activity (Figure 2.4D) and TUNEL staining (apoptotic endothelial cells: 38.2±5.6% 
versus 23.1±6.2%, p<0.05). Similarly, the capacity of HDLHealthy to attenuate TNF-α-induced endothelial 
apoptosis was reduced in the presence of clusterin blocking antibody (Figure 2.4E). Vice versa, 
supplementation of HDLCAD with purified clusterin increased its endothelial anti-apoptotic effects (Figure 
2.4F). Notably, purified clusterin alone had no significant effect on endothelial apoptosis, indicating that 
binding of clusterin to the HDL particle was important for its full endothelial anti-apoptotic effects. To 
further investigate the role of HDL-associated clusterin for endothelial anti-apoptotic effects of HDL, we 
prepared reconstituted HDL with and without clusterin. Addition of clusterin to rHDL resulted in a more 
profound endothelial anti-apoptotic effect (Figure 2.4G), supporting a role of HDL-bound clusterin for 
endothelial anti-apoptotic properties of HDLHealthy. Of note, corresponding amounts of HDL-bound 
clusterin after supplementation of reconstituted HDL or HDLCAD were within a similar range as compared 
to clusterin levels observed in HDLHealthy, further supporting the concept that reduced levels of HDL-
bound clusterin in HDLCAD impact on the capacity of HDL to limit endothelial apoptosis (Supplementary 
Figure 2.1A).  
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Figure 2.4 Role of HDL-associated clusterin for effects of HDLHealthy on endothelial anti-apoptotic 
pathways. (A) MS/MS spectrum of a proteotypic peptide of clusterin. (B) Concentration of clusterin 
associated with HDLHealthy, HDLsCAD or HDLACS as quantified using ELISA. (C) HDLHealthy (50µg/ml) was 
pre-incubated with specific blocking antibody against clusterin (2-4µg/ml) and the effects of HDL on 
endothelial cell apoptosis induced by serum withdrawal were analyzed using annexin-V staining by FACS 
analysis, and (D) caspase-3 activity assay. (E) Effect of the clusterin blocking antibody on the anti-
apoptotic capacity of HDLHealthy (50µg/ml) as examined in TNF-α stimulated endothelial cells. (F) Effects 
of HDLCAD (50µg/ml) on endothelial cell apoptosis in the presence of increasing concentrations of purified 
human clusterin (2.5-10µg/ml) were determined. (G) Effects of reconstituted HDL (50µg/ml) in the 
absence or presence of clusterin on endothelial cell apoptosis were analyzed.  
2.4.6 Increased apoC-III levels in HDLsCAD and HDLACS and relevance for effects of HDL on  
endothelial apoptosis  
Based on the spectral index of the proteomics analysis, levels of apoC-III were increased in HDLsCAD and 
HDLACS as compared to HDLHealthy (spectral index of 0.197) (Supplementary Table 2.1). An MS/MS 
fragmentation pattern of a proteotypic peptide of apoC-III is shown in Figure 2.5A. To further validate this 
finding we quantified apoC-III in HDLHealthy and HDLCAD isolated by either ultracentrifugation or gel 
filtration. HDLsCAD and HDLACS were enriched with apoC-III as compared to HDLHealthy (Figure 2.5B, 
Table 2). Pre-incubation of HDLCAD with a specific blocking antibody for apoC-III (1:50 dilution), but not 
with an isotype-control-antibody, improved its capacity to reduce endothelial apoptosis, both after serum 
withdrawal (Figures 5C-F) or TNF-α-exposure (Figures 2.5G-I). Similarly, the blocking antibody against 
apoC-III increased the endothelial anti-apoptotic capacity of HDLCAD as measured by TUNEL staining 
(25.2±5.6% versus HDLCAD alone 37.1±6.2%, p<0.05). Conversely, pre-incubation of HDLHealthy with 
purified apoC-III impaired its capacity to attenuate endothelial apoptosis (Figure 2.5J). The corresponding 
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amounts of HDL-bound apoC-III after supplementation of HDLHealthy with apoC-III were in a similar 
range as compared to HDL-bound apoC-III levels observed in HDLCAD (Supplementary Figure 2.1B). 
Figure 2.5 Role of HDL-associated apoC-III for impaired endothelial anti-apoptotic effects of HDL 
in patients with CAD. (A) MS/MS spectrum of a proteotypic peptide of apoC-III. (B) The amount of 
apoC-III in HDLHealthy, HDLsCAD or HDLACS was quantified with ELISA. (C,D,E) HDLCAD (50µg/ml) was 
pre-incubated with specific blocking antibody against apoC-III (20µg/ml or 1:50 dilution) or isotype 
control and the effects of HDL on serum withdrawal induced- endothelial apoptosis were analyzed with 
annexin-V staining using FACS analysis and (F) caspase-3 activity measurement. (G,H,I) Effects of 
HDLCAD pre-incubated with a specific blocking antibody against apoC-III or isotype control on TNF-α-
induced-endothelial apoptosis were analyzed with annexin-V staining using FACS analysis. (J) Effects of 
HDLHealthy (50µg/ml) on endothelial cell apoptosis in the presence of purified human apoC-III (5µg/ml).     
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2.4.7 HDLHealthy activates the endothelial anti-apoptotic Bcl-2 protein Bcl-xL via PI3K/Akt 
pathway, whereas HDLCAD upregulates the endothelial pro-apoptotic Bcl-2 protein tBid via 
MAPK-p38 – role of HDL-associated clusterin and apoC-III. 
Further assessment of signaling mechanisms involved in effects of HDL on endothelial apoptosis showed 
that the anti-apoptotic capacity of HDLHealthy was mediated via PI3K/Akt, since PI3K inhibition by 
wortmannin or LY294002 prevented endothelial anti-apoptotic effects of HDLHealthy, whereas these anti-
apoptotic pathways were not activated by HDLCAD (Figure 2.6A). HDLHealthy phosphorylated endothelial 
Akt at Ser473, which was not observed using HDLsCAD or HDLACS (Supplementary Figure 2.2A).  
Figure 2.6 Activation of the endothelial anti-apoptotic signaling pathways by HDLHealthy. (A) Pre-
treatment of endothelial cells with PI3K inhibitors, wortmannin (100nM) or LY294002 (50µM) reversed 
the anti-apoptotic effects of HDLHealthy (50µg/ml). (B) Effects of HDLHealthy, HDLsCAD or HDLACS 
(50µg/ml) on the expression of endothelial Bcl-xL expression and (C) endothelial tBid expression  were 
assessed by western blot analysis (n=6 per group). (D) Effects of HDLHealthy (50µg/ml) on Bcl-xL 
expression in HAECs pre-treated with PI3K inhibitor as analyzed by western blot analysis. (E) Effects of 
HDLHealthy pre-incubated with specific blocking antibody against clusterin (4µg/ml) on the 
phosphorylation of Akt at Ser473, (F) Bcl-xL expression (n=6 per group), as detected by western blot 
analysis. 
Chapter 2 Altered activation of endothelial apoptotic pathways by HDL in CAD: Role of proteome remodeling 
 
 
48 
 
Our further analysis of downstream targets of HDL on endothelial apoptotic pathways revealed a 
differential regulation of anti-apoptotic and pro-apoptotic proteins from the Bcl-2 family by HDLHealthy and 
HDLCAD. HDLHealthy activated Bcl-xL, an anti-apoptotic Bcl-2 protein
32, 33
 whereas HDLCAD activated 
tBid, a pro-apoptotic Bcl-2 protein
34, 35
 (Figures 2.6B and 2.6C). No significant differences were observed 
on the expression of other Bcl-2 proteins, anti-apoptotic protein Bcl-2 and pro-apoptotic protein Bak by 
HDLHealthy and HDLCAD (data not shown). Wortmannin or LY294002 inhibited effects of HDLHealthy on 
Bcl-xL expression (Figure 2.6D). Notably, pre-incubation of HDLHealthy with clusterin blocking antibody 
reduced HDL-dependent phosphorylation of Akt at Ser473 (Figure 2.6E) and impaired upregulation of 
Bcl-xL expression  (Figure 2.6F). These findings indicate that clusterin contributes to effects of HDLHealthy 
on  stimulation of PI3K/Akt which in turn modulates endothelial expression of the anti-apoptotic Bcl-xL.  
Furthermore, assessment of the role of mitogen-activated protein kinase (MAPK) demonstrated that 
HDLCAD increased endothelial phosphorylation of p38-MAPK, whereas HDLHealthy had no effect (Figure 
2.7A). Inhibition of HDLCAD induced p38-MAPK-activation using the inhibitor SB203580 blocked the 
increase in endothelial expression of tBid (Figure 2.7B). Pre-incubation of HDLCAD with the specific 
blocking antibody against apoC-III inhibited the increased phosphorylation of p38 MAPK (Figure 2.7C) 
and the increased expression of tBid (Figure 2.7D). These observations suggest that HDL-associated 
apoC-III stimulates pro-apoptotic signaling by phosphorylation of p38-MAPK and upregulation of 
endothelial expression of pro-apoptotic tBid.  
Figure 2.7 Stimulation of the endothelial pro-apoptotic signaling pathways by HDLCAD. (A) Effects 
of HDLHealthy and HDLCAD on phosphorylation of MAPK p38 were analyzed by western blot analysis 
(n=8-10 per group). (B) Effects of HDLCAD on endothelial tBid expression pre-incubated with SB203580 
(10µM). (C) Effects of HDLCAD pre-incubated with specific blocking antibody against apoC-III on the 
phosphorylation of MAPK p38, (D) tBid expression (n=6-8 per group), as detected by western blot 
analysis.              
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2.4.8 Assessment of clusterin and apoC-III content in other lipoprotein fractions  
The content of clusterin in serum or in the LDL/VLDL fraction was not reduced in patients with CAD as 
compared to healthy subjects (Table 2.2), whereas clusterin levels were substantially lower in HDLCAD  as 
compared to HDLHealthy isolated by both ultracentrifugation or gel filtration methods, compatible with the 
concept of a reduced binding of clusterin to HDLCAD (Table 2.2).  
The apoC-III content was mainly increased in HDLCAD, but was also to some extent elevated in serum and 
the LDL/VLDL fraction of patients with CAD as compared to healthy subjects using both, 
ultracentrifugation or gel filtration lipoprotein isolation protocols (Table 2.2). These observations suggest 
a systemic increase of apoC-III levels in patients with CAD. 
 
Table 2.2  Concentrations of apolipoprotein C-III and clusterin in serum and lipoprotein fractions of 
patients with CAD and healthy subjects. 
    Healthy (n=12) CAD (n=12) P-value 
     Apolipoprotein C-III, mg/l 
   
 
Serum 129.8±23.3 180.4± 33.5 0.0003 
  
   
 
UC-HDL 84.7±17.8 112.6±28.8 0.0092 
 
UC-LDL/VLDL 35.7±20.2 62.5±18.2 0.0025 
  
   
 
FPLC-HDL 88.0±29.7 114.2±26.7 0.0277 
 
FPLC-LDL/VLDL 39.4±18.6 66.5±22.1 0.0037 
  
   
Clusterin, mg/l    
 
Serum 77.6±13.5 78.6±23.3 0.91 
  
   
 
UC-HDL 56.5±11.7 38.3±11.7 0.0026 
 
UC-LDL/VLDL 16.6±7.1 24.1±8.0 0.0244 
  
   
 
FPLC-HDL 59.0±23.0 40.4±14.6 0.0439 
 
FPLC-LDL/VLDL 16.9±8.1 25.1±12.2 0.0876 
     
UC refers to lipoprotein preparation with ultracentrifugation. FPLC refers to lipoprotein separation with 
fast protein liquid chromatography. Data are expressed as mean ± SD. P-values were determined by 
Student’s-t-test. 
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2.5 Discussion 
In the present study we have for the first time compared the effects of HDL from healthy subjects and 
from patients with CAD on endothelial cell anti- and pro-apoptotic signaling pathways.  Importantly, 
while HDLHealthy substantially reduced endothelial cell apoptosis in vitro and in vivo, no such effects were 
observed for HDL from patients with sCAD or ACS.   
Of note, our studies revealed differential effects of HDLHealthy and HDLCAD on endothelial anti- and pro-
apoptotic signaling pathways, in particular on members of the Bcl-2 family of proteins, that are critical 
regulators of apoptosis.  HDLHealthy, but not HDLCAD, activated the endothelial anti-apoptotic Bcl-xL 
pathway.  In contrast, HDLCAD activated endothelial tBid, a pro-apoptotic Bcl-2 protein.  Our studies 
further suggest that differences in the proteome of HDLCAD, in particular reduced HDL-associated 
clusterin and increased HDL-associated apoC-III, play an important role for altered activation of 
endothelial anti- and pro-apoptotic signaling pathways (Figure 2.8).  
Endothelial dysfunction and injury are thought to play an important role in initiation and progression of 
atherosclerotic CAD.
13-15
  Experimental studies have shown that atherosclerotic lesion-prone vascular 
regions such as bifurcations are characterized by high endothelial cell turn-over,
16
 likely indicating an 
increased rate of endothelial cell apoptosis.
22
 Furthermore, coronary atherosclerotic plaque erosion with 
loss of an intact endothelial cell monolayer is frequently observed in patients with an acute coronary 
syndrome,
18, 19
 and areas of endothelial denudation may promote superficial thrombosis and progression of 
coronary atherosclerosis.
17, 36, 37
  The capacity of HDL to inhibit endothelial cell apoptosis has therefore 
been suggested as an important potential anti-atherogenic property of HDL.
23-26
  
In the present study delipidated HDLHealthy exerted a more profound endothelial anti-apoptotic effect as 
compared to purified or recombinant apoA1 and reconstituted HDL, compatible with the concept that the 
HDL proteome is important for the regulation of endothelial anti-apoptotic pathways by HDL. Our HDL 
proteomics and gene ontology analysis suggested that changes in HDL-bound clusterin and apoC-III in 
HDLCAD could be relevant for altered effects on apoptosis. Subsequent validation experiments using HDL 
obtained by different preparative methods provided evidence that a reduced HDL-associated clusterin and 
an increased HDL-associated apoC-III content contribute importantly to altered effects of HDLCAD on 
endothelial apoptosis.  A previous study by Vaisar et al.
31
 on shotgun proteomics analysis of HDL 
observed a trend for a lower clusterin and a higher apoC-III content in HDL from patients with CAD 
according to the peptide index analysis, however, no validation experiments were performed.  The present 
study demonstrates for the first time that proteome remodeling in HDLCAD has direct implications on 
functional properties, i.e. vascular effects of HDL.  These findings point to a novel mechanism leading to 
altered vascular effects of HDL in patients with coronary disease, that at present is of particular interest, 
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given the disappointing results of several clinical trials examining therapeutic strategies of HDL-
cholesterol raising in these patients.  
 
Figure 2.8 Summary of major findings of the study. HDL proteome remodeling in CAD leads to altered 
effects on endothelial anti-apoptotic and pro-apoptotic pathways. HDLHealthy  carries higher amounts of 
clusterin, that upon induction of apoptosis promotes activation of endothelial PI3K/Akt leading to 
increased expression of anti-apoptotic Bcl-xL. In CAD, the level of HDL-associated clusterin is reduced, 
whereas HDL-associated apoC-III content is increased. HDL-associated apoC-III activates MAPK 
signaling via phosphorylation of p38 leading to increased activation of pro-apoptotic tBid. Our findings 
therefore suggest that  HDL proteome alterations in CAD have implications for the function of HDL with 
respect to its effects on endothelial integrity and survival. 
Clusterin overexpression via adenovirus transfection has been suggested to render endothelial cells more 
resistant against TNF-α-induced apoptosis.
38
  In the present study, however, we have examined the effects 
of HDL-bound clusterin on endothelial apoptosis using extracellular administration which represents a 
different setting as compared to overexpression in cultured cells. Notably, addition of clusterin alone did 
not result in an endothelial anti-apoptotic effect, that was only observed when clusterin was bound to HDL. 
Clusterin has been suggested to associate with apoA-I
39
 and paraoxonase-1.
40
 A recent study by Hoofnagle 
et al.
41
 observed that HDL-clusterin levels are reduced in insulin resistant men with a high body-mass-
index. It was therefore speculated that a reduced HDL-clusterin-content may have functional implications 
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for vascular effects of HDL. Of note, a potential anti-atherogenic role of clusterin has been supported by 
studies examining administration of a clusterin-peptide fragment to apoE-deficient mice and monkeys.
42
  
In a study of 6 patients with coronary disease it has been observed that combined statin/niacin therapy may 
promote higher HDL-clusterin-levels in patients with coronary disease.
43
 Our present findings provide 
novel evidence that reduced HDL-clusterin-levels are functionally important with respect to the impaired 
capacity of HDLCAD to exert endothelial anti-apoptotic effects.  
Serum clusterin levels have been reported to be increased in patients with developing coronary heart 
disease, or myocardial infarction, or type II diabetes
44
 and also in response to endotoxin and cytokines
45
. 
In the present study there was a trend towards increased clusterin-serum-levels. These observations further 
suggest that changes in the clusterin-content of HDLCAD are specific for HDL, and that the underlying 
cause is likely a reduced association of clusterin with HDL in patients with CAD rather than systemically 
reduced clusterin levels.  
We observed that HDL-associated clusterin activates via PI3K/Akt the endothelial anti-apoptotic protein 
Bcl-xL,  Bcl-xL belongs to the family of Bcl-2 proteins,
32
  has been proposed to be regulated by Akt in 
tumor cells,
46
 and was reported as an important anti-apoptotic protein in endothelial and other cell types.
33
 
The capacity of HDLHealthy to reduce endothelial apoptosis was not abolished when eNOS was inhibited, 
although the activation of PI3K/Akt was required for the anti-apoptotic activity of HDL. In line with this 
observation, a study by Suc et al. has suggested that the protective effect of HDL on endothelial cell 
survival  was not dependent on HDL-associated paraoxonase activity,
25
 that we have observed to be 
critical for the capacity of HDL to stimulate endothelial NO production.
10
  
In addition, our study demonstrates that increased levels of apoC-III associated with HDLCAD were 
responsible for activation of the pro-apoptotic p38-MAPK-signaling pathway in endothelial cells followed 
by increased expression of the pro-apoptotic protein tBid, a member of Bcl-2 family of proteins.
34, 47
 
Increased apoC-III levels have been associated with hypertriglyceridemia, metabolic syndrome and 
diabetes.
48-50
 ApoC-III inhibits the clearance of triglyceride-rich lipoproteins.
51
 A previous study has 
shown that LDL containing apoC-III was independently associated with an increased risk of CAD.
52
   
Furthermore, a recent case-control study has suggested that HDL containing apoC-III is associated with a 
higher risk of future CHD.
53
 Transfers of apoC-III between lipoprotein particles have been previously 
described.
54
 However, in the present study the apoC-III content was not only increased in the HDL 
fraction but also in the serum and the LDL/VLDL fraction of patients with CAD, suggesting an increased 
synthesis or a reduced clearance of apoC-III in patients with CAD.  
Of note, our findings do not exclude that HDL-associated lipids may also promote endothelial anti-
apoptotic effects of HDL. In particular, HDL-associated lysosphingolipids have been suggested to exert 
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endothelial anti-apoptotic effects,
23
 although this has not been observed when sphingosine-1-phosphate 
(S1P) was added to reconstituted HDL.
26
 Interestingly, however, a recent study has examined the S1P 
content of HDL in patients with coronary disease and an acute coronary syndrome.
55
 Notably, in patients 
within the first hours of an acute coronary syndrome an increased S1P content of HDL was observed, 
suggesting that it would be unlikely that an altered S1P content could explain the loss of endothelial anti-
apoptotic effects of HDL in these patients.
55
 
A recent study by Khera et al.
12
 supports the notion that HDL function may be more relevant as compared 
to HDL-cholesterol serum levels alone for development of coronary disease.  Khera et al. analyzed the 
cholesterol efflux capacity of apoB-depleted serum, that was lower in cases with coronary disease as 
compared to controls, independently of HDL-cholesterol levels.  The present study describes for the first 
time, that effects of HDL on endothelial cell apoptosis are markedly different between HDLHealthy and 
HDLCAD, that may limit the capacity of HDL to counteract clinical complications of atherosclerosis, since 
an impaired endothelial integrity has been suggested as an important mechanism promoting clinical 
complications of coronary disease. 
Study limitations. A potential limitation of the present study is the use of cardiovascular drugs in patients 
with CAD, but not in healthy subjects, that may impact on functional properties and composition of HDL. 
Previous studies have suggested that statin therapy may reduce apoC-III levels in plasma, HDL or apoB-
containing lipoproteins.
56, 57
  In the present study most patients were on statin therapy, however, apoC-III 
levels in LDL/VLDL and HDL were still higher as compared to healthy subjects. While we cannot exclude 
that medical treatment in addition to the underlying coronary disease may have impacted on altered HDL 
composition and function in patients with CAD, the present data are consistent with the notion that despite 
current medical therapy the function and composition of HDL remain abnormal as compared to healthy 
subjects. Another potential limitation of our study is the use of chloroform/methanol method for 
delipidation of HDL where we cannot exclude extraction of  hydrophobic proteins from HDL. However, 
since delipidated HDL still exerted a similar effect on endothelial apoptosis as compared to HDLHealthy 
before lipid extraction (Figure 3B), the anti-apoptotic protein components were likely largely present in 
the delipidated HDL protein fraction.      
In summary, our findings provide novel evidence that remodeling of the HDL proteome in patients with 
coronary disease has important functional implications with respect to effects of HDL on endothelial cell 
survival. In particular, we have observed that a reduced clusterin and increased apoC-III content in 
HDLCAD lead to an impaired effect of HDL on endothelial anti-apoptotic pathways and an activation of 
pro-apoptotic-signaling in endothelial cells. These findings provide novel insights into mechanisms 
underlying altered vascular effects of HDL in patients with coronary disease.   
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2.7 Supplementary material 
2.7.1 Supplementary methods 
Patient Characteristics.  Patients with stable CAD or an ACS (STEMI or NSTEMI) and healthy subjects 
(without cardiovascular risk factors) were recruited at the University Hospital of Zurich.  The diagnosis of 
stable CAD or an ACS was made according to the guidelines of the American College of 
Cardiology/American Heart Association task force.
1, 2
 Patients with an ACS (STEMI and NSTEMI) were 
recruited if they presented within 12hours after the onset of symptoms and were in a fasting state for at 
least 12hours.  
Endothelial cell culture. Human aortic endothelial cells (HAEC) were obtained from Clonetics and 
cultured in endothelial cell basal medium-2 (Clonetics, USA) supplemented with endothelial growth 
medium–SingleQuots as indicated by the manufacturer (37°C, 95% air / 5% CO2). SingleQuots contain 
human epidermal growth factor (hEGF), hydrocortisone, gentamicin and amphotericin-B, fetal bovine 
serum, vascular endothelial growth factor (VEGF), human fibroblast growth factor-basic (hFGF-B), 
insulin-like growth factor (R3-IGF-1), and ascorbic acid.  HAECS were grown to sub-confluency and 
rendered quiescent before experiments by incubation in medium containing 0.5% FCS. Endothelial 
apoptosis induced by serum withdrawal was done by changing the medium to basal medium without 
supplements. As another stimulus for endothelial apoptosis, cells were exposed to TNF-α (40 ng/ml) for 
24 hours as described previously.
3
  
Isolation of High-Density Lipoprotein. HDL was isolated as described previously by sequential 
ultracentrifugation (d = 1.063-1.21 g/ml) using solid potassium bromide (Merck KGaA, Germany) for 
density adjustment.
4-6
   Furthermore, a second method for HDL isolation, i.e. a recently described gel 
filtration chromatography protocol used for the analysis of the HDL proteome was applied largely as 
described previously.
7
  In brief, 200 microliters serum was applied to two Superdex-200 gel filtration 
columns (10/300 GL; GE Healthcare, USA) arranged in series on a FPLC system (ÄKTA;  GE Healthcare, 
USA), with a flow rate of 0.3 ml/min in Tris buffer (10 mM Tris, 0.15 mM NaCl, 1 mM EDTA, 0.2% 
NaN3).  The eluate was collected using a fraction collector maintained at 4°C.   
HDL-delipidation. For proteomics studies and functional studies HDL was delipidated using 
methanol/chloroform extraction.
8
 In brief, HDL was precipitated by the addition of methanol:chloroform 
(2:1 vol/vol). Two volumes of water were added and the aqueous upper phase was removed. Then 2 
volumes of methanol were added, protein were precipitated and dissolved in 25 mM ammonium 
bicarbonate at pH 8.0. For proteomics studies of HDL, the samples were reduced and and 
carboxymethylated prior to digestion by sequencing grade trypsin (Promega, USA) overnight at 37ºC. 
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Tryptic digests were desalted with a C18 ZipTip (Millipore, USA) before analyzed on a hybrid LTQ-
Orbitrap mass spectrometer (ThermoFischer Scientific, USA) interfaced with a nanoelectrospray ion 
source. For further details of sample preparation and LC-ESI-MS/MS analysis please see the Supplemental 
Methods. Lipid-free apoA-I was isolated as reported in detail previously.
9
 
Preparation of Reconstituted HDL.  Reconstituted HDL (rHDL) comprising apoA1, POPC, and 
cholesterol was prepared with sodium cholate dialysis method
9
 using an apoA-I/POPC/cholesterol molar 
ratio of 1:80:10, as previously reported.
10
 Reconstituted HDL containing clusterin or apoC-III was 
prepared using a similar method with purified clusterin (Prospec, USA) or apoC-III (Academy 
Biomedicals, USA).  
Measurement of Endothelial Cell Apoptosis In Vitro using FACS Analysis. Human aortic endothelial 
cells (HAECs; Clonetics, USA) were collected after detachment with Accutase (PAA Laboratories, 
Austria) and were resuspended in 140 mM NaCl, 10 mM Hepes, and 2.5 mM CaCl2 and incubated with 
Annexin V-FITC (Roche Diagnostics, Switzerland) for 30 minutes at room temperature according to the 
manufacturer’s instructions. Flow cytometric analyses were performed using a BD-FACScan flow 
cytometer (BD Biosciences, USA). Data were analyzed using FlowJo software (Treestar. Inc.). For 
TUNEL staining, endothelial cells were fixed with 4% paraformadehyde, permeabilized with 0.1% Triton 
X-100 and stained with TUNEL labeling solution (In Situ Cell Death Detection Kit, Fluorescein, Roche, 
Switzerland) according to the manufacturer’s instructions. 
Measurement of Endothelial Cell Apoptosis In Vitro Using Fluorescence Microscopy. Endothelial 
cells were grown on glass chamber slides. Following apoptosis induction with or without the presence of 
HDL, endothelial cells were washed and incubated with Annexin V-FITC (Roche, Switzerland) for 30 
minutes at room temperature according to the supplier’s instructions. Cells were counterstained with 4',6-
diamidino-2-phenylindole (DAPI) suspended in mounting medium (Dako, Baar, Switzerland).and 
analyzed using a fluorescent microscope (DM-IRB) connected to a digital imaging system (Spot-RT; 
Diagnostic Instruments/Visitron Systems). 
Measurement of Endothelial Cell Apoptosis In Vitro Using the Caspase-3 Activity Assay. Caspase-3 
activity was measured using a colorimetric assay according to the manufacturer's instructions (CASP-3-C, 
Sigma, USA). In this assay system, the colorimetric substrate (Ac- DEVD-pNA) is hydrolyzed by caspase-
3, releasing p-nitroaniline (pNA) which is monitored by a Versamax microplate reader (Molecular 
Devices, USA) at 405 nm.  
Measurement of Endothelial Cell Apoptosis In Vivo using FACS Analysis and Active Caspase-3 
Staining.  Male apoE(-/-).C57BL/6 mice, aged 12-16 weeks, were used for tail-vein injection of HDL (14 
mg HDL protein/kg body weight), following anaesthesia with inhalation of isoflurane (3%). Twenty-four 
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hours after the injection of HDL or PBS-buffer, mice were euthanized and the aorta were harvested and 
immediately digested for FACS analysis of endothelial cell apoptosis or fixated for histological staining.  
For flow cytometry analysis of endothelial cell apoptosis, the aorta was digested using 2 mg/ml 
collagenase buffer at 37 ºC for 45 minutes. Cells were stained with anti-mouse CD31 (BD Pharmingen, 
USA) and Annexin V-APC (BD Pharmingen, USA). As another approach to verify endothelial cell 
apoptosis in vivo immunofluorescence staining was used.  Aortic sections were fixed with 4% 
paraformaldehyde for 30 minutes, permeabilized with Triton X-100, and blocked with FBS.  The anti-
mouse CD31 antibody (BD Pharmingen, USA), cleaved caspase-3 antibody (Cell Signaling Technology, 
USA) and TUNEL In Situ Cell Death Detection Kit, Fluorescein (Roche, Switzerland) were used for 
staining and the cell nucleus was stained with DAPI. All animal protocols were approved by the local 
animal care and use committee. 
Endothelial cell transfection with eNOS specific small interference RNA. Endothelial cells were 
transfected with small interfering RNA targeted to eNOS (5´-CCUACAUCUGCAACCACAU-3´) or 
nontargeting scrambled RNA duplex (5`-GAUCAUACGUGCGAUCAGA-3´) at a final concentration of 
15nM using N-TER nanoparticle siRNA transfection system (Sigma-Aldrich, USA) and serum-free cell 
culture medium according to the manufaturer‘s protocol.   
Sample preparations for MS. HDL was precipitated by chloroform:methanol (2:1 vol/vol) extraction 
followed by centrifugation at 4000 x g for 30 minutes at 4ºC. The protein pellet was dissolved in 25 mM 
ammonium bicarbonate at pH 8.0. 40 μg of the protein was separated  on 1-dimensional SDS PAGE. The 
protein containing gel lane was cut into 8 pieces. Each individual protein containing gel piece was reduced 
for 45 minutes at 60ºC in 50 mM ammonium bicarbonate buffer (pH 8.0) containing 20 mM DTT, 
followed by alkylation of the cysteine residues with the addition of iodoacetamide to a final concentration 
of 25 mM for 45 minutes at room temperature and darkness. Enzymatic digestion was performed in 25 
mM ammonium bicarbonate, pH 8.0 overnight at 37 ºC with 50 ng sequencing grade trypsin (Promega). 
Peptides were extracted with 80% Acetonitrile / 5% trifluoroacetic acid and dried under vacuum. Tryptic 
digests were desalted with a C18 ZipTip (Millipore), according to the manufacturer’s instructions, prior to 
MS analysis. 
LC-ESI-MS/MS. Samples were analyzed on a hybrid LTQ-Orbitrap mass spectrometer (ThermoFischer 
Scientific) interfaced with a nanoelectrospray ion source. Chromatographic separation of peptides was 
achieved on an Eksigent nano LC system (Eksigent Technologies, Dublin, CA, USA), equipped with a 8 
cm in-house made tip column, 75 μm inner diameter, packed with a reverse phase C18 material (AQ, 3 μm 
200 Å, Bischoff GmbH, Leonberg, Germany). Peptides were loaded from a cooled (10°C) Spark Holland 
auto sampler and separated using ACN/water solvent system containing 0.2% formic acid with a flow rate 
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of 200 nl/min. Peptide mixtures were separated with a gradient from 3 to 40% ACN in 60 minutes. Up to 
five data-dependent MS2 spectra of the most abundant doubly or triply charged precursor signals were 
acquired in the linear ion trap using collision induced dissociation.  FT-MS spectra were acquired at 60 
000 FWHM @ 400 m/z nominal resolution with an overall cycle time of approximately 1.3 second. 
Dynamic exclusion was switched on, entailing that up to 500 m/z ± 20 ppm values were excluded from 
tandem MS for 120 second. The automatic gain control was set to 5e5 and 1e4 for full FT-MS and linear 
ion trap MS2, respectively. The instrument was calibrated externally according to manufacturer’s 
instructions. The Orbitrap calibration was readjusted during data acquisition using internal lock mass 
calibration on m/z 429.088735 and 445.120025. 
Analysis of MS data. Peak lists were generated using Mascot Distiller software 2.3.2 (Matrix Science Ltd., 
London, UK). The resulting Mascot Generic Files (mgf) were searched using Mascot server 2.2 
11
 against 
a human protein database downloaded from the European Bioinformatic Institute (EBI, release date: 
19/01/2010). The database has been reversed and concatenated to the original database to calculate the 
false discovery rate. Modifications used for searches included carbamidomethyl (C, fixed, nonhistone 
searches), phosphorylation (STY, variable), pyro-Glu (N-term Q, variable). Only strictly tryptic peptides 
12
 
with a maximum of 1 missed cleavage site was allowed in database searches. Monoisotopic precursor 
signals were searched with a tolerance of 6 ppm and an MS/MS signals with a tolerance of 0.5 Da 
13, 14
. 
Relative quantification based on spectral counts. Normalized spectral counts were calculated using 
Scaffold™ version 2_04_00 (2007 Proteome Software Inc). Database search files generated by Mascot 
were imported into Scaffold. Peptide and protein identifications were accepted if established at >95.0% 
probability as specified by the Peptide Prophet 
15
 and Protein Prophet algorithms 
16
, respectively. Each 
identified protein required at least two unique peptides to be part of the data set. To correct for MS/MS 
sampling differences between individuals, Scaffold outputs were expressed on the basis of the unweighted 
spectral count assigned to each identified protein. To increase stringency of identification, proteins were 
required to be present in at least four of the six groups analyzed. The spectral index was used for the 
relative quantification of each protein of interest.
17
 The spectral index was calculated as: 
[(SCAD/(SCAD+SHealthy)) x (NpCAD/NtCAD)] – [(SHealthy/(SCAD+SHealthy)) x (NpHealthy/NtHealthy)], where SCAD and 
SHealthy represent unweighted spectral count in HDLHealthy and HDLCAD respectively, NpCAD and NpHealthy 
represent number of samples where peptides were found for a protein in HDLHealthy and HDLCAD 
respectively, and NtCAD and NtHealthy represent total number of samples of HDLHealthy and HDLCAD 
respectively. A positive spectral index suggests enrichment of peptides derived from the protein of interest 
in HDLCAD, whereas a negative spectral index suggests reduction of peptides derived from the protein of 
interest in HDLCAD. 
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125I-HDL Binding, Assays. Binding assays were performed as previously described.
18
  In brief 
transfected HEK cells were seeded into 12-well dishes at a concentration of 3x10
5 
cells/well. The assays 
were performed 48h after seeding in DMEM/25 mM Hepes/0.2% BSA  containing 10 μg/ml 
125
I-HDL, in 
the absence (total binding) or in the presence (non-specific binding) of a 40-fold excess of unlabelled 
HDL . After incubation, the amounts of cell associated radioactivity were determined using a Perkin Elmer 
gamma-counter and the protein content was analyzed as described previously.
18
 Specific cell binding were 
determined by subtracting the values obtained in the presence of the excess unlabelled HDL (nonspecific) 
from those obtained in the absence of the unlabelled HDL (total).  
HEK293 Cell Transfection. The plasmid construct expressing human SR-BI were prepared by cloning 
human full-length cDNAs into pcDNA 3.1 vector (Invitrogen), and the cDNA sequence was confirmed by 
DNA sequencing. The HEK293 cells were transfected with the cDNA construct or pcDNA 3.1 vector  and 
clones stably expressing SR-BI, or vector were obtained by G418 selection.  
2.7.2 Supplementary results 
Role of SR-BI for the endothelial anti-apoptotic effects of HDL 
One possible explanation for the anti-apoptotic effect of clusterin could be that it increases binding of 
HDL to SR-BI.  We therefore further investigated the effect of clusterin on the SR-BI-dependent binding 
of HDL. To examine the specific binding of HDL to SR-BI, we transfected HEK293 cells with SR-BI. 
There was, however, no significant difference in the SR-BI-specific binding of reconstituted HDL in the 
presence or absence of clusterin (Supplementary Figure 2.3C), suggesting that the SR-BI mediates, at least 
in part, the clusterin-dependent endothelial anti-apoptotic effects of HDL, but does not strongly enhance 
SR-BI-dependent binding of HDL. In contrast, addition of apoC-III to reconstituted HDL did not result in 
an anti-apoptotic effect that could be blocked by a SR-B1 blocking antibody (Supplementary Figure 2.1C). 
Furthermore, SR-BI-specific binding of reconstituted HDL was significantly reduced in the presence of 
apoC-III, that may contribute to the adverse effects of HDL-bound apoC-III on apoptosis (Supplementary 
Figure 2.3C). 
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Supplementary Table 2.1  HDL-associated proteins identified in this study. 
Protein name 
Protein 
short form 
Accession 
number 
Spectral 
index 
Median 
spectral 
count in 
HDLHealthy 
Median 
spectral 
count in 
HDLCAD 
Adipocyte plasma membrane-
associated protein  APMAP 
Q9HDC9-
1 0.314 
2.5 8.5 
Alpha-1-acid glycoprotein 2  ORM2 P19652 0.255 3 2 
Alpha-1-antichymotrypsin  SERPINA3 P01011-1 0.255 2 3 
Alpha-1-antitrypsin  SERPINA1 P01009-1 -0.069 38.5 28 
Alpha-2-antiplasmin  SERPINF2 P08697 0.048 2 3.5 
Alpha-2-HS-glycoprotein  AHSG P02765 0.260 3.5 3.5 
Alpha-2-macroglobulin  A2M P01023 -0.003 1.5 1 
Aminopeptidase N  ANPEP P15144 -0.368 2.5 2 
Angiotensinogen  AGT P01019 -0.166 3 3 
Anthrax toxin receptor 1  ANTXR1 
Q9H6X2-
1 0.149 
2 5 
Anthrax toxin receptor 2  ANTXR2 P58335-4 0.049 8 12 
Antithrombin-III  SERPINC1 P01008 -0.038 2 5 
Apolipoprotein A-I  APOA1 P02647 -0.056 512.5 504.5 
Apolipoprotein A-II  APOA2 P02652 -0.070 43 45 
Apolipoprotein A-IV  APOA4 P06727 0.027 56.5 63.5 
Apolipoprotein A-V  APOA5 Q6Q788 0.581 1.5 7.5 
Apolipoprotein B-100  APOB P04114 0.111 350.5 593.5 
Apolipoprotein C-I  APOC1 P02654 -0.046 29 25 
Apolipoprotein C-II  APOC2 P02655 -0.016 19 15.5 
Apolipoprotein C-III  APOC3 P02656 0.197 25 30 
Apolipoprotein C-IV  APOC4 P55056 0.173 4.5 8 
Apolipoprotein D  APOD P05090 -0.096 77 77 
Apolipoprotein E  APOE P02649 -0.005 136.5 111.5 
Apolipoprotein F (APOF) APOF B2RC09 -0.179 7 4.5 
Apolipoprotein L1  APOL1 O14791-1 -0.008 55.5 44.5 
Apolipoprotein M  APOM O95445 -0.113 30.5 36 
Apolipoprotein(a)  LPA P08519 0.044 45 49.5 
Beta-1A of Integrin beta-1  ITGB1 P05556-1 -0.317 2 2.5 
Beta-2-glycoprotein 1  APOH P02749 0.154 2 4 
Beta-3A of Integrin beta-3  ITGB3 P05106-1 -0.534 3.5 2 
C4b-binding protein alpha chain  C4BPA P04003 0.428 5 4 
Carbonic anhydrase 6  CA6 P23280 -0.230 4 2 
Cathelicidin antimicrobial peptide  CAMP P49913 -0.085 4 3.5 
Cholesteryl ester transfer protein  CETP P11597-1 0.230 1 3 
Clusterin  CLU P10909-1 -0.323 14 10.5 
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Complement C3  C3 P01024 0.091 34 62 
Complement component 4B (Childo 
blood group)  C4B B0UZ85 0.068 
11.5 21 
Complement component C9  C9 P02748 0.096 5.5 9 
Dermcidin  DCD P81605 -0.106 7.5 8 
DPI of Desmoplakin  DSP P15924-1 -0.068 2.5 2 
Endosialin  CD248 
Q9HCU0-
1 -0.392 
2.5 2 
GTP-binding protein SAR1a  SAR1A Q9NR31 0.047 3 4 
Haptoglobin  HP P00738 0.416 2 5 
Haptoglobin-related protein  HPR P00739-1 0.070 4 7.5 
Hemoglobin subunit alpha  HBA1 P69905 -0.053 2 1 
Hemoglobin subunit beta  HBB P68871 -0.160 1.5 1 
Heparin cofactor 2  SERPIND1 P05546 0.575 1.5 3.5 
HLA class I histocompatibility 
antigen, A-24 alpha chain  HLA-A P05534 0.083 
1.5 2.5 
IGH@ protein  IGH@ Q6GMX6 0.601 4.5 3 
IGK@ protein  IGK@ Q6PIL8 -0.241 1 1 
Inositol monophosphatase 3  IMPAD1 Q9NX62 -0.089 2 1 
Integrin alpha-2  ITGA2 P17301 -0.221 2 1 
Integrin alpha-IIb  ITGA2B P08514-1 -0.364 4.5 2 
Inter-alpha-trypsin inhibitor heavy 
chain H4  ITIH4 Q14624-1 0.042 
1 3 
Junction plakoglobin  JUP P14923 -0.260 3 2.5 
Lipopolysaccharide-binding protein  LBP P18428 0.553 2.5 8 
Long palate, lung and nasal 
epithelium carcinoma-associated 
protein 1  LPLUNC1 
Q8TDL5-
1 0.277 
2.5 7 
Multimerin-2  MMRN2 Q9H8L6 -0.322 3 1 
Phosphatidylcholine-sterol 
acyltransferase  LCAT P04180 -0.192 
5.5 4 
Phosphatidylinositol-glycan-specific 
phospholipase D  GPLD1 P80108-1 -0.550 
7.5 2 
Phospholipid transfer protein  PLTP P55058-1 -0.142 19.5 20 
Plasma protease C1 inhibitor  SERPING1 P05155 -0.170 2.5 1 
Platelet-activating factor 
acetylhydrolase  PLA2G7 Q13093 0.533 
1 4 
Prenylcysteine oxidase 1  PCYOX1 Q9UHG3 -0.108 23 20.5 
Protein AMBP  AMBP P02760 0.081 1 3 
Pulmonary surfactant-associated 
protein B  SFTPB P07988 0.784 
2 5 
Serotransferrin  TF P02787 0.566 2 3 
Serum albumin  ALB P02768-1 0.024 39 54 
Serum amyloid A protein  SAA1 P02735 0.431 3.5 11.5 
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Serum amyloid A-4 protein  SAA4 P35542 0.007 51.5 61 
Serum paraoxonase/arylesterase 1  PON1 P27169 -0.150 48 41 
Serum paraoxonase/lactonase 3  PON3 Q15166 -0.121 12.5 11 
Sonic hedgehog protein  SHH Q15465 -0.349 3 1.5 
Vesicular integral-membrane protein 
VIP36  LMAN2 Q12907 0.033 
2 3.5 
Vitronectin  VTN P04004 0.281 1 3.5 
Hornerin  HRNR Q86YZ3 0.451 3 4.5 
            
HDL was isolated by sequential ultracentrifugation (d = 1.063-1.21 g/ml) using solid potassium bromide 
for density adjustment. Isolated HDL samples were reduced and and carboxymethylated prior to digestion 
by sequencing grade trypsin overnight at 37ºC. Tryptic digests were desalted with a C18 ZipTip before 
analyzed on a hybrid LTQ-Orbitrap mass spectrometer interfaced with a nanoelectrospray ion source. 
Database search files generated by Mascot were imported into Scaffold. Peptide and protein identifications 
were accepted if established at >95.0% probability as specified by the Peptide Prophet and Protein Prophet 
algorithms. Each identified protein required at least two unique peptides to be part of the data set. To 
correct for MS/MS sampling differences between individuals, Scaffold outputs were expressed on the 
basis of the unweighted spectral count assigned to each identified protein. The spectral index was used for 
the relative quantification of each protein of interest. A positive spectral index suggests enrichment of 
peptides derived from the protein of interest in HDLCAD, whereas a negative spectral index suggests 
reduction of peptides derived from the protein of interest in HDLCAD. 
 
Supplementary Figure 2.1 (A). The amount of clusterin in HDL following reconstitution or addition to 
HDLHealthy.  (B) The amount of apoC-III in HDL following reconstitution or addition to HDLHealthy (C) 
Effect of blocking antibody against apoC-III on the anti-apoptotic capacity of rHDL/apoC-III. (D) Effect 
of blocking antibody against clusterin on the anti-apoptotic capacity of rHDL/Clu.  
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Supplementary Figure 2.2 (A) Effect of HDLHealthy, HDLsCAD and HDLACS (50µg/ml) on phosphorylation 
of Akt at Ser473, normalized to total Akt. (B) Representative coomassie blue-stained SDS-PAGE gel of 
serum, LDL and HDL from healthy subject and patient with CAD. (C) Western blots analysis of ApoC-III 
and Clusterin of serum, LDL and HDL from healthy subject and patient with CAD. (D) Densitometric 
analysis of western blot against ApoC-III. (E) Densitometric analysis of western blot against clusterin. 
Supplementary Figure 2.3 (A) Effect of SR-BI inhibition with specific blocking antibody against SR-BI 
on the anti-apoptotic capacity of HDLHealthy, rHDL, rHDL/Clu and HDLCAD analyzed using FACS analysis 
with annexin-V staining, and (B) TUNEL staining. (C) Binding of rHDL, rHDL/Clu and rHDL/apoC-III 
on HEK293 cells transfected with SR-BI.  
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3.1 Abstract 
 As low HDL-Cholesterol levels are associated with an increased cardiovascular risk at least in 
epidemiology, raising HDL-Cholesterol is being examined as a potentially important therapeutic strategy. 
Treatment with cholesteryl ester transfer protein (CETP) inhibitors may increase HDL cholesterol levels 
and are currently being investigated as a potential treatment against cardiovascular disease. However, 
vascular effects of HDL have recently been found to be highly heterogeneous and benefits may be lost, at 
least partially, in patients with coronary artery disease (CAD). We therefore studied in patients with CAD 
or CAD-risk equivalent the effect of the CETP inhibitors, dalcetrapib or torcetrapib, as compared to 
placebo on HDL function.  
HDL was isolated by sequential ultracentrifugation from patients randomized to treatment with dalcetrapib 
(600 mg/day; n=25) or placebo (n=25) at baseline, 12 and 36 weeks, and from age matched healthy 
subjects. In parallel, HDL was isolated from patients randomized to receive treatment with torcetrapib (60 
mg/day; n=31) or placebo (n=36) at baseline and 6 months. The effect of HDL on endothelial nitric oxide 
(NO) production was measured by ESR spectroscopy and on endothelial pro-inflammatory and pro-
apoptotic activation determined by VCAM-1 and active caspase-3 expression assays, respectively.   
There was no significant improvement in the capacity of HDL to stimulate endothelial NO production 
following dalcetrapib treatment or placebo in patients with CAD or risk equivalents, that remained 
impaired as compared to HDL-Healthy.  HDL isolated from the dalcetrapib group showed an increase in 
the capacity to reduce endothelial VCAM-1 activation (9.0±6.3% at 12 weeks, 9.7±6.7% at 36 weeks, vs. 
5.3±4.5% at baseline; p<0.05); but remained significantly impaired (HDL-Healthy: 15.2±6.5%; p<0.05).  
There was also an increase of the capacity of this HDL to reduce active endothelial caspase-3 expression 
(12.1±8.7% at 36 weeks vs. 6.9±9.9% at baseline; p<0.05); however, these endothelial anti-apoptotic 
capacities remained largely impaired as compared to healthy subjects (18.9±6.6%; p<0.05).  
No significant improvement was observed in the capacity of HDL to stimulate endothelial NO production, 
reduce VCAM-1 activation or inhibit active caspase-3 expression following torcetrapib or placebo 
treatment in patients with CAD. These vascular effects of HDL remained largely impaired as compared to 
HDL from healthy subjects. Importantly, however, there was no further impairment in the capacity of 
HDL to stimulate endothelial NO production, reduce VCAM-1 activation or active caspase-3 activation 
following treatment with torcetrapib. 
Despite a significant increase in HDL-C levels (+31% at 36 weeks with dalcetrapib, +63% at 6 months 
with torcetrapib), treatment with these CETP inhibitors did not restore the potential anti-atherosclerotic 
properties of HDL on the endothelium as found in the healthy controls. Importantly, these treatments did 
not further impair the endothelial effects of HDL. This finding may contribute, at least in part, to the lack 
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of benefit on endothelial function seen in dal-VESSEL and ILLUMINATE trials and demonstrates the 
importance of measuring not just HDL-C plasma levels but also its vascular impact when assessing novel 
treatments.  
3.2 Introduction 
Despite the significant achievement of low-density lipoprotein cholesterol (LDL-C) lowering therapy in 
reducing the cardiovascular risk, there remains a significant residual cardiovascular risk even after intense 
statin treatment.
1-4
 Low levels of high-density lipoprotein cholesterol (HDL-C) have been identified in 
epidemiological studies to be inversely correlated to the risk of coronary artery disease.
5
 Low HDL-C is an 
independent predictor of cardiovascular events even in patients intensely treated with statin.
6
 HDL-raising 
therapy is therefore intensely investigated as a potentially important treatment strategy. 
The potential anti-atherogenic effects of HDL are attributed not only to its capacity to promote 
macrophage cholesterol efflux,
7-9
 but also to exert endothelial vasoprotective effects, including the 
capacity to stimulate endothelial nitric oxide production, anti-inflammatory and anti-apoptotic effects.
10, 11
 
However, recent studies have demonstrated that the protective effects of HDL may be impaired in patients 
with coronary disease.
12, 13
 Importantly, HDL particles isolated from these individuals may rather turn pro-
atherogenic.
12
  
Cholesteryl ester transfer protein (CETP) is a plasma hydrophobic glycoprotein secreted by the liver that 
mediates the transfer of cholesteryl ester from HDL to apoB-containing and triglyceride-rich lipoproteins 
such as LDL and VLDL and reciprocal transfer of triglyceride from from VLDL to LDL and HDL.
14-16
  
By virtue of the fact that CEs are delivered to the liver by LDL/VLDL for excretion in bile via the indirect 
pathway, CETP-mediated transfers are part of the RCT pathway and are potentially antiatherogenic.
17
 
Furthermore, CETP inhibition due to either genetic deficiency or use of inhibitors results in larger HDL-C 
particles with elevated CE and decreased triglyceride content and a non-HDL fraction with increased 
triglyceride and decreased CE. These changes lead to an increased HDL-C due to its delayed clearance 
from plasma.
18
  
Treatment strategy that inhibits the activity of CETP leads to increased plasma HDL-C levels. The first 
CETP inhibitor, torcetrapib, effectively increased HDL-C and lowered LDL-C but was associated with 
increased mortality,
19
 which may be due to off-target effects.
20
 Dalcetrapib, a CETP modulator, modestly 
increased HDL-C without any clinically significant side effects.
21, 22
 However, the dal-OUTCOMES trial 
was stopped recently due to a lack of clinically meaningful efficacy.
23
 While the safety studies did not 
show adverse vascular effects of dalcetrapib on endothelial function, there was no significant improvement 
on these parameters either.
22, 24
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Figure 3.1  HDL cholesterol is returned to the liver through two pathways: selective uptake of cholesterol 
by the hepatic scavenger receptor, class B, type I (SR-BI, blue arrow), or the transfer of cholesteryl ester 
by cholesteryl ester transfer protein (CETP) to VLDL–LDL, with uptake by the liver through the LDL 
receptor (red arrows). FC denotes free cholesterol, PL phospholipids, LRP LDL-related protein, and LPL 
lipoprotein lipase. Source: Brewer HB Jr., N Engl J Med 2004; 350:1491-1494 
These recent failures in treatments that raise HDL-C levels have cast doubt on whether HDL plays a truly 
protective role in cardiovascular disease. HDL function hypothesis has gained increasing recognition in 
the field as a better indicator of HDL value in reducing cardiovascular disease risk and it is likely, that 
only raising of HDL with vasoprotective properties will exert cardiovascular protection. It is therefore 
essential to develop new metrics for assessing HDL’s cardioprotective effects. One diagnostic approach 
might be the cell-based assays that we recently uncovered to have the potential to distinguish 
dysfunctional HDL particles in CAD patients.
12, 25
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As discussed in the previous chapter, there may be several mechanisms in play contributing to the altered 
endothelial protective effects of HDL in CAD. While inactivation of PON-1 may lead to compromised 
anti-oxidant, anti-inflammatory effects as well as impaired capacity to stimulate NO production,
12
 
remodeling of the HDL proteome in CAD with respect to clusterin and apoC-III levels may contribute to 
the activation of pro-apoptotic signaling pathway by HDL.
25
 Therefore, our study sought to develop new 
assays for assessing different HDL functions, in a relatively high-throughput manner. In particular, these 
assays were developed and optimized to assess the capacity of HDL to stimulate endothelial NO 
production, promote endothelial anti-inflammatory and anti-apoptotic effects.  
Using these assays, we investigated the capacity of dalcetrapib to modulate these endothelial effects of 
HDL, using HDL isolated from patients with CAD or CAD-risk equivalent treated with CETP inhibitor 
dalcetrapib or placebo. In addition, using the same study parameters, we sought to investigate the impact 
of torcetrapib on the endothelial effects of HDL, using HDL isolated from patients with CAD treated with 
torcetrapib or placebo. 
3.3 Cell-based assays for assessment of HDL function 
3.3.1 In-cell western assays for assessment of VCAM-1 and active caspase-3 expression 
In-cell-western (ICW) technique is a cell-based assay for the measurement of protein expression levels in 
their cellular context. It is increasingly used to substitute the western immunoblotting technique that is 
generally labour-intensive, time-consuming and low-throughput. ICW uses near-infrared (NIR) 
fluorophore–conjugated antibodies which can be analyzed with NIR scanners (Odyssey®) equipped with 
two separate channels. This enables simultaneous detection of two different proteins, providing that the 
primary antibodies are raised in different species and that the species-specific secondary antibodies are 
labeled with different fluorophores. This segregation of signals is particularly useful for normalization of 
the protein signal to that of the reference protein, e.g. actin, glyceraldehyde-3-phosphate-dehydrogenase 
(GAPDH). ICWs utilize 96-well or 384-well microplates into which adherent or non-adherent cells can be 
plated and analyzed using the Odyssey® scanner. ICWs eliminate the need for protein harvesting, lysate 
preparation, electrophoretic separation and electrophoretic transfer steps.  
HDL has been shown to inhibit TNF-α stimulated VCAM-1 expression in endothelial cells,
26, 27
 and this 
capacity is lost in patients with CAD.
12
 Measurement of VCAM-1 expression upon TNF-stimulation may 
therefore be relevant for the assessment of the anti-inflammatory property of HDL. Using ICW technique, 
TNF-α induced endothelial VCAM-1 expression is assessed in the presence or absence of HDL with 
VCAM-1 primary antibody and near-infrared (NIR) fluorophore–conjugated secondary antibody (Figure 
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3.2). In addition, measurement is normalized with DRAQ5, near infrared DNA dye. The intra- and inter-
assay variabilities are 11.1 and 12.0, respectively. 
 
Figure 3.2 Comparison of western blot technique and in-cell western of VCAM-1 expression with 
increasing amount of TNF-α and different concentrations of HDL. 
 
The capacity of HDL to inhibit endothelial apoptosis has been suggested to be another important anti-
atherogenic property of HDL, as demonstrated by inhibition of endothelial caspase-3 activation.
28, 29
 
Interestingly, the anti-apoptotic effect of HDL has been shown to be independent of eNOS activation and 
the remodeling of HDL proteome with respect to the clusterin and apoC-III contents were suggested to 
modulate the endothelial apoptotic signaling pathways by HDL.
25
 Measurement of active caspase-3 
expression may therefore provide another independent and relevant assessment of HDL function. Using 
ICW technique, endothelial active caspase-3 expression is assessed in the presence or absence of HDL 
with active caspase-3 primary antibody and near-infrared (NIR) fluorophore–conjugated secondary 
antibody (Figure 3.3). In addition, measurement is normalized with DRAQ5, near infrared DNA dye. The 
intra- and inter-assay variabilities are 13.6 and 15.4, respectively. 
 
 
Figure 3.3 Comparison of western blot technique and in-cell western of active caspase-3 expression with 
different duration of serum starvation and different concentrations of HDL. 
 
3.3.2 Electron Spin Resonance (ESR) spectroscopy for the assessment of endothelial NO 
bioavailability 
Endothelial NO bioavailability was determined by ESR spectroscopy using the spin-probe colloid 
Fe(DETC)2 (Noxygen),  after stimulation with HDL, as previously described.
12
 The formed nitrosyl 
iron(II) complex, NO-Fe(DETC)2, exhibits a characteristic signal with three peaks (Figure 3.4). Signals 
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were quantified by measuring the total amplitude after correction of baseline. The amount of NO was 
determined by measuring the total amplitude of the ESR signal for each treatment. 
 
Figure 3.4 After one hour of stimulation with 50μg/ml HDL, which was isolated from healthy subjects, 
there was a significant increase in NO production. Following stimulation with HDL from patients with 
stable CAD there was no increase in NO bioavailability. (Source: Besler et al. J Clin Invest 2011; 
121:2693-2708) 
 
3.4 Endothelial effects of HDL remain impaired following dalcetrapib treatment in 
patients with coronary heart disease (CHD) or risk equivalent 
HDL was isolated from 50 patients with CHD or CHD risk equivalent treated with either placebo or 
dalcetrapib 600 mg/day at baseline level, 12 weeks and 36 weeks. The characteristics of the study 
population are shown in Table 3.1. 
3.4.1 Effects of dalcetrapib on HDL capacity to stimulate endothelial nitric oxide (NO) 
production and to promote anti-inflammatory and anti-apoptotic functions   
HDL isolated from patients with CAD or risk equivalent treated with dalcetrapib or placebo showed no 
significant capacity to stimulated endothelial NO production. In contrast, HDL from healthy subjects 
markedly stimulate endothelial NO production as measured by ESR spectroscopy. HDL isolated from 
patients treated with dalcetrapib showed an increased capacity to inhibit endothelial VCAM-1 activation 
(9.0±6.3% at 12 weeks, 9.7±6.7% at 36 weeks, vs. 5.3±4.5% at baseline; p<0.05).  
 
Table 3.1 Baseline demographics and clinical characteristics 
Parameter Placebo (N=25) Dalcetrapib (N=25) 
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Age, years 61.3 (1.6) 61.9 (1.4) 
Male sex, n (%) 25 (100) 25 (100) 
BMI, kg/m
2
 28.8 (0.8) 28.8 (0.8) 
Systolic blood pressure 24 hour mean  120.8 (2.5) 130.9 (2.0) 
Diastolic blood pressure 24 hour mean  73.4 (1.4) 77.3 (1.7) 
Total cholesterol, mg/dL 144.5 (3.7) 156.6 (6.0) 
HDL-C, mg/dL 38.2 (1.4) 38.4 (1.4) 
LDL-C, mg/dL 80.0 (2.2) 85.7 (5.0) 
Triglycerides, mg/dL 131.6 (12.1) 161.9 (15.6) 
hsCRP, mg/L  2.5 (0.7) 4.2 (1.8) 
Data are mean (SE), unless otherwise stated. BMI, body mass index; HDL-C, high-density lipoprotein; 
LDL-C, low-density lipoprotein; hsCRP, high sensitivity C-reactive protein.  
 
Table 3.2 Percent change from baseline in HDL-C level post-treatment 
Treatment Arm Mean (SD) Median (Q1, Q3) Min Max 
Dalcetrapib, week 12 30.48 (14.42) 28.57 (19.35, 38.46) 9.52 71.43 
Dalcetrapib, week 36 43.62 (20.04) 39.39 (30.95, 54.29) 4.17 103.23 
Placebo, week 12 -0.25 (11.81) 0 (-6.38, 3.33) -28.95 29.03 
Placebo, week 36 0.14 (11.99) 0 (-7.89, 6.90) -21.05 31.25 
 
Chapter 3 Endothelial effects of HDL following treatment with CETP inhibitors 
 
 
 
77 
 
However, the effect is significantly lower as compared to the capacity of HDL from healthy subjects to 
reduce endothelial VCAM-1 expression (HDL-Healthy: 15.2±6.5%; p<0.05). HDL isolated from patients 
treated with dalcetrapib showed an increased capacity to reduce active endothelial caspase-3 expression 
(12.1±8.7% at 36 weeks vs. 6.9±9.9% at baseline; p<0.05); however, these endothelial anti-apoptotic 
capacities remained largely impaired as compared to healthy subjects (18.9±6.6%; p<0.05) (Figure 3.5). 
Furthermore, there was no statistical difference between the dalcetrapib and placebo groups for the change 
from baseline in the capacity of HDL to stimulate endothelial NO production, to reduce VCAM-1 
expression or to inhibit caspase-3 expression (Figure 3.5). 
Figure 3.5 Effects of dalcetrapib on HDL capacity to stimulate endothelial NO production (A), endothelial 
anti-apoptotic activity (B), and endothelial anti-inflammatory activity (C). 
 
3.5 Impact of torcetrapib treatment on HDL effects on endothelial cells  
HDL was isolated from 50 patients with CHD treated with either placebo or torcetrapib 600 mg/day at 
baseline level, 12 weeks and 36 weeks. The characteristics of the study population are shown in Table 3.3. 
Change from baseline in HDL cholesterol levels following treatment is 63.1±28.7% in the torcetrapib 
treatment arm group, in comparison to 1.7±12.7% in the placebo treatment arm group. 
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Table 3.3  Baseline demographics and clinical characteristics 
Parameter Placebo (N=30) Torcetrapib (N=42) 
Age, years 63.2 (7.5) 65.6 (7.4) 
Male sex, n (%) 38.9 (100) 52.8 (100) 
BMI, kg/m
2
 33.1 (7.1) 29.9 (3.4) 
Systolic blood pressure 24 hour mean  122.9 (8.6) 122.9 (11.0) 
Diastolic blood pressure 24 hour mean  72.8 (7.3) 72.1 (9.3) 
HDL-C, mg/dL 40.3 (11.3) 43.6 (8.6) 
LDL-C, mg/dL 79.3 (25.0) 72.1 (20.0) 
Triglycerides, mg/dL 182.0 (99.6) 159.6 (75.1) 
hsCRP, mg/L  2.7 (2.0) 4.1 (11.0) 
Data are mean (SD), unless otherwise stated. BMI, body mass index; HDL-C, high-density lipoprotein; 
LDL-C, low-density lipoprotein; hsCRP, high sensitivity C-reactive protein.  
 
3.5.1 Effects of torcetrapib on HDL capacity to stimulate endothelial nitric oxide (NO) 
production and to promote anti-inflammatory and anti-apoptotic functions.   
There was no significant improvement in the capacity of HDL to stimulate endothelial NO production, 
reduce VCAM-1 activation or inhibit active caspase-3 expression following torcetrapib or placebo 
treatment in patients with CAD (Figure 3.6). These vascular effects of HDL remained largely impaired as 
compared to HDL from healthy subjects. Importantly, however, there was no further impairment in the 
capacity of HDL to stimulate endothelial NO production, reduce VCAM-1 activation or active caspase-3 
activation following treatment with torcetrapib. 
3.6 Discussion 
In this study, we have optimized and used cell-based assays for the assessment of HDL effects on the 
endothelium following treatment with CETP inhibitors, dalcetrapib and torcetrapib. We observed no 
statistical difference between the dalcetrapib and placebo treatment arm groups for the change from 
baseline in all HDL functions measured. Interestingly, HDL isolated from patients following treatment 
Chapter 3 Endothelial effects of HDL following treatment with CETP inhibitors 
 
 
 
79 
 
with dalcetrapib showed an increased in the capacity to inhibit VCAM-1 activation and to reduce active 
caspase-3 expression. However, these effects were still very much impaired as compared to HDL isolated 
from age matched healthy subjects. On the other hand, there was also no significant improvement in the 
HDL functions measured following torcetrapib or placebo treatment in patients with CAD. Notably, no 
impairment in HDL functions was observed following torcetrapib treatment. 
Figure 3.6. Effects of torcetrapib on HDL capacity to stimulate endothelial NO production (A), endothelial 
anti-apoptotic activity (B), and endothelial anti-inflammatory activity (C). 
 
Treatment with CETP inhibitors raises HDL-C levels, which has been proposed to reduce cardiovascular 
disease risk. However, despite significant elevations in the HDL-C levels, results from recent trials have 
not shown the clinical benefits of torcetrapib or dalcetrapib. Treatment with torcetrapib, the first CETP 
inhibitor, increased cardiovascular mortality,
19
 which may be due to off-target effects.
20
 Meanwhile, 
clinical trial assessing dalcetrapib treatment was terminated due to a lack of clinically meaningful 
efficacy.
23
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These observations likely suggest that measurement of HDL-C level is not sufficient to reflect the 
cardioprotective capacity of HDL and other functional readouts may be better indicators for assessing the 
cardiovascular risk in an individual. However, given the heterogeneity of HDL particle compositions, 
different components of HDL may account for different biological functions. As described in Chapter 1, 
the anti-inflammatory capacity of HDL has largely been attributed to apolipoprotein A-I
30-33
 and 
impairment in the anti-inflammatory effects of HDL have been proposed to be due to displacement by 
serum amyloid A (SAA)
34-38
 as well as oxidative modifications of the apolipoprotein.
39-42
 On the other 
hand, we have observed that HDL-associated antioxidant enzyme paraoxonase-1 (PON1) is an important 
mediator of the capacity of HDL to stimulate endothelial NO production.
12
 In contrast, lipid-free apoA-I 
did not stimulate eNOS.
9
 Other components of HDL, i.e. clusterin and apolipoprotein C-III, have been 
shown to contribute to the effects of HDL on endothelial apoptotic signaling processes.
25
 Measurements of 
these endothelial effects may therefore provide functional assessment of the different particles or 
subpopulations that contribute to distinct HDL functions. 
Interestingly, despite improvement in the capacity of HDL to inhibit VCAM-1 activation and to reduce 
caspase-3 expression following dalcetrapib treatment, these effects were still largely impaired when 
compared to healthy subjects. Treatment with dalcetrapib failed to restore HDL functions to the level of 
healthy subjects. Importantly, there was no difference when we compared changes from baseline between 
placebo and dalcetrapib treatment groups in all the HDL functional readouts. Our observations may 
explain, at least in part, the lack of benefit on endothelial function seen in the dal-VESSEL trial.
24
    
Interestingly, in a phase IIb study, dalcetrapib treatment was shown to increase apoA-I level and improve 
HDL-induced cholesterol efflux mediated by ABCA1 and SR-B1, as compared to placebo-treated group.
43
 
However, the study did not include comparison with HDL isolated from healthy subjects. It is therefore 
difficult to evaluate whether dalcetrapib treatment fully restore the cholesterol efflux capacity of HDL. 
Another possible explanation is that the measurement parameters in the study do not reflect clinically 
relevant HDL function for the assessment of cardiovascular risk.   
We observed no significant improvement in the HDL functions measured following torcetrapib or placebo 
treatment in patients with CAD. Nonetheless, no impairment in HDL functions was observed following 
torcetrapib treatment. These findings may contribute to understanding the reason for the failure of 
torcetrapib. One of the main questions in the failure of torcetrapib is whether the pronounced elevations in 
the HDL-C levels may give rise to HDL particles that are pro-inflammatory. In this study, we found that 
while no improvement in endothelial functions afforded by HDL was observed, no further impairment in 
these parameters were seen either. While our findings support the lack of improvement in the quality of 
HDL following torcetrapib treatment, the adverse effects observed in the clinical trial of torcetrapib were 
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likely caused by off-target side effects, which may have been due to direct deleterious actions of 
torcetrapib on endothelial function,
44
 independent of the HDL-cholesterol raising effect. 
3.7 Conclusion 
HDL cholesterol level is not an ideal marker to capture the cardioprotective potential of HDL. 
Accumulating evidence has shown that HDL functionality may better predictor of cardiovascular risk. 
Measurements of specific functional readouts such as the anti-inflammatory, anti-apoptotic and the NO-
stimulating capacity may provide better assessment of the quality of HDL particles. Importantly, there is 
still a need to further understand which functional readouts are most relevant to cardiovascular protection, 
since it is likely that raising HDL with atheroprotective properties may have beneficial effects on reducing 
cardiovascular risk. Treatment with CETP inhibitors dalcetrapib and torcetrapib did not restore the 
potential anti-atherosclerotic properties of HDL on the endothelium as found in the healthy controls, which 
may contribute, at least in part, to the lack of benefit on endothelial function seen in dal-VESSEL and 
ILLUMINATE trials. Our findings highlight the importance of measuring not just HDL-C plasma levels 
but also its vascular impact when assessing novel treatments 
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3.8 Methods 
Isolation of High-density lipoprotein. HDL was isolated as described previously by sequential 
ultracentrifugation (d = 1.063-1.21 g/ml) using solid potassium bromide (Merck KGaA, Germany) for 
density adjustment.
12, 45, 46
    
Measurement of endothelial nitric oxide (NO) production by electron spin resonance spectroscopy. 
The effects of HDL (50 μg/ml; 60 min, 37°C) on endothelial NO production (HAECs; passage 4-7; 
Clonetics) was examined by electron spin resonance (ESR) spectroscopy using the spin-probe colloid 
Fe(DETC)2 (Noxygen), as described and validated previously.
45, 47-49
 In brief, ESR spectra of samples 
frozen in liquid nitrogen were recorded on a Bruker e-scan spectrometer (Bruker BioSpin) with the 
following instrumental settings: center field (B0) 3425 G, sweep width 80 G, microwave power 39.72 db, 
amplitude modulation 10.34 G, sweep time 10.49 sec, number of scans 10.  
Measurement of endothelial VCAM-1 expression. Endothelial cells were seeded in 96-well plates 
(2x10
4
 cells per well) and used for experiments upon reaching confluency. When indicated, cells were pre-
incubated with HDL (50ug/ml) overnight at 37°C. Endothelial VCAM-1 expression was induced by 
addition of TNF-α (10ng/ml) for 4 hours at 37°C. In-Cell Western assays were performed using a In-Cell 
Western Kit (LI-COR Biosciences, Lincoln, NE). Cells were fixed using 3.7% formaldehyde, 
permeabilized with 0.1% Triton X-100, blocked with Odyssey Blocking Buffer, and incubated with goat 
anti-human VCAM-1 antibody (R&D Biosciences) at a dilution of 1: 1000 overnight at 4°C. The 
secondary antibody for goat IgG, which were labeled with IRDye 800CW were subsequently added at a 
dilution of 1:1,000 in the dark. DRAQ5 was used for normalization. The cells were imaged using a LI-
COR Scanner and analyzed by the Odyssey System (Li-COR Biosciences). 
Measurement of endothelial active caspase-3 expression. Endothelial cells were seeded in 96-well 
plates (2x10
4
 cells per well) and used for experiments upon reaching confluency. Endothelial apoptosis 
was induced by serum and growth factor deprivation for 20hours at 37°C. When indicated, cells were co-
incubated with HDL (50ug/ml). In-Cell Western assays were performed using a In-Cell Western Kit (LI-
COR Biosciences, Lincoln, NE). Cells were fixed using 3.7% formaldehyde, permeabilized with 0.1% 
Triton X-100, blocked with Odyssey Blocking Buffer, and incubated with mouse anti-human active 
caspase-3 antibody (Abcam) at a dilution of 1: 1000 overnight at 4°C. The secondary antibody for goat 
IgG, which were labeled with IRDye 800CW were subsequently added at a dilution of 1:1,000 in the dark. 
DRAQ5 was used for normalization. The cells were imaged using a LI-COR Scanner and analyzed by the 
Odyssey System (Li-COR Biosciences). 
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4.1 Abstract 
Epidemiological evidence suggests that a higher HDL-C level is associated with a lower cardiovascular 
disease risk in general populations. Raising HDL is therefore being examined as a potential therapeutic 
strategy. However, vascular effects of HDL appear to be highly heterogenous and benefits of HDL 
function may be lost, at least partially, in patients with coronary artery disease (CAD). Recent proteomics 
studies suggest that HDL proteins that are associated with diverse biological functions. In CAD patients, 
HDL protein compositions are altered which may have adverse effects on the atheroprotective properties 
of HDL. 
In this study, we used quantitative proteomics to evaluate changes in the HDL proteome and its relation to 
cardiovascular outcome. HDL was isolated from patients with coronary artery disease derived from the 
Ludwigshafen Risk and Cardiovascular Health (LURIC) study who died from cardiovascular events 
versus those who did not develop any events during the entire follow-up study period. HDL-associated 
proteins were analyzed by a selected reaction monitoring (SRM) experiment in a tandem mass 
spectrometer resulting in the direct detection and quantification of both the native peptide and isotope 
labeled AQUA internal standard peptide.  
Statistical analysis using SRMStats identified statistically significant differences in the protein 
compositions of HDL between CAD patients who had a major cardiovascular event versus patients 
without any cardiovascular event. Alterations in the protein composition of HDL may provide insight into 
the adverse changes in the vascular effects of HDL and potentially identify new mechanisms of action of 
HDL, which may be important in the development of novel HDL-targeted therapy.  
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4.2 Introduction 
As highlighted in previous sections, alterations in HDL function are likely, at least in part, attributed to 
changes in the compositions of HDL particles. The HDL class of particles is structurally and metabolically 
heterogeneous, due its diverse metabolic origin and by continuous remodeling of the particles by lipolytic 
enzymes, lipid transporters, and furthermore by lipid and apolipoprotein exchange with other circulating 
lipoproteins and tissues.
1, 2
  
Early study has identified that HDL isolated during the acute phase response have profound changes in its 
associated proteins and apolipoprotein composition.
3
 This HDL is enriched in C-reactive protein (CRP), 
secretory phospholipase A2-IIa (sPLA2-IIa), serum amyloid A (SAA), and cholesterol ester transfer protein 
(CETP). While such remodeling has been suggested to preserve the acceptor role of HDL particles in 
cholesterol efflux from cells,
4
 it may also compromise other functions of HDL. HDL carrying oxidatively 
modified apolipoprotein A-I (apoA-I) has also been shown to lose its anti-inflammatory effects.
5
 Recently, 
we observed that reduced clusterin and increase apolipoprotein C-III (apoC-III) contents in HDL isolated 
from patients with CAD may lead to activation of pro-apoptotic signaling in endothelial cells.
6
 These 
observations suggest that a more complete picture of the relationship between HDL functions in 
physiological and pathological conditions and changes in its protein compositions may be obtained by 
unbiased evaluation of the HDL-associated proteins. Such knowledge will also be important in identifying 
novel functions of HDL.  
Various functions of HDL have been identified that include participation in lipid metabolism, 
atheroprotective effects, and also in the innate immune response. Early HDL proteomic studies aimed to 
identify proteins that could provide clues about the diverse postulated function of this lipoprotein. On the 
other hand, more recent studies have compared the lipoprotein proteome of healthy controls with that from 
patients suffering atherosclerotic cardiovascular disease or other metabolic alterations in which changes in 
HDL levels or subclasses distribution have been previously documented.  
Application of quantitative proteomics will allow for the identification of targets for novel HDL-based 
therapies and the discovery of biomarkers which can be used for diagnostics, prevention and monitoring of 
cardiovascular disease risk. Importantly, quantitative assessment of HDL proteome will enable a greater 
understanding of the mechanisms of action of HDL and its alterations in cardiovascular diseases. 
4.2.1 Proteomic platforms used for evaluation of the HDL proteome 
Qualitative and quantitative analyses of HDL proteins have been reported with the use of 1-D/ 2-DE in 
combination with proteolytic fragmentation, peptide separation by high performance liquid 
chromatography (HPLC), and protein identification with double MS in tandem (MS/MS) or with matrix-
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assisted laser desorption/ionization–time flight mass spectrometry (MALDI-TOF-MS).
7, 8
 Proteomics 
analysis with 2-DE has several limitations including reproducibility issue and laborious time-consuming 
processes. Furthermore, considerable loss of materials is often an issue during protein fractionation 
procedure. 
Recent studies have used direct evaluation of protein digests separated by 2D-LC or directly analyzed by 
MS/MS. Shotgun proteomics has been applied to analyze HDL protein compositions.
6, 8-10
 It should be 
noted, however, that quantification of individual proteins or peptides from complex mixtures or proteolytic 
digests by MS/MS is still difficult because the most abundant components of proteins/peptides mixtures 
limit ionization of the less abundant ones. In addition, as pointed out by Duncan et al,
11
 in complex 
proteomes several proteins can be precursors of the same peptide and as a result, depending on the 
peptide(s) selected, the precursor protein levels may be significantly under- or overestimated.  
More recently, SELDI TOF-MS, or ProteinChip technology, has emerged to allow for more convenient 
comparative analysis of the proteome associated with specific metabolic alterations or pathologies with 
those of lipoproteins from healthy individuals. SELDI was used to analyze LDL
12
 or HDL
13-16
 that were 
directly adsorbed onto the SELDI plate. This method allows handling of several individual analyses per 
week and requires minute amounts of the protein mixtures. However, the limitation of this technique is 
that protein identities are not revealed in the process because the analytes cannot be subjected to digestion 
or tandem mass spectrometry. It requires downstream analysis, digestion, and identification of analytes 
after the quantification step, and its advantages and limitations have been recently reviewed.
17
 
Furthermore, identification in SELDI is based on low mass resolution data, thereby limiting its application.  
Most of the techniques used in the analysis of the HDL proteome currently available in the literature have 
so far been semi quantitative analyses to compare changes in the lipoprotein proteomes associated with 
specific metabolic alterations or pathologies with those of lipoproteins from healthy individuals, and often 
with low number of samples due to highly laborious processes. Meanwhile, recent advances in the mass 
spectrometry field has allowed for more quantitative analysis or even absolute quantification of proteins in 
highly complex mixture, with the use of targeted proteomics using selected reaction monitoring (SRM).
18, 
19
 The main advantage of SRM is the capacity for faster and cost-efficient assay development.
18
 SRM has 
also the feature of being able to quantify multiple proteins in parallel (multiplexing) at a low limit of 
detection (LOD) and high accuracy. Furthermore, study has shown that protein quantification by SRM in 
complex samples using predefined assay coordinates is reproducible across different laboratories and 
instrument platforms.
20
 
Targeted mass spectrometry through selected reaction monitoring (SRM) exploits the unique capabilities 
of triple quadrupole (QQQ) MS for quantitative analysis. In SRM, the first and the third quadrupoles act as 
Chapter 4 HDL proteomics analysis with SRM: Relation to clinical outcome 
 
 
91 
 
filters to specifically select predefined m/z values corresponding to the peptide ion and a specific fragment 
ion of the peptide, whereas the second quadrupole serves as collision cell. Several such transitions 
(precursor/fragment ion pairs) are monitored over time, yielding a set of chromatographic traces with the 
retention time and signal intensity for a specific transition as coordinates. The two levels of mass selection 
with narrow mass windows result in a high selectivity, as co-eluting background ions are filtered out very 
effectively. Unlike in other MS-based proteomic techniques, no full mass spectra are recorded in QQQ-
based SRM analysis. The non-scanning nature of this mode of operation translates into an increased 
sensitivity by one or two orders of magnitude compared with conventional ‘full scan' techniques. In 
addition, it results in a linear response over a wide dynamic range up to five orders of magnitude. This 
enables the detection of low-abundance proteins in highly complex mixtures, which is crucial for 
systematic quantitative studies. 
4.2.2 Recent advances in the analysis of HDL Proteome and its pathological remodeling in 
cardiovascular disease 
Using 2-DE in combination with MALDI-TOF-MS, HDL was found to contain besides the classical 
apolipoproteins: apoAI (6 isoforms), apoAII, apoAIV (6 isoforms), apoE (6 isoforms), apoM (2 isoforms), 
apoCII, apoCIII (3 isoforms), other proteins as SAA (2 isoforms), α-amylase, and α-1-antitrypsin. 
Interestingly, although the methods used in these ground-breaking studies are considered semiquantitative, 
the authors already reported differences in the distribution of apolipoprotein and associated proteins 
between the large HDL2 and the small HDL3 subclasses that have been confirmed by more recent 
studies.
21
  
It has been suggested that proteins associated with HDL could be separated into clusters whose members 
shared participation in defined functional areas. These areas were: lipid metabolism and transport, 
inflammatory markers, immune system and complement factors, growth factors, hormone-binding 
proteins, and proteins involved in hemostasis.
8, 22
 Recent data from Davidson et al
.
 supports the hypothesis 
that proteomics of HDL subpopulations may lead to a more comprehensive understanding of differential 
functions of individual particle subclasses.
23
 In these experiments HDL2b,- 2a, -3a, -3b, and HDL3c were 
isolated by isopycnic density gradient ultracentrifugation in neutral salts, and 28 different HDL-associated 
proteins and apolipoproteins were identified in each subclass using LC/ESI/MS and a quadropole TOF 
analyzer. The identified proteins appear to associate into 5 distinct clusters with different abundance of the 
individual proteins in the HDL subclasses. Furthermore, there are strong correlations between levels of the 
components in the clusters of individual subclasses and their potential antioxidant properties. The authors 
proposed that this is specially the case for the dense HDL3 subclass that shows elevated content of the 
cluster containing PON 1/2, PON 3, and apoL-I. Moreover this dense HDL3 subclass appears to be the 
Chapter 4 HDL proteomics analysis with SRM: Relation to clinical outcome 
 
92 
 
unique carrier of apoA-IV, PON1, phospholipid transport protein (PLTP), apoJ, apoF, and apoL-I. In the 
other hand, the apparent preference of apoE, apoCII and apoCIII for the light HDL2 subclass was 
proposed to be related to the known interaction of these particles with components of the LDL receptor 
family.
23
  
Given the complexity of HDL and its multitude of biological functions, it is conceivable to expect that sets 
of functionally associated proteins can provide information about their participation in the spectrum of 
atheroprotective actions attributed to HDL. This has further led to studies in which the aim became to 
compare the HDL proteome of healthy subjects with that of particles from patients with dyslipidemias or 
CAD.
6-9
 Some of the studies aim to document differences that may allow the assignment of specific 
proteins to functional defects of HDL.  
In the study by Vaisar et al., HDL was shown to carry apolipoproteins and proteins with functions in lipid 
metabolism, the acute phase response, complement regulation, and blood coagulation.
8
 In a recent study 
from the same laboratory the proteome of HDL3 from 6 CAD patients was compared before and after 1-
year treatment with combined statin/niacin therapy.
9
 In this study, HDL3 of CAD patients is significantly 
enriched in apoE and apoCII and contain less apoJ and phospholipid transport protein (PLTP) than the 
particles from controls. Niacin/statin treatment of the patients decreases HDL3 apoE to the levels of 
healthy controls.
9
 The authors proposed that an increase in apoE could accelerate hepatic removal of apoE-
rich HDL3 and that this is responsible for its low plasma level in patients with CAD. Thus, decrease in 
apoE-rich HDL removal, caused by the niacin/statin treatment, may lead to the increase number of 
circulating particles. The treatment, on the other hand, raises apoJ and PLTP in HDL3; a change that was 
suggested may improve the participation of HDL3 in reverse cholesterol transport (RCT).
9
  
In our recent study (please refer to Chapter 2), we have observed that reduced clusterin and increased 
apolipoprotein C-III content in HDL isolated from patients with CAD lead to activation of pro-apoptotic 
signaling pathways in endothelial cells.
6
 In contrast to HDL from healthy subjects, HDL isolated from 
patients with stable CAD or an acute coronary syndrome failed to inhibit endothelial cell apoptosis in vitro 
and in apoE-deficient-mice in vivo. Instead, HDL isolated from these patients stimulated endothelial pro-
apoptotic pathways, in particular p38-MAPK-mediated activation of the pro-apoptotic Bcl-2-protein tBid. 
Our studies further suggest that differences in the proteome of HDL from patients with CAD, in particular 
reduced HDL-associated clusterin and increased HDL-associated apoC-III, play an important role for 
altered activation of endothelial anti- and pro-apoptotic signaling pathways.
6
 
Taken together, these studies indicate that the HDL proteome can change in a variety of disease states and 
these changes are often related to at least in vitro measures of HDL function. However, it remains to be 
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seen whether these changes are secondary to other processes occurring during disease progression or if the 
HDL particles themselves contribute to the disease etiology.  
4.3 Experimental design 
4.3.1 Study cohort 
To examine the relationships between HDL proteome and total and cardiovascular mortality, we studied 
participants of the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study, a large and well defined 
cohort of patients. LURIC was an ongoing prospective study of environmental, biochemical, and genetic 
risk factors for CAD in a hospital-based cohort of white individuals. We studied patients who had 
undergone coronary angiography between June 1997 and January 2000, at the Ludwigshafen General 
Hospital and did not suffer from major non-cardiovascular disease. The study was approved by the 
institutional review board at the “Ärztekammer Rheinland-Pfalz”. Informed written consent was obtained 
from each of the participants. All participants were profiled in detail with regard to established risk factors 
for cardiovascular disease. The cohort is followed for morbidity and mortality. The median follow up time 
is 8 years.  
CAD was assessed by angiography using the maximum luminal narrowing estimated by visual analysis. In 
LURIC, clinically relevant CAD was defined as the occurrence of at least 1 stenosis 20% in at least 1 of 15 
coronary segments. Samples were classified into cases and controls. Cases were defined as patients who 
died from cardiovascular causes and who may have had previous myocardial infarction (MI) or stroke (not 
within three months prior to recruitment). Controls were defined as patients who have not had any 
previous MI or stroke and did not develop any cardiovascular events during the entire follow-up study 
period. 
 
Figure 4.1 Illustration of the study design. Blood samples were collected at the start of the study upon 
patient recruitment. Patients who died during the course of follow-up due to cardiovascular causes were 
defined as cases. Patients who survived the entire follow-up, without developing any cardiovascular events, 
were classified as controls.  
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4.3.2 HDL isolation, delipidation and in-solution digestion 
Serum was stored at −70 °C and thawed on 1 occasion for lipoprotein isolation. HDL was isolated as 
described previously by sequential ultracentrifugation (d = 1.063-1.21 g/ml) using solid potassium 
bromide (Merck KGaA, Darmstadt, Germany) for density adjustment.
24, 25
  HDL was delipidated using 
methanol/chloroform extraction as previously described.
6
 The protein pellet was dissolved in 50 mM 
ammonium bicarbonate at pH 8.0. Yeast protein, alcohol dehydrogenase (100ng/ml), was added as an 
internal standard control. Rapigest (0.1%) was added prior to reduction with 15 mM DTT for 30 minutes 
at 60ºC followed by alkylation of the cysteine residues with the addition of iodoacetamide to a final 
concentration of 40 mM for 45 minutes at room temperature and darkness. Enzymatic digestion was 
performed in 50 mM ammonium bicarbonate, pH 8.0 overnight at 37 ºC with 1 μg sequencing grade 
trypsin (Promega). Tryptic digests were desalted with silica C18 MacroSpin column (The Nest Group) and 
the peptides were dried in a speed vac concentrator and re-solubilized in 0.1% formic acid for mass 
spectrometric analysis. 
Figure 4.2  Diagram of the experimental workflow. 
4.3.3 Generation of SRM assays 
In contrast to conventional shotgun proteomic studies, SRM measurements are quantitative analyses 
strictly targeting a predetermined set of peptides and depend on specific SRM transitions for each targeted 
peptide. Previous information is required to define these transitions. Specifically, three types of 
information are of critical importance. First, the proteins that constitute the targeted protein set have to be 
selected. Second, for each targeted protein, those peptides that present good MS responses and uniquely 
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identify the targeted protein, or a specific isoform thereof, have to be identified. Such peptides have been 
termed as proteotypic peptides (PTPs).
26
 Third, for each PTP, those fragment ions that provide optimal 
signal intensity and discriminate the targeted peptide from other species present in the sample have to be 
identified. 
4.4 Results 
4.4.1 Pilot experiment 
Using SRM in combination with AQUA peptides, we first performed a pilot study of 10 cases and 10 
controls to assess potential variability of the samples. We used skyline for the visualization of the acquired 
transitions and manual inspection of the signals were performed to correct for any discrepancies. The 
quantified transitions can be influenced by the technical MS run variability,e.g., due to changes in the 
instrument performance over a large number of MS runs. This technical variation can be removed by a 
global between-run normalization, e.g. by constant normalization that equalizes the median peak 
intensities of all reference transitions between runs. The normalization is based on the assumption that the 
intensities of the reference transitions are stable across all MS runs.  
 
Figure 4.3 QC plots before (Left) and after (Right) normalization. QC plot illustrates the systematic bias 
between MS runs. After normalization, the reference signals for all proteins should be stable across MS 
runs. X-axis is run. Y-axis is log-intensities of transition. Reference/endogenous signals are in the left/right 
panel.  
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Figure 4.4 Quantified transition signals of a protein from each of the biological replicates, after a global 
normalization. Transitions of the reference peptides had a roughly constant abundance between runs. In 
contrast, transitions of the endogenous peptides indicated systematic differences between conditions, and 
these changes are of primary interest. The measurements were subject to biological variation of protein 
abundance and technical between-run variation. X-axis is run. Y-axis is log-intensities of transitions. 
Reference/endogenous signals are in the left/right panel. Line colors indicate peptides and line types 
indicate transitions. 
 
Figure 4.5 Illustration of the calculated minimal number samples size to obtain the statistical power based 
on the desired fold changes, the number of peptides per protein as well as number of transitions per 
peptide.  
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4.4.2 Quantification of candidate markers in HDL using SRM 
We used SRM in combination with AQUA in order to detect and quantify the candidate proteins in HDL. 
We isolated HDL by sequential ultracentrifugation from serum samples of 61 cases, 70 controls and 7 
healthy subjects. SRM assays were extracted from the SRMAtlas for 43 candidate HDL-associated 
proteins of interest identified in previous studies.
6, 8
 Two to three proteotypic peptides were selected and 
corresponding C13 AQUA peptides were synthesized by Thermo Scientific and used as internal standards, 
allowing realiable quantification and accurate quantification of the peptides.
27
 The resulting SRM data was 
visualized using skyline.
28
 Statistical analysis was performed using a mixed effects model implemented in 
SRMstats.
29
 Proteins were considered significantly up- or down- regulated with a p-value below 0.05 
adjusted by Benjamini-Hochberg
30
 and  fold change larger than 1.2. 
Interestingly, we observed 10 proteins that are significantly regulated between healthy subjects and 
control, and 15 proteins between healthy subjects and cases. These proteins are shown in Figure 4.6 and 
listed in Table 4.1. Some of these proteins have previously been reported to be differentially enriched in 
patients with CAD/ACS versus healthy control subjects, thereby further validating our experimental 
methods. 
Figure 4.6  Volcano plots illustrating the results of the statistical analysis of HDL proteins from cases and 
controls versus healthy subjects. In the plots, proteins that are significantly down-regulated or up-regulated 
in HDL from cases or control as compared to healthy subjects are colored in blue or red, respectively. 
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Table 4.1  Proteins quantified by SRM that are significantly regulated in HDL from cases versus healthy 
and controls versus healthy. The fold change (log2FC), standard error (SE), T-value and adjusted p-value 
are given in the table.  
Protein Label log2FC SE T-value P-value 
      APOA2 healthy-control 2.045 0.412 4.970 2.76E-05 
APOC3 healthy-control 1.311 0.269 4.877 2.76E-05 
A1AT healthy-control -1.552 0.351 -4.416 1.60E-04 
SAA healthy-control 1.627 0.482 3.378 8.59E-03 
SAA4 healthy-control 1.008 0.307 3.285 9.48E-03 
CO3 healthy-control -1.307 0.442 -2.958 2.21E-02 
APOD healthy-control 1.081 0.375 2.885 2.37E-02 
PAFA healthy-control -1.190 0.424 -2.808 2.63E-02 
CLUS healthy-control -1.339 0.488 -2.745 2.85E-02 
APOF healthy-control 1.294 0.482 2.687 3.03E-02 
 
     
APOC3 healthy-cases 1.743 0.267 6.528 3.40E-09 
APOA2 healthy-cases 2.665 0.409 6.516 3.40E-09 
APOD healthy-cases 1.595 0.372 4.282 2.90E-04 
SAA4 healthy-cases 1.249 0.305 4.097 5.68E-04 
APOF healthy-cases 1.910 0.478 3.993 5.94E-04 
APOC2 healthy-cases 1.682 0.439 3.835 9.61E-04 
SAA healthy-cases 1.799 0.479 3.759 1.23E-03 
CO3 healthy-cases -1.510 0.439 -3.439 3.23E-03 
A1AT healthy-cases -1.177 0.349 -3.372 3.59E-03 
LBP healthy-cases 1.017 0.310 3.286 4.72E-03 
APOL1 healthy-cases 0.850 0.276 3.082 7.99E-03 
A2MG healthy-cases -1.231 0.406 -3.033 8.59E-03 
PAFA healthy-cases -1.176 0.421 -2.794 1.69E-02 
AACT healthy-cases 1.066 0.393 2.714 2.07E-02 
HPTR healthy-cases 0.820 0.312 2.632 2.45E-02 
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We also observed some protein that are differentially regulated between cases and control (Figure 4.7, 
Table 4.2). Interestingly, the distribution of these proteins is narrower than those of healthy-cases and 
healthy-control. This suggests that the HDL proteome have been altered/remodeled even in the early stage 
of the disease (stable CAD). Some of these proteins are not differentially regulated between cases and 
control, suggesting that these proteins albeit may represent a good marker for the disease, has no value 
when identifying patients at risk of future events. 
 
Figure 4.7 Volcano plot illustrating the results of the statistical analysis of HDL proteins from cases 
versus controls. In the plot, proteins that are significantly down-regulated or up-regulated in HDL from 
cases as compared to control are colored in blue or red, respectively. 
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Table 4.2  Proteins quantified by SRM that are significantly regulated in HDL from cases versus controls. 
The fold change (log2FC), standard error (SE), T-value and adjusted p-value are given in the table.  
Protein Label log2FC SE Tvalue P-value 
      LBP control-cases 0.718 0.137 5.246 1.29E-05 
PCYOX control-cases 0.743 0.162 4.582 1.45E-04 
APOC3 control-cases 0.432 0.118 3.662 3.68E-03 
HPTR control-cases 0.498 0.138 3.612 3.71E-03 
APOA2 control-cases 0.619 0.181 3.424 4.76E-03 
APOC2 control-cases 0.662 0.194 3.411 4.76E-03 
APOD control-cases 0.514 0.165 3.112 1.14E-02 
APOL1 control-cases 0.359 0.122 2.941 1.52E-02 
APO1B control-cases 0.571 0.195 2.925 1.52E-02 
APOF control-cases 0.616 0.212 2.912 1.52E-02 
A2MG control-cases -0.512 0.180 -2.853 1.67E-02 
PLTP control-cases -0.506 0.182 -2.777 1.94E-02 
A1AT control-cases 0.375 0.154 2.429 4.85E-02 
CO4 control-cases 0.491 0.220 2.231 8.01E-02 
APOA4 control-cases 0.378 0.192 1.966 1.22E-01 
APOE control-cases 0.355 0.181 1.965 1.22E-01 
            
 
Notably, proteins which are significantly up/down-regulated between cases and controls can be classified 
into different biological processes (Figure 4.8). Besides the apolipoproteins and phospholipid transfer 
protein (PLTP) which are involved in lipid metabolism, other proteins are associated with innate 
immunity, oxidative stress, and protease inhibition. Apolipoprotein C-III (APOC3) inhibits lipoprotein 
lipase-mediated hydrolysis of triglycerides and its presence in HDL has been associated with incidence of 
coronary heart disease.
31
 We recently showed that increased APOC3 content in HDL from patients with 
CAD activate the pro-apoptotic signaling in endothelial cells.
6
 Lipopolysaccharide binding protein (LBP), 
haptoglobin related protein (HPTR) and apolipoprotein L1 (APOL1) have previously been described to 
play a role in the innate immune response.
32
 LBP binds and neutralizes the bioactivity of the potent 
bacterial lipids, LPS and lipoteichoic acid, that stimulate host innate immune responses.
33
 Depending on 
its concentration, LBP can either potentiate or inhibit responses to LPS.
34
 Studies have also shown that 
HDL particles containing APOL1 and HPTR mediate the lysis of trypanosomes
35
 and also inhibit 
Leishmania infection.
36
 Prenylcysteine oxidase is an enzyme crucial for the degradation of prenylated 
proteins, generates free cysteine and hydrogen peroxide, suggesting a role in oxidative stress.
37
 
Apolipoprotein D is also known to be involved in aging and oxidative stress.
38, 39
  Alpha-2-macroglobulin 
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(A2MG) has many diversified and complex functions, but it is primarily known by its ability to inhibit a 
broad spectrum of proteases.
40
 Another protease inhibitor found to be differentially regulated between 
cases and controls is alpha-1-antitrypsin (A1AT) which is also an acute phase reactant.
41
 
Figure 4.8  Classification of proteins identified into their associated biological functions and processes. 
 
4.5 Discussion 
Multiple prospective epidemiological studies support the importance of HDL cholesterol in atherosclerosis. 
However, the increase in HDL cholesterol observed with some lipid modifying drugs has not been 
uniformly associated with clinical benefit,
42, 43
 indicating that the association between HDL and 
cardiovascular disease is more complex than previously suspected, and probably is mediated by different 
HDL functional properties, independent of the cholesterol component of the HDL particle.
44
 A key 
challenge in understanding the physiology and pathophysiology of HDL in coronary disease is the 
heterogeneity of HDL particles, with different associated proteins modulating specific functions. One 
approach is to dissect the complexities of HDL by qualitative and quantitative evaluation of the proteins 
and lipids associated with HDL. And the next challenge is to understand how these changes may relate to 
clinical outcome. 
Proteomics studies of HDL have been limited in number and size because of the labor-intensive nature of 
the present proteomics platforms. Due to the diverse concentration range of the proteins in the HDL 
particles, some proteomics approaches may fail to reflect the actual amount or alteration of low abundant 
proteins due to signal suppression in the presence of highly abundant proteins. Targeted proteomics using 
selected reaction monitoring is a powerful tandem mass spectrometry method that can be used to monitor 
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target peptides within a complex protein digest.
18, 19
 The approach is highly specific and sensitive, and it 
also allows multiplexing measurement of many analytes in parallel.  
In this study, we have used quantitative proteomics with SRM to evaluate the differences in the protein 
compositions of HDL isolated from patients with CAD who died from cardiovascular events versus 
patients with CAD who did not have cardiovascular events. HDL isolated from these patients has 
markedly altered protein compositions as compared to HDL from healthy subjects, which may account for 
the altered vascular effects of HDL in CAD shown in recent studies. 
Differences in the protein compositions of HDL from patients who died from cardiovascular events versus 
patients who survived may identify potential markers in determining patients at risk of developing future 
cardiovascular events. An important finding from this study is that some of the proteins identified may 
allow better understanding of the mechanisms of action of HDL and its alterations in cardiovascular 
disease. Of note, some of the proteins identified to be differentially regulated are not related to lipoprotein 
metabolism, indicating that HDL physiology and its pathophysiology in CAD is beyond simply regulation 
of lipid metabolism but also other metabolic processes such as innate immunity and regulation of oxidative 
stress.     
Nonetheless, the next key question is to understand whether these differences in the protein compositions 
can be translated into differences in HDL function. Furthermore, it is also crucial to evaluate whether the 
proteomic changes found in this study reflect a causal relationship or purely an association. 
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Low serum concentration of HDL cholesterol is considered by many to be the strongest lipid risk factor for 
cardiovascular disease.
1
 Clinical and epidemiological studies have shown a strong inverse association of 
plasma levels of HDL cholesterol with coronary heart disease.
2
 Besides promoting macrophage cholesterol 
efflux and reverse cholesterol transport, HDL from healthy subjects has been shown to exert direct 
vasoprotective effects.
3-7
 These have led to the development of the ‘HDL cholesterol hypothesis’, which 
suggests that intervention to raise HDL cholesterol will result in reduced risk of coronary heart disease. 
Consequently, considerable efforts have been devoted to the development of HDL cholesterol raising 
therapies.  
However, several lines of evidence have raised serious doubts about the validity of the HDL cholesterol 
hypothesis. Recent clinical trials using the HDL cholesterol raising agents torcetrapib, dalcetrapib and 
niacin have shown that no significant reduction of cardiovascular events was observed in patients with 
coronary disease.
8-10
 Moreover, recent mendelian randomization analyses showed that genetic variants 
associated with HDL cholesterol levels had a weak or nonexistent relationship with cardiovascular disease 
risk, particularly when they were only associated with HDL cholesterol levels and not with LDL 
cholesterol or triglyceride levels.
11
 Taken together, these observations suggest that the association between 
HDL cholesterol levels and cardiovascular disease risk is not a causal relationship. HDL cholesterol may 
simply be a biomarker and elevating HDL cholesterol levels is not necessarily therapeutic. 
We are beginning to appreciate that it is the quality and function of HDL, not the cholesterol levels, which 
may be mechanistically more important in relation to cardiovascular disease protection. Importantly, 
accumulating evidence suggests that the vascular effects of HDL can be highly heterogeneous and HDL 
may lose important anti-atherosclerotic properties and turn dysfunctional in patients with chronic 
inflammatory disorders.
12-21
 Therefore, there is a great medical need for assays or markers that reflect the 
functionality of HDL better than HDL cholesterol levels. One approach towards this goal is to better 
understand the mechanisms of actions of HDL and its pathophysiology in cardiovascular diseases. 
Hitherto, the relative importance of many physiological and pathological roles of normal and 
dysfunctional HDL for the pathogenesis of atherosclerosis is unknown. The overall goal of this thesis was 
therefore to identify the components and biological activities of HDL that are most relevant for the 
protections against coronary artery disease. 
The first pivotal finding of this thesis was that HDL isolated from patients with CAD, in comparison to 
HDL from healthy subjects, has altered effects on endothelial anti- and pro-apoptotic signaling pathways, 
leading to a loss of the endothelial anti-apoptotic capacity of HDL.
21
 This study further demonstrates that 
reduced HDL-associated clusterin and increased HDL-associated apoC-III play an important role for 
altered activation of endothelial anti- and pro-apoptotic signaling pathways in HDL from patients with 
CAD. These observations raise the possibility that certain proteins in HDL play previously unsuspected 
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roles in regulating endothelial cell apoptosis. This action might be centrally important for preventing 
endothelial cell dysfunction and blocking multiple key steps in atherogenesis. Of note, it was observed that 
the signaling pathways activated by HDL in the regulation of endothelial apoptosis seem to be independent 
of its capacity to stimulate eNOS-mediated NO production, suggesting that different biological functions 
of HDL may be modulated independently by different HDL components, via specific signaling pathways. 
Whether certain pathological condition alters a particular component of HDL and whether this leads to 
specific impairment in biological function of HDL remains to be determined.  
A major clinical challenge is to link molecular mechanisms underlying HDL's cardioprotective activities 
to robust, quantitative metrics that can be widely applied in translational and clinical studies. Reduced 
endothelial nitric oxide availability, pro-inflammmatory activation and endothelial cell apoptosis are 
regarded as key mechanisms in the development and progression of atherosclerosis. The capacity of HDL 
to modulate these endothelial effects may therefore represent a potentially important anti-atherogenic 
property of HDL. Furthermore, the effects of HDL on these endothelial functions have been shown to be 
regulated via specific signaling pathways and more importantly, these endothelial protective effects have 
to been shown to be impaired in coronary artery disease.
20, 21
 Therefore, one potential approach for 
assessing HDL function is to measure the capacity of HDL to modulate these endothelial signaling 
pathways. In this regard, we have optimized cell-based assays to measure the capacity of HDL to inhibit 
TNF-α-induced VCAM-1 expression, to reduce active caspase-3 activation and to stimulate nitric oxide 
production. 
We have used these assays to evaluate the impact of CETP inhibitor treatment on the endothelial effects of 
HDL. The first CETP inhibitor, torcetrapib, effectively increased HDL-C and lowered LDL-C but was 
associated with increased cardiovascular mortality.
8
 Meanwhile, earlier-phase clinical trials have shown 
that dalcetrapib contribute to the reduction of atherosclerotic progression and vascular inflammation 
without adversely affecting blood pressure or aldesterone levels.
22, 23
 However, despite these encouraging 
signals, the Phase III dal-OUTCOMES trial was terminated prematurely due to lack of clinically 
meaningful efficacy.
9
 How do we reconcile our findings with the failure of CETP inhibitors in clinical trial? 
We observed that there was no difference in the improvement of HDL functions from baseline level when 
we compared placebo and dalcetrapib treatment groups. Furthermore, treatment with dalcetrapib failed to 
restore HDL functions to the level of healthy subjects, which may explain, at least in part, the lack of 
benefit on endothelial function seen in the dal-VESSEL trial.
24
  
Interestingly, despite the failure of torcetrapib in clinical trial resulting in increased cardiovascular 
mortality, no impairment in HDL functions was observed following torcetrapib treatment in this study. 
This finding may explain the lack of improvement in the quality of HDL following torcetrapib treatment, 
however the adverse effects observed in the clinical trial of torcetrapib were likely caused by off-target 
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side effects, which may have been due to direct deleterious actions of torcetrapib on endothelial function,
25
 
independent of the HDL cholesterol raising effect. 
Whereas the endothelial effects of HDL were not significantly altered following dalcetrapib or torcetrapib 
treatment, raising HDL cholesterol levels via these CETP inhibitors have not proven to be effective in 
reducing cardiovascular disease risk in clinical trials. These findings further support the notion that HDL 
cholesterol level is a noncausal biomarker. It seems prudent to re-evaluate the use of HDL cholesterol 
level as a biomarker predictive of cardiovascular disease risk in intervention studies.  
Nevertheless, it is important to note that CETP inhibition may not provide a direct answer for testing the 
HDL hypothesis.  A recent genetic study has shown that the CETP alleles associated with lower CETP 
activity, higher HDL cholesterol, lower LDL cholesterol, lower triglycerides, and lower lipoprotein(a) are 
indeed associated with decreased risk for cardiovascular disease,
26
 suggesting that drugs that inhibit CETP 
activity are likely to reduce the risk for cardiovascular disease. While torcetrapib failure may be attributed 
to off-target side effects, dalcetrapib treatment primarily alters HDL cholesterol level with minimal effects 
on other lipid parameters.
9, 22
  It is worth noting that large-scale outcome studies of anacetrapib and 
evacetrapib are ongoing. Anacetrapib and evacetrapib profoundly increase HDL cholesterol levels and also 
reduce LDL cholesterol levels by 35-40%,
27, 28
 raising a distinct possibility that these CETP inhibitors will 
likely show benefit in reducing cardiovascular disease risk. However, the potential benefit from this CETP 
inhibition will likely be independent of their effects on HDL cholesterol elevation.   
While recent events seem to have cast doubts on the HDL hypothesis, the anti-atherogenic role of HDL 
cannot be undermined and HDL remains an interesting target for treatment against cardiovascular diseases. 
A major challenge is to identify the components of HDL that are most relevant for the protections against 
coronary artery disease. HDL forms a heterogeneous class of lipoproteins which differ by protein and lipid 
compositions, some of which may contribute to the pleiotropic functions of HDL. Another pivotal finding 
of this thesis was that proteome remodeling in HDL has direct implications on functional properties, i.e. 
vascular effects of HDL. We observed that reduced HDL-associated clusterin and increased HDL-
associated apoC-III may play a role for altered activation of endothelial apoptotic signaling pathways in 
HDL from patients with CAD. This further supports the notion that HDL dysfunction is associated with 
different structural changes in HDL including enrichment with acute phase proteins as well as protein 
modifications in pathological conditions. 
There is a need to carefully dissect the complexities of HDL composition and function and identify 
relevant HDL components in order to generate important novel insights into the molecular 
pathophysiology of HDL-associated cardiovascular diseases. In this regard, we have developed and 
optimized quantitative proteomics analysis with selected reaction monitoring (SRM) to monitor alterations 
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in HDL-associated proteins in specific pathological conditions. The results of the analyses presented in 
this thesis are preliminary and work is currently ongoing to generate the full data sets of this targeted 
proteomics study. Nevertheless, based on our preliminary findings, we have observed that HDL from 
patients with CAD has significantly altered protein compositions as compared to HDL from healthy 
subjects, further supporting our earlier observations. Notably, significant differences were observed in the 
HDL proteome between patients with CAD who died from cardiovascular events versus patients who did 
not develop any events during the entire follow-up study period. This finding may identify potential 
markers in determining patients at risk of developing future cardiovascular events. More importantly, 
some of the proteins identified will allow better understanding of the mechanisms of action of HDL and its 
alterations in cardiovascular disease. Of note, some of the proteins identified to be differentially regulated 
are not related to lipoprotein metabolism, indicating that HDL physiology and its pathophysiology in CAD 
is beyond simply regulation of lipid metabolism but also other metabolic processes such as innate 
immunity and regulation of oxidative stress. Furthermore, quantifying the HDL proteome may provide 
insights into the therapeutic efficacy of antiatherosclerotic interventions.  
In conclusion, I believe this thesis has contributed a step closer to understanding HDL physiology and its 
pathophysiology in coronary artery disease, in particular the endothelial effects of HDL. The proteomics 
study has yielded several novel HDL-associated protein candidates that may have played previously 
unsuspected roles in the pathogenesis of HDL-associated diseases. Nonetheless, in order to successfully 
exploit HDL as a treatment target in cardiovascular diseases, much remains to be done. Future work is 
needed to understand whether alterations in the HDL proteome are causal or simply an association. 
Furthermore, it is important to investigate how these HDL-associated proteins affect their cellular 
interaction partners and downstream effectors. Last but not the least, the complexity of HDL is further 
intensified with the presence of associate lipids and micro-RNAs. The contribution of these components 
towards HDL functionality will need to be explored. These important studies will generate important novel 
insights into the complexities of HDL and the molecular pathophysiology of cardiovascular disease. 
Importantly, this knowledge will drive the discovery and development of novel HDL-targeted therapies 
against cardiovascular diseases.     
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